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SUMMARY 
 
 
The therapeutic advantages offered by the use of implantable intraocular devices are numerous and 
significant. Intravitreal drug delivery technologies that provide continuous controlled drug release may in 
time find significant application in the treatment of ophthalmic diseases that are otherwise difficult to treat 
effectively. Disease due to cytomegalovirus retinitis (CMV-R) is among the most common opportunistic 
infection in patients with the Acquired Immune Deficiency Syndrome (AIDS). The virus can give rise to 
multiple organ disease and retinitis accounts for 75-85% of CMV-R disease in patients. It is a serious 
sight-threatening infection that occurs in approximately 25% of patients with AIDS. If left untreated the 
disease follows a relentless course which inevitably results in blindness. Several intraocular devices have 
been developed for the treatment of posterior segment eye diseases. However, these have significant 
limitations in providing effective treatment. This research was approached from a pharmaceutical 
technology development and formulation viewpoint aimed at the development and optimization of a 
biodegradable ganciclovir (GCV)-loaded Donut-Shaped MiniTablet (DSMT) device for the efficacious 
treatment of posterior segment eye diseases. This research was performed in the New Zealand White 
Albino (NZWA) rabbit eye model. A GCV-loaded DSMT device using various poly(lactic-co-glycolic acid) 
(PLGA) combinations was prepared on a Manesty F3 tableting press using a novel central rod and punch 
setup developed in our laboratories. The effect of irradiation sterilization on the physical and chemical 
stability of the DSMT device was investigated employing structural transition analysis, porositometry, 
thermal analysis, textural profiling and chemometric modeling. In addition, a blueprint surgical procedure 
for implantation of the device in the rabbit eye model and a sensitive Ultra Performance Liquid 
Chromatography (UPLC) assay method employing 3D chromatography was developed. The safety, 
biocompatibility or potential toxicity of the device was examined via direct and indirect ophthalmoscopy, 
slit lamp examination, intraocular pressure measurements, histopathological examinations and clinical 
observations to assess any changes in the vitreous (vitreous haze) and retina (edema, chorio-retinal 
atrophy, vascular changes, exudative changes, and necrosis) adjacent to the implanted device. The ex 
vivo micro-environmental pH variation in close proximity to the DSMT was monitored and variations were 
evaluated from pH-time profiles. Twelve NZWA rabbits (divided in two groups of six rabbits each) were 
used for the in vivo study. The DSMT was implanted into the rabbit through the pars plana/peripheral 
retina of the right eye and sutured with 9-0 nylon. Vitreous humor (VH) from the left eye was used as 
controls. Two rabbits from each group of six were euthanized on days 3, 7, 14, 28, 48 and 72. The 
residual devices, VH, plasma samples and ocular tissue were retrieved and stored at -70ºC prior to GCV 
concentration analysis by 3D UPLC technology. The in vivo release of GCV from the DSMT device was 
pharmacokinetically evaluated employing compartmental and non-compartmental pK models. Results 
revealed that the affected transitions during γ-irradiation sterilization favored the DSMT to be employed as 
an implantable intraocular device. PLGA was regarded as suitably stable under compression and γ-
sterilization for manufacture of the DSMT device. The DSMT device was well tolerated in the rabbit eye 
model without any adverse effects or toxicity to intraocular tissue structures over the entire duration 
reaching 72 days in this study as confirmed by histopathological examination. GCV release in the VH of 
the rabbits from the DSMT device was maintained within the ED50 range for the treatment of human CMV-
R. Our study has shown that constant drug release can be obtained with the DSMT device due to its 
unique geometry as well as the use of PLGA with varying molecular mass, lactide:glycolide ratios, drug-
loading capacities and compressive forces during tableting. GCV exhibited superior prolonged release 
characteristics without any dose dumping. On average 2.02±0.01µg/h of GCV was released into the VH 
from every 5mg GCV-loaded DSMT device over 72 days. Results also indicated that the method adopted 
for the previous in vitro drug release study was sufficiently powerful, convenient and discriminating for 
predicting the in vivo release of GCV from the device. An in vitro-in vivo (IVIVC) was obtained in keeping 
with the complexities of the study conditions and described by a Levy plot with a time-scaled Level A 
IVIVC correlation obtained (R2=0.90). The DSMT device was found to be sufficiently flexible and may be 
used for the effective long-term intravitreal delivery of drugs for the treatment of various posterior segment 
eye diseases. 
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CHAPTER 1 
INTRODUCTION 
 
1.1. Background and Rationale for this Research 
 
Disease due to cytomegalovirus (CMV) is among the most common opportunistic infections in patients 
with HIV/AIDS. It is a serious sight-threatening infection and if left untreated the disease follows a 
relentless course which inevitably results in blindness (Smith et al., 1992; Jabs et al., 2003). Treatment 
of CMV retinitis (CMV-R) requires chronic suppressive maintenance therapy with antiviral bioactives to 
prevent relapse. In the last decades delivery of antiviral drugs to the vitreous cavity for treating CMV-R 
has been attempted by various routes which suffer from some weakness or the other. As outlined later 
in Chapter 2 of this thesis, promising developments are polymeric implants designed to deliver drugs 
intravitreally. They allow for higher intraocular drug levels than could be achieved by systemic 
administration and avert the inconvenience of direct intravitreal injection therapy. 
 
The Vitrasert® implant (Chiron Vision Inc, Irvine, CA, USA) which was approved by the USA Food and 
Drug Administration (FDA) in March 1996, has been used with some success in practice. It is a 
sustained-release intraocular implant consisting of semi-permeable polymers with a 6mg ganciclovir 
(GCV) pellet. The polymers employed are non-biodegradable and this causes the implant to have the 
distinct disadvantage of having to be removed from the vitreous humor (VH) once its drug-load has been 
depleted. It is also extremely complicated to produce the Vitrasert® implant as it requires a number of 
carefully controlled coating processes. Since it is manufactured as a two-piece device (a suture tab and 
drug-loaded pellet) there has been several incidences reported where the drug-loaded pellet separated 
from the suture tab once implanted. This has resulted in significant patient discomfort. In addition, the 
cost of such a device is approximately $US 5000 which is not an option for the average CMV-R patient 
with HIV/AIDS living in South Africa or other Developing Countries.  
 
To solve these challenges a novel Donut-Shaped MiniTablet (DSMT) was developed and evaluated as 
a biodegradable intraocular drug delivery system using poly(lactic-co-glycolic) acid polymer 
combinations for rate-modulated delivery of antiviral drugs (Choonara et al., 2006, 2007) (Figure 1.1). 
  2
The DSMT device was manufactured in our laboratories using a special set of punches fitted with a 
central rod in a Manesty tableting press. In previous studies, the erosion kinetics was assessed by 
gravimetric analysis and scanning electron microscopy. The device gradually eroded when immersed in 
simulated vitreous humor (SVH) (pH 7.4, 37°C) and released drugs in a sustained manner. Since the 
device is bioerodible, there will be no need to remove the device once it has released its entire drug 
load. The device is simple to manufacture, and is reproducible since it is produced on a conventional 
tableting press using novel tooling. A digital image of the DSMT device is depicted in Figure 1.1. The 
novel geometric design and veracity of the DSMT device was retained over 24 weeks of in vitro erosion 
indicating that the device was suitable as a biodegradable drug delivery system. When considering the 
duration of drug released from the DSMT device, it was found that by the careful selection of the type 
and concentration of polymer employed in formulating the DSMT device, it was possible to produce a 
device that could release drug for any period up to 12 months (Choonara et al., 2006, 2007). 
 
 
Figure 1.1: A digital image depicting the DSMT device in relation to a typical USA one dime coin. 
 
Although in vitro release testing can supply useful and valid information regarding the release of drug 
from the DSMT device, it cannot totally simulate in vivo conditions. The safety of the DSMT has also not 
yet been evaluated. Therefore, the current research focused on the in vivo evaluation of the DSMT 
device in terms of physical and chemical stability characterization (effect of γ-sterilization), intravitreal 
drug release, toxicity and pharmacokinetics in the New Zealand White Albino rabbit eye model. 
Knowledge of GCV distribution following administration is important if the disease is to be appropriately 
treated and damage to ocular tissues by higher concentrations of drug is to be avoided. When GCV is 
released from the DSMT matrix it must be assumed that the rate of GCV release should be much 
smaller than the concentration of GCV present in the VH. This assumption is reasonable because if the 
introduction of an intravitreal prolonged release device is to serve any purpose, the time over which it 
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releases a useful quantity of drug should be considerably longer than the half-life of the free drug in the 
VH. Therefore pharmacokinetic studies were undertaken to evaluate the GCV levels reached in the VH 
after intravitreal implantation of the DSMT device into the New Zealand White Albino rabbit eye. The 
DSMT device was sutured to the scleral flap where it released GCV over a number of months. Figure 
1.2 shows a schematic comparing the DSMT device and the marketed Vitrasert® device implanted in the 
posterior segment of the human eye. Since the DSMT device is biodegradable, it would not be 
necessary to remove it once the drug-load is depleted (Athanasiou et al., 1990; Bodmeier et al., 1991; 
Colo et al., 1992; Bhardwaj et al., 1998; Avery et al., 1999; Dorta et al., 2002). The device is 
reproducible and easy to manufacture, as it is produced on a conventional tableting press with 
specialized tooling able to produce a disc-shaped minitablet with a perfect central hole.  
 
 
 
 
 
 
 
 
 
Figure 1.2:  Envisaged implantation of the DSMT device in the human eye, (Adapted from Sanborn et 
al., 1992). 
 
Whenever a new device for delivering drugs to the posterior segment of the eye is being considered, it is 
to be expected that many pathological parameters such as retinal tissue toxicity must also receive 
consideration. There is the potential of harm to the eye due to chemical toxicity as a result of polymer 
degradation and higher concentrations of drug within the posterior segment of the eye. Consequently it 
is imperative that the safety of the device be accurately evaluated. Biocompatibility tests can be 
extremely useful. However no one individual test is conclusive proof of compatibility. Therefore, a 
combination of as many tests as is practical and economically viable was employed in this research to 
assess the potential toxicity of the DSMT device. 
 
 
DSMT device
 
DSMT device Vitrasert® device
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1.2. Aim and Objectives of this Research  
 
This research was approached from an impact viewpoint of the pharmaceutical technology 
formulation and development of the DSMT device aimed at considering all factors that are responsible 
for optimization of the DSMT device in terms of its in vivo performance. A drug-loaded DSMT device 
using various poly(lactic-co-glycolic acid) (PLGA) combinations was formulated with GCV employed 
as the model drug. The device was prepared on a Manesty F3 tableting press, using a novel central 
rod and punch setup developed in our laboratories. The specific objectives of this research were:  
 
 To determine the possible effects of irradiation sterilization on the physical and chemical stability of 
the DSMT device. 
 To blueprint and develop a surgical procedure for implantation of the DSMT device in the New 
Zealand White Albino rabbit eye model. 
 To develop a stable and sensitive Ultra Performance Liquid Chromatography (UPLC) assay method 
using 3D chromatography for quantification of GCV from VH samples. 
 To assess the safety, biocompatibility or potential toxicity of the DSMT device. 
 To pharmacokinetically evaluate the in vivo release of GCV from the DSMT device. 
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1.3. Overview of this Thesis 
 
Chapter 1 of this thesis provides a concise background and introduction to the challenges faced with 
current intraocular drug delivery and the rationale for undertaking this research. An ingenuous solution 
to these potential challenges is then defined with reference to previous in vitro studies by Choonara et 
al., (2006; 2007) pertaining to the novel Donut-Shaped MiniTablet (DSMT) device developed for the 
treatment of a common posterior segment eye disease namely, cytomegalovirus retinitis (CMV-R). 
Lastly, a summary of the aims and objectives, approach and methodology embarked on our current 
research is delineated at the end of this Chapter. 
 
Chapter 2 of this thesis provides a comprehensive literature survey on intravitreal implantable device 
technologies for the treatment of posterior segment eye diseases. This section elaborates on the various 
approaches taken by other researchers who have developed drug delivery devices for treating the 
relentless disease and also highlights the pertinent advantages and limitations of these devices, in 
particular the Vitrasert® device.  
 
Chapter 3 of this thesis describes and evaluates the effects of γ-irradiation on the physical and chemical 
stability of the PLGA-based DSMT device loaded with 5%w/w GCV and intended for intraocular 
implantation in the New Zealand White Albino rabbit eye model. The influence of PLGA radiolysis and 
the identification of possible irradiation mechanisms are also discussed after investigations employing 
Fourier Transform Infra-red (FTIR) analysis, porositometry, thermal analysis, textural profiling and 
chemometric model analysis. The DSMT devices were prepared by direct compression technology 
utilizing novel tablet tooling and γ-irradiated for sterilization prior to implantation. The stability of the 
GCV-loaded DSMT device was evaluated on the basis of molecular structural transitions, changes in 
porosity, thermal analysis, physicomechanical profiling and chemometric model analysis. The device 
was found to be desirably stable with no significant transitions in its physicochemical and 
physicomechanical properties that could negatively impact the overall, performance of the device.    
 
Chapter 4 of this thesis delineates the pragmatically undertaken in vivo animal studies performed in the 
New Zealand White Albino rabbit eye model once the stability of the DSMT device was established. This 
  6
component of the research focused on the in vivo investigation of the GCV-loaded biodegradable DSMT 
device in the rabbit eye model. The DSMT was manufactured with PLGA used as the GCV delivery 
platform as it displayed superior control of GCV release during previous in vitro studies. A total of 12 
rabbits were used for the in vivo studies. This Chapter details the implantation procedure of the DSMT 
through the pars plana/peripheral retina of the rabbit eye. The possible adverse effects of the DSMT on 
ocular tissues are also outlined in terms of histomorphological and slit lamp examinations, the 
measurement of intraocular pressure and indirect ophthalmoscopy. The ex vivo micro-environmental pH 
variation studies are also discussed with the use of pH-time profiles. The Chapter concludes with a 
comprehensive discussion of the assay development for GCV content analysis and description of the in 
vivo GCV concentration-time profile obtained after VH and plasma sample retrieval and analysis by a 
liquid-liquid phase extraction technique and 3D Ultra Performance Liquid Chromatography (UPLC) 
technology.   
 
Chapter 5 of this thesis enlightens the reader with the modus operandi of developing a suitable 
pharmacokinetic (pK) model and in vitro-in vivo (IVIVC) correlation to describe the release of GCV from 
the DSMT device in the New Zealand White Albino rabbit eye model. This mathematical and 
computational software-based component of the research focused on compartmental and non-
compartmental pK modeling of GCV release from the DSMT device.  
 
Chapter 6 of this thesis discusses the suitability of the novel DSMT device developed and 
recommendations are provided for future studies in human subjects. 
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CHAPTER 2 
A LITERATURE REVIEW OF INTRAVITREAL IMPLANTABLE DEVICE TECHNOLOGIES FOR THE 
TREATMENT OF POSTERIOR SEGMENT EYE DISEASES 
 
2.1. Introduction 
 
The design of ophthalmic drug delivery systems is a unique challenge that is restricted by the 
anatomical position of the eye as well as the functional physiology of the eye tissues. The eye is a 
relatively isolated organ divided into an anterior and posterior segment with numerous avascular 
structures (Bourges et al., 2006). In this regard, the efficacy of topical drug delivery via eye-drops is only 
limited to the treatment of anterior segment eye diseases. The anterior segment includes the cornea, 
iris, crystalline lens, ciliary body and aqueous humor while the posterior segment comprises the vitreous 
body, retina, and choroid. Historically, the bulk of ophthalmic research focused on drug delivery to the 
anterior segment of the eye (Rapoport, 1977; Velez and Whitcup, 1999). Due to the number of 
protective anterior segment barriers, typically less than 5% of an applied dose via an eye-drop will be 
delivered to the ocular tissues of the anterior segment and almost negligible quantities to none may 
enter the posterior segment if required (Laties and Rapoport, 1976; Cunha-Vaz, 1979; Foulds et al., 
1980; Cunha-Vaz, 1997).  
 
Various attempts have focused on trying to improve the bioavailability of eye-drop formulations. These 
include the addition of viscosity and penetration enhancers such as hydrogel-based polymers (Ahmed 
and Patton, 1985), chelating agents (Schoenwald and Huang, 1983), preservatives (Sieg and Robinson, 
1977), surfactants (Liaw and Robinson, 1992), bile salts (Rojanasakul et al., 1992), the use of prodrugs 
and liposomal carriers (Schoenwald and Ward, 1978), mucoadhesives (Chang and Lee, 1987), 
thermoreponsive gels (Brechu and Maren, 1993), and colloidal particulate formulations (Grass and 
Robinson, 1988). These approaches have the ability to prolong the pre-corneal residence time and 
improve the bioavailability of drugs within the anterior segment (Maren and Jankowska, 1985; Huang et 
al., 1989). However they have no bearing on improving the delivery of drugs to the posterior segment of 
the eye where the majority of sight-threatening diseases are likely to emanate and prevail. 
 
  8
Systemic drug administration has been used to treat a few vitreoretinal diseases (Chang et al., 1988; 
Charles et al., 1991; Urtti et al., 1994). However, previous studies reported that only minimal quantities 
of drug could reach the eye and hence large doses are required to obtain therapeutic drug levels in the 
posterior segment of the eye due to the restrictive blood-ocular barriers. Studies have revealed that the 
systemic route of drug administration for the treatment of posterior segment eye disease results in 
increased peripheral side-effects due to the large doses required for penetrating the blood-ocular 
barriers. Thus diseases affecting the posterior segment of the eye are difficult to treat and take longer to 
combat by employing conventional topical or systemic drug delivery (Maurice, 2001). Therefore 
research has been directed at specialized drug delivery technologies to the tissues of the posterior 
segment of the eye (Winfield et al., 1990; van Ooteghem, 1993; Visor, 1994; Lang, 1995; Le Bourlais et 
al., 1998; Oyster, 1999; Geroski and Edelhauser, 2000; Mort, 2000; Van Santvliet and Ludwig, 2004; 
Baudouin, 2005; Gulsen and Chauhan, 2005; Hosoya et al., 2005; Salyani and Birt, 2005; Barbu et al., 
2006; Choonara et al., 2006; 2007). 
 
2.2. The blood-ocular barriers: An impediment to intraocular drug delivery 
 
The blood-ocular barriers located at the level of the retinal vascular endothelial cells and retinal pigment 
epithelium inhibits the entry of drugs from the systemic circulation into the retinal tissue. The 
circumstances at the blood-ocular barriers are better understood considering two main barrier systems 
present (Figure 2.1). The blood-aqueous barrier regulates the exchange between the blood and 
intraocular fluid and concerns primarily the ciliary body where inward movements from the blood into the 
eye predominate. Aqueous humor is secreted into the posterior segment by the ciliary processes 
through the pupil into the anterior segment and leaves the eye by bulk flow at the segment angle by the 
trabecular or uveoscleral routes. Diffusional solute exchange between the aqueous humor and 
surrounding tissue, the posterior segment, and the vitreous compartment exists (Hayreh et al., 1966). 
The other well defined barrier is the blood-retinal barrier responsible for homeostasis of the 
neuroretina and involves the outward movement of substances from the eye into the blood while the 
penetration of only a few important metabolic products is allowed into the eye. Hence the vitreous humor 
is located between the blood-aqueous barrier anteriorly and the blood-retinal barrier posteriorly. The 
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extent of drug absorption intended to be delivered to the posterior segment of the eye is therefore 
severely hampered by these physiological barriers (Cunha-Vaz, 1979). 
 
BLOOD BLOOD
RET
AC VITREOUS HUMOR
PC
 
Figure 2.1: Schematic of the blood-ocular barriers, RET (retina); PC (posterior segment); AC (anterior 
segment), (Reproduced with permission from: Cunha-Vaz, 1979). 
 
2.3. Potential sites for intraocular drug delivery device implantation and mechanisms of drug 
release 
Currently, commercialized ocular drug delivery systems have been limited to the administration by 
topical and intravitreal routes. However, both clinical and non-clinical studies are ongoing to evaluate 
systems administered by subconjunctival, sub-tenon’s capsule, intrascleral, subretinal, and 
suprachoroidal routes as well as improvements to topical application by using unique fornix devices or 
punctual placement (Figure 2.2). Systemic delivery using oral tablets is still a viable alternative to 
ocular administration, although unique delivery systems may not be preferred as it is usually easier for 
patients to comply with normal oral medication schedules, even if given more than once a day, 
instead of undergoing a surgical implantation procedure. 
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Figure 2.2: Potential sites for ocular drug delivery device administration (Reproduced with permission 
from Weiner, 1994).  
 
An intraocular device can be designed as either a reservoir or matrix system. Reservoir systems are 
non-eroding devices that provide superior control of drug release by virtue of a specific physical rate 
control feature linked with the internal drug reservoir. This feature may be an opening in the device, a 
porous membrane or a coating through which drug diffusion is retarded. It is easier to achieve zero-
order drug release kinetics using a reservoir system as there is only a single rate controlling variable 
that may impact drug delivery. In order to engineer non-eroding intraocular devices, there are a 
number of useful biocompatible biomaterials such as the polyimides, polysulfones, polyvinyl alcohols, 
polyvinylidine fluorides, ethylene vinyl acetates, siloxane polymers, and various methacrylate and 
ethylacrylate polymers. Alternatively, in a matrix system, drug is co-mixed with the rate controlling 
polymer. A matrix device can be engineered to produce zero-order drug release kinetics, for example, 
if the polymer is non-eroding and the release is then governed by polymeric chain relaxation and the 
dissolution rate of the drug. However, in such a device, the drug concentration must be high enough 
such that, when erosion occurs from the matrix, it produces sufficient fenestrated channels in the 
device for aqueous diffusion media to reach the internally located drug particles. In a non-eroding 
matrix system, the strength or resilience of the device could be compromised as diffused drug 
produces a series of interconnected voids through the device.  
 
If the polymer in the matrix device is bioerodible then the device may exhibit more complex drug 
release kinetics due to the erosion factor of the polymer which may contribute independently to the 
drug dissolution or diffusion behavior, unless the geometry of the device is considered to produce a 
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constantly eroding drug releasing  surface. In addition, biodegradable polymers may erode, either by 
bulk and/or surface erosion. Poly-lactides, poly-glycolides, and polycaprolactone polymers are the 
most common biocompatible polymers employed for the design of biodegradable intraocular drug 
delivery matrices. Surface eroding biodegradable polymers include certain polyanhydrides and 
polyorthoesters. Generally, for intraocular drug delivery, the selection of a particular system depends 
on the duration that is anticipated for treatment of the disease site. It is also critical to have drugs with 
potencies in the μg/day range, to accommodate the limited space in the human eye. Other aspects of 
ophthalmic drug delivery systems have been presented elsewhere (Weiner, 1994; Kumar, 2000; 
Chowhan et al., 2002; Edlund and Albertsson, 2002; Divvuri et al., 2003; Davis et al., 2004; Heller, 
2005; Hughes et al., 2005; Ludwig, 2005; Ghate and Edelhauser, 2006). 
 
2.4. Various approaches employed for ophthalmic drug delivery to overcome the blood–ocular 
barriers 
 
A number of approaches for drug delivery to the posterior segment of the eye have been explored over 
the last few decades (Lloyd et al., 2001). These approaches include direct intravitreal injection of drug 
solutions, drug-loaded microparticle carriers such as microspheres, nanospheres (Diebold et al., 2007), 
and liposomes (Moritera et al., 1991; Veloso et al., 1997), transscleral drug delivery devices (Lee et al., 
1999; Ambati et al., 2000), targeting of drugs via the systemic circulation (Ogura et al., 1993), and 
intravitreal devices using polymers (Sanborn et al., 1992; Martin et al., 1994, 1999). 
 
2.4.1. Direct intravitreal injection 
Direct intravitreal injection of drugs into the vitreous cavity is employed to achieve higher drug 
concentrations in the vitreous and the retina (Smith et al., 1992; Akula et al., 1994; Yang et al., 1998; 
Benz et al., 2006). However, repeated injections are needed to maintain drug concentrations at an 
effective therapeutic level over a certain period of time since the half-life of drugs in the vitreous is 
relatively short. Repeated intravitreal injections results in extreme patient discomfort and may lead to 
complications such as vitreous hemorrhage, infection, and lens or retinal injury. The direct intravitreal 
injection route of drug administration is able to reduce the systemic side-effects and depending on the 
formulation approach it may be capable of retarding drug release. However intravitreal injections 
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introduce further challenges, such as the progression of endophthalmitis and cataract due to repeated 
injections (Heinemann, 1989) (Figures 2.3a and b). 
 
a) b)
 
Figure 2.3: Digital images of a) a human eye showing a case of endophthalmitis and b) an intravitreal 
injection made at the ora serrata (Reproduced with permission from Yoon et al., 2009). 
 
 
Intravitreal injection of sustained-release drug delivery systems such as microspheres (Herroro-Vanrell 
et al., 2000), lipospheres (Cheng et al., 2000; 2002) and nanospheres (Merodio et al., 2002; Bonferonia 
et al., 2004; Yasukawa et al., 2004; Kassem et al., 2007; Motwani, et al., 2007) offer attractive options. 
Colloidal-based systems are capable of delivering drug over a longer period of time than conventional 
intravitreal formulations used for injection into the vitreous cavity. Microparticles like microspheres or 
liposomes can be injected into the vitreous cavity with a fine needle and are able to release drug in the 
vitreous and maintain concentrations at a therapeutic level over a certain period of time (Le Bourlais et 
al., 1996; Martinez-Sancho et al., 2004). Microspheres of biodegradable polymers such as poly(lactic 
acid) (PLA) or poly(lactic-co-glycolic acid) (PLGA) have shown to effectively deliver drugs to the vitreous 
and retina and can be tolerated by the ocular tissues (Kimura et al., 1992; 1994). Microspheres consist 
of a polymer matrix, which erodes over time releasing drug that is dispersed within the matrix. Drug 
release kinetics from polymeric microspheres could be controlled by changing the molecular mass of the 
polymers or the co-polymerization ratio of PLA and PLGA. Bioerodible polymeric microspheres were 
shown to be effective in the treatment of ocular infections such as cytomegalovirus retinitis (CMV-R) 
(Moritera et al., 1991; Akula et al., 1994; Veloso et al., 1997). Figure 2.4 depicts scanning electron 
microscopy (SEM) images of PLGA microspheres developed by Hickey and co-workers (2002). 
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Figure 2.4: SEM images of poly(lactide-co-glycolide) microspheres (Reproduced with permission from 
Hickey et al., 2002). 
 
The pharmaceutical world is becoming more and more aware of intraocular drug delivery challenges, 
and revolutionary therapeutic advances are being invented and implemented which may have the 
potential to vastly improve patient care and quality of life. Among these most promising developments 
are intravitreal drug delivery devices designed to deliver drugs with precision directly to the vitreous, 
retina, and choroid (Ashton et al., 1992; 2000). 
 
2.4.2. Intravitreal implantable device technology 
Implantable sustained-release intravitreal device technology has been given much impetus due to the 
perceptible benefits afforded over the use of topical eye-drops, systemic drug administration and direct 
intravitreal injections as modes of drug delivery to the posterior segment of the eye as described earlier 
(Yasukawa et al., 2005; Sultana et al., 2006). Solid biocompatible implantable devices for sustained or 
controlled intravitreal drug delivery to the posterior segment of the eye have been developed employing 
diverse approaches and includes the use of implantable devices such as osmotic mini-pumps, non-
bioerodible and bioerodible drug-loaded pellets, configured capillary fibres, biodegradable scleral plugs, 
scleral discs, polymeric matrices and scaffolds of various geometries providing unique mechanisms of 
drug release for the delivery of drugs to the posterior segment of the eye (Ding, 1998; Herrero-Vanrell 
and Refojo, 2001; Barbu et al., 2005; Choonara et al., 2006; 2007). The intraocular structures are easily 
(and visually) accessible and are confined and isolated from the systemic circulation by the inner and 
outer blood-ocular barriers that allow for the local delivery of drugs. Furthermore, the eye benefits from 
an “immune privilege” particularly observed in the anterior segment and in the sub-retinal space, limiting 
the risk of an exaggerated inflammatory reaction to foreign antigens and cell graft rejection (Danckwerts 
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and Fassihi, 1991). In a study by Danckwerts and co-workers (1991), the advantages offered by 
intravitreal implantable delivery systems have been published and are listed in Table 2.1. However, such 
systems are not without their risks. These are highlighted throughout the course of this Chapter. 
 
Table 2.1: Advantages offered by intravitreal implantable drug delivery systems. 
 
 Drugs are delivered close to their target sites of action and undesirable effects on other sites in the 
body are minimized. 
 For drugs that cannot be administered by other routes and where compliance is likely to be a major 
challenge. 
 In cases of extreme allergies or side-effects to drugs already administered, immediate removal of 
implantable devices is possible in contrast to injectable drug delivery systems.   
 Less drug is required to treat the disease state, minimizing possible side-effects and enhanced 
efficacy of treatment.  
 Capable of protecting drugs which are unstable in vivo and that would normally require frequent 
dosing intervals. 
 The improved sustained release action offers better patient compliance. 
 They bypass the blood-ocular barriers allowing higher intraocular drug levels than could be 
achieved by systemic administration. 
 
(Source: Danckwerts and Fassihi, 1991; Musch et al., 1997) 
 
2.4.2.1. Bioerodible and non-bioerodible intravitreal implantable devices 
Bioerodible and non-bioerodible implantable devices have been developed with the drug release 
kinetics dependant on both the solubility and diffusion coefficient of the drug in the polymer, the drug-
loading capacity, the device configuration and the in vivo degradation rate of the polymer. There are 
several major factors to consider during the development of implantable intravitreal drug delivery 
devices. Biocompatibility is essential and all components are required to be chemically inert, non-
carcinogenic, hypoallergenic, and mechanically stable at the implantation site. Furthermore, the material 
should not be physically or chemically modified by local tissue nor cause any unexpected immune or 
inflammatory response at the site of implantation (Zaheer et al., 1982; Park and Park, 1996). The overall 
development of these devices can be both time-consuming and complex, and may consist of various 
stability and biocompatibility tests.  
 
Non-bioerodible devices are able to offer the advantages of sustained release and reduced host 
response. However, bioerodible intravitreal drug delivery devices have gained much popularity over 
non-bioerodible devices due to the fact that they are eventually absorbed or excreted by the body 
eliminating the need for surgical removal of the device after the drug-load has been depleted thereby 
increasing patient acceptance and compliance (Wood, 1980; Lewis, 1990). However, developing 
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bioerodible devices is a more complicated task as numerous variables such as the in vivo erosion 
kinetics of the polymer is required to remain at a constant rate in order to maintain sustained-release of 
the drug, yet their benefits far supersede these challenges. Furthermore, numerous factors may affect 
the rate of in vivo polymer erosion. Alterations in body pH or temperature may cause a transient 
increase or decrease in the erosion rate of the device. The surface area of the drug delivery device also 
plays a significant role in its erosion. As erosion proceeds the surface area of the device decreases. 
Thus, changes in the shape of the device need to be taken into account during the formulation design. 
In order to attain uniform and constant release kinetics it is therefore necessary to use geometrical 
shapes with surface areas that do not drastically change as a function of time during erosion (Graham, 
1978). Another challenge with bioerodible devices is the extremely slow diffusion of drug from the 
polymeric matrix (Danckwerts and Fassihi, 1991). Diffusion of drug usually occurs at a slower rate than 
the bioerosion of the device and is dependent upon the chemical nature of the polymeric substance 
utilized in the formulation of the device. This poses a significant challenge to overcome in situations 
where the drug has a narrow therapeutic index (Dash and Cudworth II, 1998). 
 
2.5. Specialized intravitreal implantable technologies for the treatment of anterior and 
posterior segment eye disease 
 
2.5.1. A mucoadhesive hydrogel-based thin coiled metallic wire device (Ophthacoil) 
Pijls and co-workers (2004; 2005) have developed an intraocular drug delivery device called 
“OphthaCoil” that is implanted in the conjunctival fornix after ethylene-oxide gas sterilization (Figure 2.5). 
The device consists of a drug-loaded mucoadhesive hydrogel on a thin coiled metallic wire providing the 
device with flexibility and integrity. The ends of the coil are capped using a photo-curable cyanoacrylate 
adhesive. On contact with tear fluid the hydrogel coating swells and drug is released into the tear film. 
The OphthaCoil device has been shown to be well tolerated in the eyes of Beagle dogs and results have 
shown that the device is able to release ciprofloxacin for the treatment of bacterial infections in the 
posterior segment of the eye as well as for conjunctivitis or keratitis over a period of 16 hours (Parks et 
al., 1993; Pijls et al., 2005). In order to improve the drug-loading capacity and the drug release kinetics 
two further approaches were explored where the interior of the coil was used as an additional drug 
reservoir and poly(2-hydroxyethyl methacrylate) and poly(2-hydroxyethyl methacrylate-co-1-vinyl-2-
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pyrrolidone) polymeric microspheres were incorporated as drug carriers (Rosemary et al., 2003). In vitro 
drug release profiles revealed a six-fold increase of the drug-loading capacity. Preliminary in vivo 
evaluation of the Ophthacoil device was performed over a 2 hour period to assess the tolerance of the 
device in the human eye. Ophthalmologic examinations of the eye indicated no signs of irritation. An 
Ophthacoil device with a drug bioavailability of 50% can be compared to 8-12 eye drops and the 
researchers foresee several potential applications of the device such as for the treatment of corneal 
ulcers, severe bacterial conjunctivitis, fungal keratitis and controlled delivery of drugs to the posterior 
segment of the eye, prior to cataract surgery (Iyer et al., 2006). Depending on the potency of the 
antibiotic agent, sustained delivery over a minimum of 5 hours could be achieved (Pijls et al., 2004; 
2005). It is not surprising that the use of an intraocular device that consists of a metallic core may 
cause concern even though the wire may be thin (76μm in diameter) and the coil is extremely flexible. 
However, according to Pijls and co-workers (2005; 2007) who have developed the OphthaCoil device, 
there is no contact between the metal wire and the ocular epithelium due to the hydrogel coating and 
the polymer caps. The essential role of the coiled metallic wire is to ensure device integrity throughout 
the application time window. Further proposed advantages of the Ophthacoil device (owing to the use 
of a metallic substrate) are the possible removal of the device with a magnet (instead of tweezers) 
and the enhanced x-ray visibility of the metallic coil, which is a purported safety issue. A disadvantage 
of the Ophthacoil device is the fact that removal of the device is required after the drug-load is 
depleted. However, the insertion and removal of the insert could be combined with controlled clinical 
examinations (Pijls et al., 2007). Reminiscent designs are discussed later in this Section, such as the 
I-vation® triamcinolone-coated screw that was developed by SurModics (Pty) Ltd. (Eden Prairie, MN, 
USA), as a vehicle for drug delivery to the posterior segment of the eye. 
 
 
 
Figure 2.5: Image of the OphthaCoil drug delivery device (Reproduced with permission from Pijls et al., 
2007). 
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2.5.2. An imprinted hydrogel contact lens device  
Zero-order or concentration-independent release kinetics is highly desirable from drug delivery devices. 
Ali and co-workers (2000), have demonstrated zero-order release of low molecular mass, ketotifen 
fumarate (MW=425g/mol), from a molecularly imprinted hydrogel device used as therapeutic contact 
lenses. In vitro drug release studies were performed within a novel microfluidic device that was able to 
simulate the volumetric flow rates, tear volume and tear composition of the eye (Figure 2.6). Imprinted 
gels with multiple functional monomers and complexation points to the drug demonstrated delayed drug 
release kinetics compared to less functionalized systems. Under infinite sink conditions, the imprinted 
contact lenses demonstrated Fickian release kinetics with diffusion coefficients ranging from 4.04×10−9 
to 5.57×10−10cm2/s (Ali et al., 2000). The authors reported the highest functionalized gel to exhibit a 
diffusion coefficient averaging <10 times than minimally functionalized hydrogels and released ketotifen 
over 5 days with 3 distinct rates of release. Under physiological volumetric flow rates, the release rate 
was constant for a duration of 3.5 days delivering a therapeutic dose and was fitted to a Power Law 
model indicating zero-order release with n=0.981±0.006 (R2=0.99). The device has the potential for 
molecular imprinting to further tailor the drug release kinetics via the imprinting process. However, it is 
rather complicated to produce and requires several intricate design processes to affect the 
reproducibility of the molecular imprinting technology employed. In addition, the device has shown to 
release drug only up to 5 days with three distinct rates of drug release. This may not be suitable for 
posterior segment eye diseases that require chronic suppressive maintenance therapy over several 
weeks to months.    
 
 
 
PDMS chip
Fluidic channels 
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Sample collection
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Figure 2.6: Schematic of the micro-fluidic chip design with physiological ocular flow for contact lens drug 
delivery evaluation (Reproduced with permission from Ali et al., 2000). 
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2.5.3. A cyclosporine-loaded discoid device  
Gilger and co-workers (2000) reported on a discoid intravitreal device developed for the constant 
release of cyclosporine-A (CsA) in inflammatory episodes of uveitis in horses (Figure 2.7). This was 
accomplished by measuring clinical signs, intraocular damage, cellular infiltrates, and T-lymphocyte 
counts in conjunction with the associated level of transcribed cytokine specific mRNA. The effects of the 
device on recurrent inflammatory episodes in experimental uveitis were determined. Nine healthy horses 
were immunized peripherally with H37RA-mTB antigen twice, and then received 25mg of H37RA-mTB 
antigen intravitreally in the right eye and an equal volume of balanced salt solution intravitreally in the left 
eye. Two weeks later, the animals randomly received either the CsA-loaded device or a placebo in both 
eyes. One week after implantation of the devices, 25mg of H37RA-mTB antigen was re-injected into the 
right eye of each animal. Clinical signs of ophthalmic inflammation were graded following injections and 
implantation. Aqueous and vitreous humor protein levels, infiltrating cell counts, total number of T-
lymphocytes, and levels of IL-2 and IFNg-mRNA were significantly less in eyes containing the CsA 
device compared to the eyes with the placebo. The CsA devices did not completely eliminate the 
development of a recurrent experimental inflammatory episode in the horse model. However, the 
duration and severity of inflammation, cellular infiltration, tissue destruction, and pro-inflammatory 
cytokines RNA transcript levels were significantly less in eyes implanted with the CsA devices (Gilger et 
al, 2000). Results from the study demonstrated the effectiveness of the CsA delivery device for the 
treatment of immune-mediated intraocular inflammation. However the efficacy of the device in human 
subjects is yet to be reported.   
 
 
 
 
 
Figure 2.7: Slit-lamp image showing a cyclosporine device in the inferotemporal quadrant. The patient 
is pseudophakic (Reproduced with permission from Jaffe et al., 1998). 
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2.5.4. A Gelfoam®-based device for the delivery of insulin 
Lee and co-workers (1997; 1999b), have delivered insulin employing an acidified absorbable gelatin 
sponge-based (Gelfoam®) (Pharmacia & Upjohn Company, Division of Pfizer Inc., NY, USA) 
intraocular device that can be efficiently absorbed into the systemic circulation without the aid of an 
absorption enhancer. The Gelfoam® device is soft and pliable and may be worn with contact lenses. 
The Gelfoam® device is approximately 6mm in diameter with a 2mm thickness and is excised from a 
slab of Gelfoam® sponge comprising 0.2mg of Zn-insulin dissolved in a 30mL solution of 10%v/v acetic 
acid in water. The Gelfoam® insulin-loaded device was evaluated in the rabbit eye model. Results 
suggested that a change in the Gelfoam® upon treatment with acid was responsible for the systemic 
absorption of insulin from the device. Generally an absorption enhancer is required for the systemic 
absorption of insulin delivered by the ocular route (Chiou and Chuang, 1989; Yamamoto et al., 1989; 
Chiou et al., 1990; Chiou, 1991; Hopper et al., 1991; Chiou and Li, 1993; Bartlett et al., 1994a, b; Sasaki 
et al., 1994; 1995; Morgan 1995; Pillion et al., 1995; Morgan and Huntzicker 1996; Simamora et al., 
1996; Negvesky et al., 1999). Lee and co-workers (1997a) showed that the device could provide a 
uniform blood glucose reduction over 8 hours with the aid of Brij-78 as an absorption enhancer. 
Furthermore, this group (Lee et al., 1997b) also showed that similar results could be obtained from 
enhancer-free devices to which acetic acid had been added and removed by evaporation. They have 
shown that acetic acid enhances the systemic absorption of insulin from the gelatin-based devices by 
the intraocular route. The pH of tear fluid changed from a pH value of 7 to 5 immediately after the 
instillation of the acid-treated device and returned to pH 7 within 5 minutes while absorption continued 
for over 8 hours (Figure 2.8a and b). This indicated that tear pH was not responsible for enhancing the 
absorption of insulin (Lee et al 1999). Overall, the data suggested that the enhancement of the 
absorption of insulin is due to a change in the Gelfoam® upon acid treatment. This was confirmed by the 
devices that were not treated by acid and were inactive whereas those that were acid treated were 
active. While neither the chemical composition nor the mechanism by which the device functions are 
clearly understood, it is clear that the interaction of gelatin with dilute acetic acid produces a potent 
enhancer which promotes the systemic absorption of insulin delivered via the intraocular route. Although 
the Gelfoam® device is currently employed for the systemic delivery of drugs via the ocular route, future 
research into the applications of this device may realize its potential for the intraocular delivery of drugs 
to the posterior segment of the eye. 
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Figure 2.8: a) Experimental set-up for the determination of Zn-insulin concentrations released from the 
Gelfoam® device and b) chemical structures of the various compounds comprising the Gelfoam®-based 
device (Reproduced with permission from Lee and Yalkowsky, 1999). 
 
 
 
2.5.5. An ethylene vinyl acetate and poly(vinyl) alcohol reservoir device (Vitrasert®) 
Non-biodegradable polymers were first used clinically for intraocular sustained release of ganciclovir in 
the treatment of cytomegalovirus retinitis (CMV-R) (Sanborn et al., 1992; Musch et al., 1997). The 
Vitrasert® reservoir-type device (Chiron Vision Inc., Irvine, CA, USA), is composed of drug and polymeric 
coats of polyvinyl alcohol (PVA) and ethylene vinyl acetate (EVA). The device is implanted in patients 
requiring the treatment of CMV-R. PVA, a permeable polymer regulates the rate of ganciclovir 
permeation through the device (Figure 2.9). EVA, an impermeable polymer, limits the surface area of 
the device through which ganciclovir can be released. The device has shown to have no initial burst 
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effect. The commercially used device requires a 4-5mm sclerotomy at the pars plana for implantation. 
Furthermore, because the device is non-biodegradable, the drug depleted device needs to be removed 
during a second surgery in order to implant another device if required. The complications related to 
multiple implantations are vitreous haemorrhage, rhegmatogenous retinal detachment, endophthalmitis, 
and cystoid macular oedema with epi-retinal membrane, which occurred in 12% of eyes in one study 
(Lim et al, 1999). The same type of implant containing dexamethasone, fluocinolone acetonide, or 
cyclosporine is being tested to treat severe uveitis (Jaffe et al., 1998; 2000; 2000). The sustained 
release of triamcinolone and 5-fluorouracil (5-FU) was studied in the treatment of experimental 
proliferative vitreoretinopathy (PVR) (Yang et al., 1998). However, the sustained release of these 
steroids may cause secondary glaucoma and cataract. Many candidate drugs tested for the treatment of 
age-related macular degeneration (AMD) may be applicable using the sustained release Vitrasert® 
device. Furthermore, occasional endophthalmitis and an increased rate of retinal detachments have 
been reported after implantation of the Vitrasert® device (Bourges et al., 2006). Most patients are 
expected to experience an immediate and temporary decrease in visual acuity which lasts for 
approximately 2-4 weeks post-operatively that is attributed to the surgical procedure. Nevertheless, the 
Vitrasert® device has witnessed the most clinical success to date as an intraocular device and has been 
extensively used for the treatment of CMV-retinitis. Other devices such as the Retisert® and Medidur® 
(Bausch & Lomb Inc., Rochester, NY, USA) devices have since been developed and refined based on 
the clinical success of the Vitrasert® device.    
 
 
 
Ethyl vinyl 
acetate 
membrane
Polyvinyl 
alcohol 
shell
Ganciclovir 
pellet 
Suture tab
C
ornea
Vitreous 
humor
 
 
Figure 2.9: Schematic of the non-biodegradable Vitrasert® device implanted in the human eye 
(Reproduced with permission from Smith et al., 1998). 
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2.5.6. The Retisert® and Medidur® devices 
Retisert® (Bausch & Lomb Inc., Rochester, NY, USA) is a reservoir-based fluocinolone-loaded implant 
designed to provide drug release over a period of approximately 1,000 days (Figure 2.10). The implant 
contains 0.59mg of drug, and delivers 0.5μg/day of the corticosteroid, fluocinolone (Kupperman, 2006). 
However, significant ocular side-effects are noted with the device. The concept of a small quantity of 
drug can be effective; however, this also highlights the efficacy of the drug delivery device. There have 
been uveitis and diabetic macular edema (DME) trials undertaken with the Retisert® technology, but 
currently the device is indicated for uveitis only. While a benefit is seen in both conditions, the ocular 
side-effects of the device are significant enough that limits its indication to uveitis. The device has shown 
significant efficacy with 1 year post-implantation (the recurrence rate for uveitis was 5.4% compared with 
46% in the control eye). In the case of DME with an extensive cystoid component, complete resolution 
of fluid was noted 6 weeks after implantation and the pre-existing laser spots that were previously 
invisible with edema were visible. The challenge is the ocular side-effects of steroids, where a 50% rate 
of glaucoma was observed which is unacceptable in DME patients. Additionally, cataracts are almost 
ubiquitous after 3 years of implantation and 93% of eyes require cataract surgery compared to 20% in a 
control group (Kupperman, 2006). In addition, reported surgical complications of the device have 
included choroidal detachment, endophthalmitis, hypotony, retinal detachment, vitreous haemorrhage, 
vitreous loss and exacerbation of intraocular inflammation. When considering such devices, 
cognisance must be taken of the ultimate risk-benefit ratio. In a recent National Institutes of Health 
(NIH) sponsored 5-year clinical trial the effectiveness of the Retisert® device as compared with 
conventional therapy (oral corticosteroids) in the management of posterior uveitis is being evaluated 
in 400 patients at 20 sites throughout North America. The Medidur® device (Bausch & Lomb Inc., 
Rochester, NY, USA) also contains fluocinolone, but it is a much smaller device (Figure 2.10). The 
device is easier to surgically implant and must be performed through a 3.5mm incision with a 25G 
needle. It is a reservoir-type non-biodegradable implant that is not sutured to the eye wall and floats 
freely in the vitreous space. A Phase 3 clinical trial is underway for the treatment of uveitis with limited 
safety data acquired from 20 patients with 900 patients in a larger Phase 3 clinical trial for the treatment 
of DME (Kupperman, 2006). There are two separate studies under evaluation - one device that 
releases fluocinolone for 18 months and another for 36 months. Medidur® may thus hold some 
advantage over Retisert®. It has been shown to have a more favorable ocular hypertension side-effect 
  23
profile. This may be due to the positioning of the device relative to the ciliary body and/or the 
trabecular meshwork (anteroposterior implant localization in the eye). The manufacturers are 
undertaking investigations to evaluate the validity of this statement. 
 
 
Figure 2.10: Comparison of the sizes of the Medidur®, Retisert®, and Vitrasert® implants (Reproduced 
with permission from Kuppermann, 2006). 
 
2.5.7. A micro-electromechanical device 
A micro-electromechanical (MEM) intraocular drug delivery device was investigated by Li and co-
workers (2007), for the treatment of incurable ocular diseases (Figure 2.11). Unlike conventional ocular 
drug delivery devices, the MEM device is capable of being refilled, features electronic control of drug 
delivery, and enables targeted intraocular drug delivery. The refillable design permits long-term drug 
therapy and avoids repetitive surgeries. Electronic control of dosing is achieved by using electrolysis-
actuated pumping to deliver drugs directly to the posterior segment of the eye. A flexible transscleral 
cannula allows targeted delivery to tissues in both the anterior and posterior segments of the eye. The 
device has demonstrated to provide flow rates suitable for ocular drug therapy from pL/min to L/min. 
Both continuous and bolus drug delivery modes may be used to achieve accurate delivery of a target 
volume of 250nL of drug. An encapsulation packaging technique was developed for acute surgical 
studies and preliminary ex vivo drug delivery experiments in porcine eyes were performed. To deliver 
drug into the eye, the device is actuated by manually depressing the drug reservoir. This action 
generates an overpressure in the reservoir which in turn causes a check valve in the cannula to open 
and allow drug to enter the intraocular space (Figure 2.11a). Upon depletion of drug, the drug reservoir 
is refilled by puncturing the reservoir wall with a syringe needle and emptying the syringe into the 
reservoir. To achieve variable delivery rates and the ability to select either bolus or continuous delivery, 
an active device having electrochemically driven drug delivery was also investigated (Li et al, 2007). The 
drug delivery device consists of an electrolysis pump, drug reservoir, and transscleral cannula. The 
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electrolysis pump consists of two inter-digitated platinum electrodes immersed in an electrolyte. The 
electrode geometry improves the pumping efficiency by reducing the current path through the solution 
which also serves to lower the heat generation (Belmont and Girault, 1994). When current or voltage is 
applied, with the drug as an electrolyte, electrolysis of water in the drug at the electrodes produces 
oxygen and hydrogen gases. The gases generated result in an internal pressure increase in the sealed 
reservoir which causes drug to be released through the cannula and into the eye. Electrolysis is a 
reversible process and ceases when the applied current or voltage is switched off. This allows the 
gradual recombination of hydrogen and oxygen to water. Drug is stored in a reservoir integrated on top 
of the electrolysis pump. Preliminary ex vivo testing was performed demonstrating the feasibility of the 
MEM device for intraocular drug delivery (Li et al 2007). However, the device is extremely difficult to 
produce and requires significant patient intervention to achieve the required therapeutic efficacy. This 
may not be suitable for chronic intraocular drug therapy.  
 
a)
b)
 
Figure 2.11: Schematic diagrams of a) A cross-section of the micro-electrochemical drug delivery 
device depicting electrochemical pumping of drug into the eye, and b) illustration of the implanted device 
under the conjunctiva in the anterior segment of the human eye (Reproduced with permission from Li et 
al 2007).  
 
2.5.8. Poly(lactic) acid scleral plug devices 
Vitreoretinal drug delivery with biodegradable scleral plug devices have been investigated (Figure 2.12). 
The drug-loaded scleral plugs of various dimensions comprise biodegradable polymers and can be 
implanted at the pars plana and gradually release effective doses of drugs with polymer biodegradation 
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over several months. For instance, the biodegradable scleral implant (Figure 2.12a and b) 
(mass=8.5mg; length=5mm) is prepared from poly(DL-lactide) (PLA) or poly(DL-lactice-co-glycolic acid) 
(PLGA) and contains various quantities of ganciclovir (GCV). The release profiles of GCV are 
dependent on the type of polymers used, the polymer molecular mass, and the quantity of GCV loaded. 
Once implanted the implantation site is replaced with connective tissue. Electroretinography and 
histological studies revealed minimal retinal toxicity. The implantable scleral plug may be advantageous 
for diseases such as CMV-R that respond to repeated intravitreal injections and for vitreoretinal 
disorders such as proliferative vitreoretinopathy that require vitrectomy. Other scleral devices such as 
the non-erodible, refillable reservoir device and coated coil matrix (Figures 2.12c and d) have also been 
developed. The devices can be implanted at the pars plana without a suture through a scleral incision. 
Since it comprises biodegradable polymers or is refillable it does not need to be removed once the drug-
load is depleted. Release profiles obtained from the scleral plug devices generally have a tri-phasic 
release pattern depicted by i) an initial burst effect, ii) a diffusional release phase, and iii) a final burst 
phase. The duration and the rate of GCV release is affected by the molecular mass and the co-
polymeric ratio, the total surface and volume of the matrices, and the drug-loading. Blending of PLA with 
various molecular masses prolonged the linear release of GCV (Yasukawa et al, 2001). A 10% GCV-
loaded scleral implant prepared from PLA (Mw=130,000g/moL) released GCV in vitro over a period of six 
months (Ogura, 1998). The in vivo release and biodegradation were studied using 25% GCV-loaded 
plugs comprising PLGA (75/25; Mw=121,000g/moL) in pigmented rabbits. The GCV concentration in the 
ED50 range of for human CMV-R was maintained in the vitreous for over 3 months and in the 
retina/choroid for over 5 months. The GCV concentration was greater in the retina/choroid than in the 
vitreous throughout the study. The scleral plugs showed two distinct phases of biodegradation, a lag-
time followed by erosion. During the erosional phase, the mass of PLGA was significantly reduced with 
the plugs being separated into two pieces at the site of scleral penetration and displaced into the 
vitreous 10 weeks after implantation. The fragments disappeared from the vitreous and the sub-
conjunctival space 5 months after implantation (Kunou et al, 1995). However, scleral plug devices do 
bring their own disadvantages, such as a second burst in the late phase of drug release. Therefore 
researchers have explored different geometrical designs in order to circumvent the undesirable drug 
release kinetics obtained and have investigated the use of scleral discoid-shaped and donut-shaped 
devices for more controlled drug releasing surface kinetics.   
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Figure 2.12: Images of a) the scleral plug drug delivery device, b) illustration of the device implanted 
through the scleral in the human eye, c) non-eroding reservoir device allowing for re-injection of 
depleted bioactive and d) non-eroding metal coil with a matrix coating (Reproduced with permission 
from Weiner, 1995; Ogura, 1998; Yasukawa et al., 2001; Varner, 2004). 
 
2.5.9. A scleral discoid device 
A scleral discoid device was developed to release triamcinolone acetonide (TA) over several months 
(Breton et al., 1998; Chan et al., 2004). Scleral disks were manufactured by a compression-molding 
method using the synthetic polymer, poly(methylidenemalonate) (PMM2.1.2), as the matrix (Figure 
2.13). PMM2.1.2 is a synthetic polymer that has been mainly used for the manufacture of particulate 
systems (Roy et al., 1997). Its use for the development of intraocular implants has been advocated 
since its non-toxic and biodegradable leading to the formation of ethanol and glycolic acid as by-
products (Breton et al., 1994; Lescure et al., 1994). The scleral discoid device displays superior 
physicomechanical properties adapted for in vivo intraocular implantation when high molecular mass 
PMM2.1.2 (100-150kDa) associated with ethoxylated derivatives of stearic acid (SimulsolTM, Seppic Inc., 
Fairfield, NJ, USA) or oligomers of methylidenemalonate as a plasticizer are used. After implantation in 
rabbit eyes, the scleral discoid device displayed ocular biocompatibility. Clinical follow-up and ocular 
inflammation parameters, such as inflammatory cell counts and protein content in the aqueous humor 
demonstrated that the devices did not provoke abnormal inflammation. The scleral device was able to 
release TA in the vitreous and the sclera over a period of 5 weeks. The study by Felt-Baeyens and co-
workers (2006), also supported the fact that the scleral route is promising for the treatment of posterior 
segment eye disease, allowing higher concentrations of drug with minimal side-effects (Felt-Baeyens et 
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al., 2006). Okabe and co-workers (2003) also developed an intrascleral implant prepared from PVA and 
EVA containing betamethasone in the form of a disk (4mg in mass, 1mm thick and 4mm in diameter). 
Their implantable disk was able to release betamethasone at a therapeutic level over a period of 4 
weeks without an initial burst-effect. Since intrascleral implantation does not require perforation of the 
eye wall, the device may reduce several complications noted with other devices that require surgical 
imposition into the vitreous compartment.  
 
 
TA-loaded 
device
Placebo 
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a) b)
 
Figure 2.13: Images of a scleral device a) drug-loaded and un-loaded, and b) implanted into the 
peribulbar space at the sclera of a beagle dog eye model (Reproduced with permission from Felt-
Baeyens et al., 2006). 
 
2.5.10. An osmotic minipump device 
A posterior segment implantable osmotic minipump device was first developed by Michelson and co-
workers (1979). The osmotic minipump was implanted subcutaneously in the temporal region of the 
rabbit eye model of endophthalmitis. The device had connective tubing directly infusing into the vitreous 
cavity through a pars plana incision and maintained a calculated dose of the antibiotic gentamicin 
(0.01mg/h) over 4 days. Other investigators attempted similar pump models (Eliason et al., 1980; 
Ohkuma and Ryan, 1984), but none of these approaches reached clinical acceptance. More recently, 
much interest has been focused on uncomplicated slow-release intravitreal implantable devices to treat 
CMV-R and PVR. 
 
2.5.11. A hyaluronic acid plug device 
A hyaluronic acid (HA) intravitreal plug device was developed comprising three different HA esters 
namely, 100% ethyl ester, 100% benzyl ester and 75% benzyl ester (Figure 2.14). The plugs were 
implanted through a sclerotomy at 3.5mm from the limbus of rabbit eyes in order to study the in vivo 
biocompatibility and the biodegradation rate (Avitabile et al., 2001). The shaft diameter of the plugs was 
measured by ultrasound bio-microscopy to assess the in vivo biodegradation of the device. Slit lamp 
microscopy, indirect ophthalmoscopy and electroretinography were performed periodically. The effects 
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of the device on ocular tissues were also evaluated histologically. All the plugs displayed biocompatibility 
and underwent slow erosion kinetics. The partial benzyl ester was completely reabsorbed after 15 days. 
Analysis of variance showed a high correlation between the biodegradation rate and the time of 
resorption. The biodegradation rate of each device was related to the chemical structure of the three 
types of HA. The study suggested that the intravitreal plug devices based on HA esters may provide 
useful biocompatible and biodegradable devices for potential drug delivery in the treatment of posterior 
segment eye diseases.  
 
Head Shaft
mm  
Figure 2.14: Digital image depicting the head and shaft configuration of the hyaluronic acid scleral plug 
delivery device (≈5mm in length) (Reproduced with permission from Avitabile et al, 2001). 
 
2.5.12. A novel helical device 
The I-vation® technology developed by SurModics (Pty) Ltd., (Eden Prairie, MN, USA) consists of a 
helical coil with an eluting polymer containing triamcinolone. The device provides a way of obtaining 
controlled release of the common ocular corticosteroid, triamcinolone. The device is implanted through a 
25G needle stick and it is self-anchoring within the sclera (Figure 2.15). Initially, there were concerns 
regarding conjunctival exposure with the metallic screw. However, these challenges were overcome 
ensuring that the hub of the screw was flush with the scleral surface and not seated at an angle. A 
prospective, randomized, double-masked multicenter trial is underway to evaluate the technology, using 
two formulations in 30 patients with DME (Kupperman, 2006).  
 
 a) b) c)
 
Figure 2.15: Digital images depicting a) the I-vation® technology from SurModics (Pty) Ltd., (Eden 
Prairie, MN, USA) consisting of a helical coil with an eluting triamcinolone-loaded polymer, b) the relative 
size of the device and c) the device implanted through a 25G needle stick and is self-anchoring within 
the sclera (Reproduced with permission from Kuppermann, 2006). 
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2.5.13. A micro-machined drug delivery device 
The Ocular Drug Delivery Group at the University of California (Irvine, CA, USA) developed a micro-
machined intraocular drug delivery device (Figure 2.16). The goal of the project was to use 
micromachining technology to engineer a passive, programmable, pulsatile drug delivery device, with 
numerous pulses, yet small enough to be used as an intraocular implantable device. The device was 
designed with null zones in the polymer and drug-loaded zones. This enables drug levels to cycle up 
and down in a pre-programmed manner, also allowing native expression of endogenous cytokines and 
growth factors (Kuppermann, 2006). A pulsatile system is of considerable interest for intraocular drug 
delivery as the programmed release of a specific dose of drug at a specific time could potentially 
minimize drug-related side-effects. The overall safety and efficacy of this device is yet to be established. 
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Figure 2.16: A schematic of the micromachined drug delivery device developed by the Ocular Drug 
Delivery Group at the University of California (Irvine, CA, USA) (Reproduced with permission from 
Kuppermann, 2006). 
 
2.5.14. Encapsulated cell technology for intraocular delivery 
The Encapsulated Cell Technology (Neurotech (Pty) Ltd., Lincoln, RI, USA) ophthalmic device is rather 
controversial (Figure 2.17). The technology uses ARPE-19 cells, a human retinal pigment epithelium 
(RPE) cell-line. The cells are commercially available and have been modified to produce ciliary 
neurotrophic factor (CNTF) and can be designed to produce various growth factors. Neurotech (Pty) Ltd. 
claims that the cells can produce rhuFab V2, a ranibizumab-like compound (Lucentis®; Genentech (Pty) 
Ltd., San Francisco, CA, USA). The controversy is that the RPE cells produce other compounds as well 
and the question is whether these are being disproportionately stimulated. RPE cells that are present in 
the human eye are able to naturally produce growth factors on a continual basis. 
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Figure 2.17: An image of the Encapsulated Cell Technology implant that is 6mm long and is surgically 
placed inside the eye. The CNTF elutes over time and the explants continue to secrete CNTF 
(Reproduced with permission from Kuppermann, 2006). 
 
2.5.15. The Visulex® non-invasive iontophoretic ocular drug delivery device 
The Visulex® technology developed by Aciont Inc., (Salt Lake City, USA) is a non-invasive, iontophoretic 
ocular drug delivery device that can deliver therapeutically relevant doses of triamcinolone acetonide 
(TA) (Figure 2.18). Researchers performed iontophoresis of TA phosphate (TAP) on the eyes of healthy 
New Zealand White rabbits (Hastings et al., 2004; Eljarrat-Binstock and Domb, 2005). An electrical 
current of 3mA for 20 minutes using a Visulex® sustained-release formulation of TAP, in vivo was 
employed. Hastings and co-workers (2004) conducted an in vivo study in the rabbit eye model in order 
to examine the quantity of TAP delivered into the eye. They dissected the enucleated rabbit eyes and 
used a High Performance Liquid Chromatography (HPLC) assay to determine the drug distribution in the 
rabbit ocular tissues. An efficacy study was also conducted to evaluate the Visulex® transscleral drug 
delivery system in an endotoxin-induced posterior uveitis rabbit model using direct ophthalmologic 
examination. A contrast agent was visually tracked as part of a precipitating sustained-release depot 
formed by the Visulex® device at various time intervals with Magnetic Resonance Imaging (MRI) to 
determine the distribution of drug released from the device. In the pharmacokinetic study, the quantity of 
TAP delivered into the sclera and retina/choroid regions were approximately 0.03mg from the Visulex® 
device. Significant levels were also found in similar tissue samples dissected from test eyes at later time 
intervals. The results of the efficacy study showed a significant improvement in the uveitis score of the 
eyes treated with the TAP-loaded Visulex® sustained release device (Csaky, 2007). The MRI study 
showed noticeable distribution of the contrast agent from the precipitating device toward the back of the 
eye. The Visulex® device can non-invasively deliver a therapeutic dose of TAP for the treatment of 
posterior segment eye diseases. However, further studies are required to fully evaluate the distribution 
of drug released over time from the Visulex® device as drug depots within the eye. In addition, the 
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duration of the drug action attained with the iontophoretic technique is less prolonged than with the 
controlled release drug delivery devices described.  
 
 
Figure 2.18: Schematic depicting the Visulex® depot-forming technology (Reproduced with permission 
from Csaky, 2007). 
  
2.5.16. A pellet device comprising a silicone shell  
Thalidomide is known to be a potent angiostatic agent. However, its systemic side-effects include 
peripheral neuropathy, central nervous system (CNS) depression, and embryo toxicity which have 
resulted in the lowering of dosages administered to patients for the treatment of subretinal 
neovascularization. Systemic inhibition of angiogenesis in elderly patients may also interfere with the 
development of collateral circulation, which has a role in the prevention of CNS as well as cardiac 
ischemic events. Velez and co-workers (1999) have developed an implant that successfully releases 
therapeutic intraocular doses of thalidomide, and could be used for the treatment of subretinal 
neovascularization (Figure 2.19). This system, however, has several disadvantages. The outer shell is 
non-biodegradable. Therefore, after the drug has been released, minor surgery is necessary for the 
removal of the delivery device from the eye. There is also the possibility that shell rupture may 
potentially lead to “dose dumping” during therapy. Depending on the type of drug loaded into the 
reservoir, “dose dumping” may result in toxic side-effects from drug concentrations that exceed 
maximum safety levels.   
 
 
Silicon shell
Thalidomide load (10mg)
 
Figure 2.19: Experimental thalidomide implant with a 10mg pellet and a silicone shell (Reproduced with 
permission from Velez et al., 1999). 
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2.6. Concluding Remarks 
 
The therapeutic advantages offered by the use of intraocular implantable devices are numerous and 
significant. In spite of this, the devices that are available have not yet gained widespread acceptance 
even though a few new products have been commercialized. This situation may change as improved 
devices such as those described in this Chapter are in various stages of development and are 
mandated by the emergence of important new drugs that have very short biological half-lives. Intravitreal 
drug delivery technologies that provide continuous controlled drug release may in time find significant 
application in the treatment of ophthalmic diseases that, because of epidemiological circumstances, are 
otherwise difficult to treat effectively. In summary, a reasonable strategy to circumvent the drawbacks of 
the challenges associated with intravitreal drug delivery is to combine technologies with the necessary 
balance in order to achieve sustained or controlled intravitreal drug release with patient comfort and 
ease of manufacturing and use. At this stage, it is apparent that no single intravitreal drug delivery 
device can fulfil all the clinician's expectations and needs. Thus, intravitreal implantable drug delivery 
devices are to be specifically designed and adapted to the targeted tissue, the physicochemical 
properties of the drug to be used, the physicomechanical properties of the polymer-based device and to 
the desired kinetics of intraocular drug release.  
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CHAPTER 3 
CHARACTERIZATION OF THE DONUT-SHAPED MINITABLET: THE EFFECTS OF IRRADIATION 
STERILIZATION ON THE PHYSICAL AND CHEMICAL STABILITY OF THE DEVICE  
 
3.1. Introduction 
 
This Chapter aims to describe the development and characterization of the novel ganciclovir (GCV)-
loaded Donut-Shaped MiniTablet (DSMT) device. As it is critical that the device remains intact 
throughout its therapeutic period in the vitreous humor (VH), as well as retain the ability to be 
reproducible on a tableting press, it is essential that certain fundamental physicochemical and 
physicomechanical properties of the device are assessed. These studies focused mainly on those 
properties that could affect the physical and chemical stability of the DSMT as a result of sterilization 
employing gamma (γ)-irradiation. A thorough understanding and investigation of these properties may 
ultimately provide a rationale for formulation design and modifications if required. There are numerous 
investigations that could be undertaken during pharmaceutical characterization studies. However, for 
this research, investigations were performed in a pragmatic manner and only immediately relevant data 
was generated to assess the stability of the DSMT device before and after sterilization in accordance 
with the UK panel on γ-irradiation guidelines for pharmaceutical products. Briefly, these guidelines 
conform to the agreement between the international standards for medical device sterilization and the 
guidelines for Gamma and Electron Beam Radiation followed by device manufacturers. The purpose 
of the validation process is to ensure that certain products are rendered free of viable 
microorganisms, and thus, is “sterile.” These standards ensure certain predetermined criteria that 
validates sterilization are met prior to the production of a sterile healthcare product and include, 
evaluation of materials to be used in the product and its packaging, determination of the product’s 
radiation stability, sterilization dose selection, product dose mapping, certification of the process and 
verification of the sterilization dose (European Guideline 3AQ4a, 1992). 
 
As mentioned earlier the development of a prolonged release intraocular implantable device for 
delivering GCV is interesting for the treatment of posterior segment eye infection such as 
cytomegalovirus retinitis (CMV-R) (Choonara et al., 2006). Poly(lactic-co-glycolic acid) (PLGA) is a 
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copolymer of lactic and glycolic acids widely used for the preparation of drug delivery devices due to its 
biocompatibility and biodegradation (Ruiz et al., 1990; Black, 1992; Park and Lake, 1992; Volland et 
al., 1994; Athanasiou et al., 1996; Sintzel et al., 1997; Bittner et al., 1999). Numerous drug delivery 
devices comprising hydrophobic biodegradable polymers have received much attention, due to their 
ability to prolong drug release and protect drugs from premature degradation (Yoshioka et al., 1995; 
Montanari et al., 1998). 
 
Drug-loaded biodegradable devices have been explored in order to improve the stability, long-term 
therapy, and targeting of drugs for the treatment of various posterior segment eye diseases (Lewis et al., 
1990). However, devices for implantation have to meet the pharmacopoeial requirements of sterility, 
which has been often neglected during their design. Terminal sterilization is preferred to aseptic 
processing of such devices in a clean room environment under Good Manufacturing Practice (GMP) 
conditions, if both sterility assurance and cost are considered. The common sterilization approaches for 
implantable medical devices are steam, dry-heat, ethylene oxide (EO) gas, and γ-irradiation (Henn et 
al., 1996; Nijenhuis et al, 1996; Mohr et al., 1999). Among these, steam and dry-heat sterilization are 
performed at high temperature and may cause severe degradation and hydrolysis of the polymeric 
device. Therefore, EO gas and γ-irradiation techniques have been preferred for the sterilization of 
implantable biodegradable polymeric devices. Sterilization is crucial in producing biodegradable devices 
for clinical applications. However, only a few studies have explored the effects of the sterilization 
procedure on biodegradable devices composed of PLGA (Volland et al., 1994; Montanari et al., 1998; 
Faisant et al., 2002). Of those available, the efforts have been focused mainly on the effects of γ-
irradiation on drug release and often the physicomechanical properties have been overlooked. Apart 
from studies showing that the simpler and lower costing EO gas sterilization procedure does not affect 
the molecular mass of PLGA unlike in γ-irradiation sterilization (Henn et al., 1996), a general lack of 
knowledge on the micro-mechanical properties of such devices after sterilization may have contributed 
to the prevailing conception that there are limited approaches for sterilizing biodegradable devices.  
 
PLGA-based devices offer various advantages compared to the use of conventional polymers, such as 
the possibility to control the resulting drug release rate accurately over prolonged periods of time as well 
as having superior biocompatibility and complete bioerosion. The effects of γ-irradiation on PLGA and 
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other drug-loaded devices have been discussed previously and varying results have been reported, 
depending on the drug utilized (Volland et al., 1994; Bittner et al., 1999). This makes it necessary to 
investigate the effects of γ-irradiation on newer formulations such as devices intended for intraocular 
implantation as local toxicity may be related to specific properties that can be affected by the sterilization 
procedure. The advantages of γ-irradiation sterilization include higher penetrating power due to 
radiation, lower chemical reactivity, lower measurable residues, smaller temperature rises and fewer 
variables to control. Ionization radiation such as γ-irradiation is a form of electromagnetic radiation, 
characterized by high penetration at a very low dose rate that may modify the performance of irradiated 
drug delivery devices through radiolytic degradation (Hausberger et al., 1995; Montanari et al., 1998; 
Bittner et al., 1999; Shameem et al., 1999; Woo and Sanforb, 2002). However, there is minimal 
knowledge available regarding the underlying micro-mechanical transitional mechanisms that may also 
affect mass transport phenomena that modulate the drug release kinetics from such devices.  
 
Therefore this study explored the effects of γ-irradiation sterilization on the PLGA-based DSMT device 
that would be suitable for further in vivo studies in order to improve the micro-mechanical understanding 
of the affects of the sterilization procedure on the DSMT device. The influence of γ-irradiation on the 
selected formulation was assessed using a combination of complimentary characterization techniques 
such as Scanning Electron Microscopy (SEM), Fourier Transform Infra-Red (FTIR) Spectroscopy, 
Differential Scanning Calorimetry (DSC), Porositometry and Textural Profiling. These techniques were 
supported by in-depth Chemometric Model Analysis to further explicate dynamic transitions at the 
macroscopic and molecular levels.  
 
3.2. Materials and Methods 
 
3.2.1. Materials 
Resomer® grade RG504 (i.v.=0.45-0.60dl/g; Mw=55,000g/moL) comprising poly(lactic-co-glycolic acid) 
(PLGA) with a 50% lactide content was selected for this study and purchased from Boehringer 
Ingelheim, GmbH, (Ingelheim, Germany). Ganciclovir (GCV) was purchased from Hoffmann-La Roche 
Inc. (Nutley, NJ, USA). Magnesium stearate (Sigma Chemical Corp., St. Louise, MO, USA) was used as 
a tableting lubricant. A test sieve shaker (Endcotts Octagon 200, London, UK) with a variety of sieves 
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(Endcotts Test Sieves, Inc., London, UK) of different aperture sizes were used for ensuiring uniformity in 
particle size for tableting. All other reagents used were of the ultrapure grade. 
 
3.2.2. Preparation of the PLGA-based DSMT device 
Special tablet tooling was previously designed in our laboratories and manufactured by Holland 
Tableting Science Ltd., (Nottingham, England). Further details on the preparation of the DSMT device 
can be found in a publication by Choonara and co-workers, (2006). Briefly, the punch set comprised a 
lower and upper punch, die, and central rod. Both the upper and lower punches contained a longitudinal 
central hole for the insertion of the rod, which enabled a donut-shaped tablet to be compressed around 
it. All blending was performed using an Erweka AR 400 Cube Blender (Erweka GmbH, Flemington, NJ, 
USA), and a Manesty F3 eccentric (single punch) tableting press (Oystar Manesty (Pty) Ltd., 
Merseyside, England) was used for directly compressing the powder blends into the design of a DSMT 
device. A model TR 104 mass balance (Denver Instrument (Pty) Ltd., Denver, Colorado, USA) was 
used for all gravimetrical analysis.  
 
3.2.3. Irradiation sterilization of the DSMT device 
DSMT device samples were conditioned according to a process described by Hausberger and co-
workers (1995). A batch of DSMT devices were weighed (100±0.05mg) and transferred to 2mL glass 
poly-top sealed cap vials. The vials were labeled and packed surrounded by dry ice into a polyurethane 
container, assuring a low temperature during the irradiation process. Although γ-irradiation may produce 
a minimal rise in temperature, maintaining a low temperature avoided a possible acceleration of PLGA 
hydrolytic degradation. Samples were couriered and irradiated with cobalt (Co)-60 at the γ-irradiation 
unit of Isotron (Pty) Ltd. (Isando, South Africa). An effective sterilizing dose of 25kGy (commonly known 
as the industrial overkill) was used for sterilizing the DSMT devices. Placebo and GCV-loaded DSMT 
devices were irradiated using Co as the irradiation source. Irradiation was performed at room 
temperature either under vacuum or in air with a 25kGy dose at a dosing rate of 1.3kGy/h. A minimum 
absorbed dose of 25kGy is regarded as adequate for the purpose of sterilizing pharmaceutical products 
without providing any biological validation (European Guideline 3AQ4a, 1992).  
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3.2.4. Surface morphological characterization of the irradiation sterilized DSMT device 
The surface morphology of the DSMT device before and after γ-irradiation was analyzed by Scanning 
Electron Microscopy (SEM). Samples were prepared for photomicrographs by applying a thin layer of 
colloidal graphite on aluminium stubs and mounting the DSMT devices on graphite to secure them in 
place during microscopic examination using an electrical potential of 15kV. The devices were then 
sputter-coated with a thin layer of gold-palladium. Several photomicrographs were produced by 
scanning fields, selected at different magnifications using a Jeol JSM-840 SEM (Tokyo, Japan). The 
shape, homogeneity and the degree of surface morphological transitions were identified to assess the 
influence of γ-irradiation on the DSMT device (N=10).  
 
3.2.5. Chemical structural transition analysis due to irradiation sterilization of the DSMT device 
Fourier Transform Infra-Red (FTIR) spectrophotometric analysis was performed on the native GCV and 
PLGA, the GCV-loaded DSMT device and 1:1 (w/w) GCV-PLGA physical mixtures at ambient 
temperature in the wavelength range of 400-4000cm-1 using a Perkin Elmer Spectrum BXII FTIR 
spectrometer equipped with a Universal Attenuated Total Reflectance and a DynaScan interferometer 
(Perkin Elmer Life and Analytical Sciences Inc., Shelton, CT, USA). FTIR spectra were recorded on 
scans of samples at a resolution of 2cm-1. FTIR spectra before and after γ-irradiation were recorded for 
GCV, PLGA and the DSMT devices. The molecular structure of native GCV, native PLGA, a physical 
mixture of GCV and PLGA and the compressed GCV-loaded DSMT device were analyzed to elucidate 
any variations in vibrational frequencies and subsequent polymeric structure as a result of interactions 
after γ-irradiation. 
 
3.2.6. Porositometric analysis of the DSMT device before and after irradiation sterilization 
The potential of PLGA degradation as a result of γ-irradiation may significantly alter the micro-
environmental physicochemical and physicomechanical properties of the DSMT device such as the H+ 
concentration within the polymeric matrix. Lactic and glycolic acids produced by degradation of PLGA 
may lead to a decrease in pH at the centre of the device matrix (Shenderova et al., 1999). As PLGA 
degradation is catalyzed by H+ ions, a micro-pH decrease may lead to autocatalytic effects and thus 
alter the porosity of the polymer matrix (Spenlehauer et al., 1989; Dunne et al., 2000). Changes in 
porosity could affect the extent to which the DSMT device is able to imbibe sufficient quantities of 
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release media for the absorption of OH- into the matrix and/or the diffusion of monomeric and/or 
oligomeric acids outward that is desirably rapid to prevent acidic micro-environments and thus 
suppress any autocatalytic effects of PLGA (Anderson and Shive, 1997; Sansdrap and Mose, 1997). 
These events occur as a function of the size and porosity of the device. Furthermore, PLGA 
degradative products initiated by the γ-irradiation process can crystallize within the device resulting in 
a modification of porosity (Gopferich and Langer, 1995; Park, 1995). 
 
Porositometric analysis was performed employing an ASAP 2020 Porositometer (Micromeritics 
Instrument Company (Pty) Ltd., Norcross, GA, USA) equipped with research grade ASAP 2020 V3.01 
software. Briefly, the surface area and pore structure was analyzed by degassing the sterilized and 
non-sterilized DSMT device samples (mass=95mg; density=1g/cm3) in order to remove sample 
moisture and atmospheric vapor by applying a heat gradient and evacuating with Nitrogen gas (N2) 
(hard-sphere diameter=3.860Å; molecular cross-section=0.162nm2) that was used as a non-
adsorbent gas. The overall hold pressure for the evacuation and heating phases during the degassing 
procedure was maintained at 100mmHg. The sample temperature was then reduced by an adaptive 
rate technique (continuous) to that of liquid N2 (-196°C) for gas adsorption (maximum manifold 
pressure set at 925mmHg) using an isothermal jacket surrounding a sample tube with a warm and 
cold free-space of 1cm3. Table 3.1 lists the parameters and settings employed for the porositometric 
analysis under standard conditions of temperature and pressure (STP: 0°C and 760torr). Adsorption 
isotherms representing the accumulated molar quantity of N2 adsorbed and the gas pressure at a 
single constant temperature was generated. The pressure was expressed as the ratio between the 
relative actual N2 pressure (P) and the vapor pressure (P0) of N2. The effect of γ-irradiation on the 
porosity and surface area transitions of the DSMT device was described by linear isotherms, 
Brunauer, Emmett and Teller (BET) surface area (Brunauer et al., 1938) and Barrett, Joyner and 
Halenda (BJH) adsorption and desorption relationships generated (Barett et al., 1951). In addition, a 
modern approach adopted in this study focused on the fundamental principles of statistical 
thermodynamics in porositometry combined with chemometric and molecular modeling in order to 
seek a single and unified theoretical understanding of pore formation and transitions applicable over 
the entire range of the isotherms generated for the DSMT device before and after sterilization.  
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Table 3.1: Porositometric parameter settings employed for analyzing the DSMT device physical and 
chemical stability transitions as a result of γ-irradiation sterilization. 
Parameter       Settings 
 
Degassing evacuation phase 
Temperature ramp rate      10°C/min 
Target temperature      30°C 
Evacuation rate       50mmHg/s 
Unrestricted evacuation limit     30mmHg 
Vacuum set-point      500µmHg 
Evacuation time      60min 
 
Degassing heating phase 
Temperature ramp rate      10°C/min 
Hold temperature      35°C 
Hold time       7200min 
 
Sample analysis phase 
Sample mass       0.95g 
Cold free spacea      56.92cm3 
Analysis absorptive      Nitrogen (N2) 
Analysis bath temperature     -197.46°C 
Warm free spaceb      18.61cm3 
Equilibration interval      20s 
 
aCapacity volume computed from the known quantity of N2 in the partially immerged sample holder 
bPhysical free volume of the sample holder 
 
 
3.2.7. Analysis of the Tensile Strength and Fracture Energy after sterilization of the DSMT 
device  
The sterilization-induced micro-mechanical transformations of the DSMT device were investigated 
employing textural profile analysis. Understanding the potential sterilization-induced transformations is 
significant to ensure device stability and quality. The objectives were therefore to develop a method for 
direct micro-mechanical analysis of the DSMT device that underwent γ-irradiation in order to establish 
an understanding of the controlling factors of matrix transformation that may influence the overall 
stability of the device. Textural analysis was performed employing a TA.XTplus Texture Analyzer (TA) 
(Stable Microsystems, Godalming, Surrey, England) fitted with a 2mm flat-tip cylindrical probe and a 5kg 
load-cell. The Tensile Strength and Fracture Energy were computed from Force-Distance and Force-
Time profiles generated. The TA settings used to generate the necessary profiles and subsequently 
compute the micro-mechanical properties are listed in Table 3.2. The Fracture Energy provided data on 
the strength of the surface structure of the DSMT device before and after γ-irradiation and was 
determined by computing the gradient between the initial Force (anchor 1) and the first point of major 
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inflection (anchor 2) on a Force-Distance textural profile (Figure 3.1a). This was indicative of primary 
matrix fracture and was noted as a reduction in force.  
 
Table 3.2: Textural parameter settings employed for physicomechanical property analysis of the DSMT. 
Test parameters                                                                       Settings 
                                                           Tensile Strength (N/mm2)             Fracture Energy (J) 
 
Pre-test speed                                       1.00mm/sec                                       2.00mm/sec 
Test speed                                             0.50mm/sec                                      0.50mm/sec 
Post-test speed                                      1.00mm/sec                                      5.00mm/sec 
Compressive distance                             0.25mm                                                     - 
Compression force         -                                                       40.00N 
Sensitivity of trigger force                        0.05N                                                    0.05N 
 
 
Figures 3.1a and b depict typical Force-Distance and Force-Time profiles generated for computing the 
Tensile Strength and Fracture Energy respectively of the DSMT device before and after γ-irradiation. 
 
Force (N)
Distance (mm)
a)
Force (N)
Time (sec)
b)
2 2 3
 
Figure 3.1: Typical textural profiles of a) a Force-Distance and b) a Force-Time curve used in 
computing the Tensile Strength and Fracture Energy of the DSMT devices before and after irradiation 
sterilization. 
 
3.2.8. Thermal characterization of the irradiation sterilized DSMT device 
The inherent and sequential transient thermal behavior of polymers after γ-irradiation may influence the 
physicochemical and physicomechanical properties as well as the final performance of the device 
(Araujo et al., 2003). Therefore, Differential Scanning Calorimetry (DSC) was selected as a practical 
technique for evaluating a range of different samples and components of the DSMT device in order to 
assess the influence of the γ-irradiation process on the thermo-energetic properties of native PLGA and 
GCV as well as the DSMT device. DSC also provided a distinct interpretation of the polymeric thermal 
transitions with improved sensitivity and the ability to detect glass transition temperatures (Tg)  that have 
minimal changes in heat capacity (Giron, 2002; Lopes et al., 2006; Silver-Junior, 2006). In this research, 
the direct compression process was used for manufacturing the GCV-loaded DSMT device. DSC 
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analysis provided qualitative and quantitative data regarding the influence of GCV and PLGA, and the 
effects of compression of GCV and PLGA to produce the DSMT device. The effect of compression and 
sterilization on the drug–polymer interactions was also investigated by DSC. Physical mixtures of 
GCV:PLGA in ratios identical to those used in the manufacture of the DSMT device were used as a 
control. DSC curves were generated with a Mettler Toledo DSC1, STARe System (Columbus, OH, 
USA). Thermal transitions were assessed in terms of the Tg measured in response to variation in the 
magnitude of the melting temperature (Tm) and crystallization temperature (Tc) peaks corresponding to 
the total heat flow (∆H). The temperature calibration was accomplished with a melting transition of 
6.7mg indium (melting point 156°C and ∆H=28.4J/g). The thermal transitions of native GCV and PLGA 
were compared to a physical mixture of GCV and PLGA as well as ground samples (5mg) of the DSMT 
device before and after γ-irradiation. Samples of sterilized and non-sterilized DSMT devices (5-10mg) 
were weighed and sealed in perforated 40μL aluminum pans and ramped within a temperature gradient 
of 30-400°C under a constant purge of an inert N2 atmosphere (100mL/min) in order to diminish 
oxidation. The instrument parameter settings employed comprised a sine segment starting at 150°C with 
a heating rate of 1°C/min at an amplitude of 0.8°C and a loop segment incremented at 0.8°C and ending 
at 500°C. 
 
3.2.9. Chemometric modeling of the effects of irradiation sterilization on the DSMT device 
The quantitative and qualitative analysis of the DSMT device was developed using chemometric 
molecular modeling. This approach provided a mechanistic understanding of the device surface 
geometry in order to analyze the physical stability of the device. Further studies were conducted to 
model the intensity variations in sterilized and non-sterilized DSMT samples. A model was used to 
describe the intensity variation as a function of solid fraction and thickness and tested on the PLGA 
devices. With this model, intensity variations from devices made before and after sterilization conditions 
were normalized, making the method transferable and facilitating the analysis over the expected range 
of formulation components and process variation. For complex processes such as compression and 
ensued by γ-irradiation, factors such as pressure, temperature and ionization may induce 
transformations within the DSMT device matrix. Induced transformations were analyzed in a quasi-static 
molecular environment using chemometric software (ACD/I-Lab, V5.11 Structure Elucidator Application 
(Add-on) biometric software, Advanced Chemistry Development Inc., Toronto, Canada, 2000). The 
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implicit design of the GCV-loaded DSMT device required customization of the novel donut-shaped 
geometry with the ability to support the micro-mechanical stability for γ-irradiation and subsequent 
intraocular implantation of the device. The componential DSMT properties were modulated through 
computational modeling to establish the effects of γ-irradiation in order to produce a viable GCV-loaded 
PLGA device. The fundamental modeling parameters were pivoted on the polymer compression, 
sterilization process, surface properties, macrostructure, micro-mechanical properties, drug-loading and 
biodegradation of the DSMT device. In order to incorporate fine control within the complexities of three-
dimensional (3D) modeling, the physical properties of the sterilized and non-sterilized device such as the 
transformation in porosity, shape, wall thickness, interconnectivity and networks for GCV diffusion 
through the matrix was regulated. The DSMT topography was predicted for intraocular implantation with 
pre-defined micro-architecture and micro-mechanical properties equilibrating ocular tissue as the site of 
implantation to provide mechanical support during sterilizability prior to function. Suppositional 3D 
graphical models with potential inter-polymeric interactions before and after γ-irradiation was generated 
based on the step-wise molecular mechanisms of matrix transformations before and after γ-irradiation of 
the DSMT device and polymer interconversion as envisioned by the chemical behavior and physical 
stability. A combination of a computationally rapid Neural Network (NN) and a modified Hierarchal 
Organization of Spherical Environments (HOSE) code approach were employed as the fundamental 
algorithms in designing the prototype models. The associated energy expressions were chemometrically 
designed based on the assumption of the DSMT device behaving initially as a plastic structure with 
higher states of combinatory energy. 
 
3.3. Results and Discussion 
 
3.3.1. Surface morphological analysis of the γ-irradiated DSMT devices 
Samples were selected to explore the influence of γ-irradiation on the surface morphology of the DSMT 
device (N=10). The analysis was based on the optimized DSMT device sterilized at 25kGy and 
compared to a non-sterilized device (Figure 3.2). Photomicrographs revealed the transition in surface 
morphology of the γ-irradiated DSMT samples and that the observed physical transformation played a 
critical role in instituting the changes in the micromechanical properties of the sterilized DSMT device as 
deduced by textural analysis studies and supported by the chemometric modeling approach employed 
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(Figure 3.2). The DSMT surfaces were dissimilar in surface geometry and porosity. The surface 
morphology of the non-sterilized DSMT device transitioned from a porous, web-like structure (Figure 
3.2a), to a more closely packed clustered surface resembling a continuous embedded crystallized 
surface (Figure 3.2b). 
 
 
10kV x200010kV x2000
a) b)
 
Figure 3.2: SEM images of the surface morphologies of a) a non-sterilized DSMT device and b) a 
sterilized DSMT device at 25kGy γ-irradiation (×1000 magnification; insert ×2000 magnification; 
N=10). 
  
A proposed explication for this observation is due to PLGA chain transition during γ-irradiation that 
subsequently alters the surface geometry or the packing efficiency of the DSMT device (Figure 3.3a 
and b). This produces a combined lamellar crystalline PLGA structure resulting from chain folding and 
shear slip of H-bonded polymeric sheets due to the γ-irradiation energy applied as depicted in Figure 
3.3c from the time-independent chemometric models derived. The conspicuous differences revealed 
by the SEM images shown in Figure 3.2 is pivoted upon the effects of the sterilization process on the 
physical surface configuration and consequently the micromechanical behavior and ability to control 
drug release from the DSMT device. 
 
a) b) c)
γrad=25kGy
Surface 
transition
H-bond slip
Chain 
folding
 
 
Figure 3.3: Structural models of the surface morphological transitions of the DSMT device upon 
exposure to γ-irradiation depicting a) the anarchic surface before irradiation, b) morphological changes 
occurring at intermittent energy levels to a maximum of 25kGy and c) complete lattice surface transition 
after irradiation. 
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3.3.2. Porositometric analysis of the DSMT device 
Porositometric analysis was undertaken to determine the total exposed surface area of the DSMT 
device as well as any transition in the volume and distribution of pores and pore size as a result of γ-
irradiation sterilization. The DSMT device was analyzed following the BET surface area, BJH method 
and the t-plot analysis of Lippins, Linsen and de Boer (Lippins et al., 1964). Table 3.3 shows the 
computed BET surface areas, BJH pore sizes and parametrics of the adsorption and desorption 
isotherms generated for the non-sterilized and sterilized DSMT devices. A distinct difference was noted 
between the porositometric values obtained for the sterilized and non-sterilized DSMT devices. The 
DSMT device displayed a net negative BET total surface area (-0.028±0.022m2/g; R2=0.71) after 
sterilization signifying an approximate 4-fold reduction in pore volume compared to the non-sterilized 
device which had a BET total surface area of 0.110±0.005m2/g (R2=0.99). The BET theory assumes 
uniform surface coverage with no favored adsorption sites and that N2 is more strongly attracted to the 
surface rather than to other N2 molecules. The typical range of BET-C values is from 5-100. Values <5 
as in the case with the sterilized DSMT device (BET-C=2.69; N=3) implied that the gas-gas affinity was 
competing with the gas-solid affinity as a result of the significantly reduced surface area and 
minimization of pores after γ-irradiation. The BET-C value for the non-sterilized DSMT device was 15.47 
(N=3). The lower surface area was attributed to the surface morphological transitions that occurred as a 
result of γ-irradiation with an ultimate reduction in porosity (Figure 3.3). This was revealed by the 
simultaneous qualitative and quantitative analysis of scanning electron micrographs (N=10) and linear 
isothermal plots generated as depicted in Figure 3.4a-d revealing the significant reduction in the porosity 
and BET surface area after sterilization of the DSMT device.  
 
The adsorption isotherms for the non-sterilized and sterilized DSMT device displayed distinctly different 
patterns typically indicative of having relatively large pores for the non-sterilized DSMT (Figure 3.4a) and 
a subsequent transition to a typical non-porous adsorbent after sterilization of the DSMT device (Figure 
3.4b). The absorption isotherm for the sterilized DSMT device (Figure 3.4b) increased comparatively 
rapidly as the relative pressure approached unity. When the relative pressure was reduced (desorption 
isotherm) this led to complete retracing of the curve (Figure 3.4b). However, the absence of a hysteresis 
loop (Figure 3.4b) is not conclusive evidence of non-porosity as certain conical, wedge and close-end 
pore geometries can also yield isotherms without hysteresis (Barrer et al., 1956). The absorption 
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isotherm of the non-sterilized DSMT device had the same general shape as the sterilized DSMT device 
(Figure 3.4a) except that it displayed a wider hysteresis loop instead of retracing the adsorption curve. 
This behavior is typical of mesoporous and macroporous materials with interconnected pore sizes of 
>20Å and >500Å respectively. The occurrence of the pronounced hysteresis loop signified the 
evaporation of N2 from the pores after condensation from the inward central-core of the pores that are 
intimately intertwined with the adsorbent surface area and pore geometry. Figures 3.4c and d display 
the BET linear plots generated with the results reported in Table 3.3.  
 
Table 3.3: Porositometric results obtained for the sterilized and non-sterilized DSMT device. 
Parameter DSMT DSMT(S:25kGy) 
   
BET total surface area (m2/g) 0.110±0.005 -0.028±0.022 
BET slope (g/cm3 STP) 36.94±1.83 -212.72±119.75 
BET y-intercept (g/cm3 STP) 2.55±0.25 57.66±17.66 
BET-Cd  15.47 2.69 
Qm (cm3/g STP)e 0.025 -0.006 
R2 (BET plot) 
Micropore volume (cm3/g) 
External surface area (m2/g) 
R2 (t-plot) 
t-plot slope (cm3/g.Å STP) 
t-plot y-intercept (cm3/g STP) 
Pore thickness rangea 
BJH adsorption pore size (Å)b 
BJH desorption pore size (Å)b 
 
0.99 
-0.000027 
0.1496 
0.97 
0.0017±0.0010 
-0.018±0.004 
3.5-5.0Å 
286.22 
693.67 
0.71 
cNC 
cNC 
cNC 
cNC 
cNC 
cNC 
192.49 
482.20 
 
aCalculated employing the Harkins and Jura pore thickness equation                  
bCumulative surface area of pores between 17.000-3000.000Å in diameter (m2/g) 
cNC=Not Computable as a positive BET surface area was not obtained for the sterilized DSMT devices 
dBET-C=intensity of the N2-surface interaction                           
eQm=monolayer surface capacity 
 
Figures 3.4e-h depict the Halsey Faas corrected BJH adsorptive cumulative pore volumes and BJH 
desorption dA/dD pore areas of the non-sterilized and sterilized DSMT devices (Halsey, 1948). The 
Halsey equation (Figures 3.4e and f) was selected as it assumes an adsorbed N2 monolayer with the 
same density and packing as normal N2. The preferred analytical representative expression of the 
standard adsorption isotherm at higher relative pressures is shown in Figures 3.4e and f. The pore size 
and pore volumes were significantly reduced after γ-irradiation of the DSMT device. Pore sizes 
displayed reduced values indicating a uniform and low quantity of pores despite variances caused by γ-
irradiation (Figure 3.4e and f). This observation is ideal as the DSMT is intended for the controlled and 
sustained delivery of GCV. Thus having a negligible porosity that is supported by the γ-irradiation 
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process, the DSMT device would rely specifically on matrix erosion as a mechanism for GCV release 
rather than the influx of release media through fluid-filled pores (Figures 3.4g and h). The lower 
distribution of pores can also be attributed to a homogenously dispersed system with few air molecules 
entrapped during compression that can be attributed to the presence of the unique central rod used in 
producing the DSMT device. This created multi-directional radial forces obliterating the significant 
presence of pores. While the pore volume in both formulations was relatively low, the presence of larger 
macropores in the non-sterilized device led us to conclude that pore size may have affected the more 
rapid release of GCV. The non-sterilized DSMT devices had a BJH adsorption of 286.22Å and BJH 
desorption of 693.67Å which is much larger than the sterilized devices (BJH adsorption of 192.49Å and 
a BJH desorption of 482.20Å). Therefore GCV release from the sterilized DSMT devices was more 
controlled than non-sterilized devices as described in Chapter 4 of this thesis.  
 
Since every adsorbate-adsorbent system yields a unique adsorption isotherm the concept of standard 
isotherms were employed by superimpositioning and normalization (Gregg and Sing, 1982). This led to 
the generation of t-plot isotherms as a means of determining the volume of micropores (<20Å), detecting 
the presence of mesopores and quantifying the thickness of the adsorbed N2 layer of the external 
surfaces and the walls of any pores that are present within the DSMT device structure. For t-plot 
isotherms, the quantity of N2 adsorbed (Va) was profiled against the thickness (t) of the adsorbed N2 
layer (Figure 3.5) (Lippins et al., 1964). Extrapolation of the linear isotherm to the extent of N2 adsorption 
provided the micropore volume. In order to describe the thickness of the adsorbed N2 layer the Harkins 
and Jura thickness equation was employed (Figure 3.5) (Harkins and Jura, 1944) for determining the 
surface area of the DSMTdevice without the use of a molecular area which is a requirement if the BET 
method was used. The quantity of N2 adsorbed was related to the statistical thickness of the adsorbed 
N2 film by the equation shown in Figure 3.5. As shown in Table 3.3 t-plot volumes were only obtainable 
for the non-sterilized DSMT device with a micropore volume of -000027cm3/g over a pore thickness 
range of 3.5-5.0Å. As expected the t-plot parametrics for the sterilized DSMT device could not be 
determined due to the negative micropore volume revealing the lack of micropores. This is further 
depicted in Figure 3.5 in which extrapolation of the linear t-plot (R2=0.97) resulted in a negative intercept 
(-0.018±0.004cm3/g). This revealed that the γ-irradiation process did not affect the porosity of the DSMT 
device in the micropore region.  
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Figure 3.4: Descriptive porositometric plots of a-b) linear isotherms with overlaid photomicrographs 
(10kV ×2000), c-d) BET surface areas, e-f) BJH adsorption cumulative pore volumes and g-h) BJH 
desorption dA/dD pore areas of the non-sterilized and sterilized DSMT devices respectively. 
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Figure 3.5: Typical t-plot generated for the sterilized DSMT device (N=3; SD<0.01 in all cases). 
 
Pores are known to twist, turn, broaden, narrow and have rugged walls and other distorted shapes. 
Therefore, a practical alternative is required to undertake dynamic modeling for the application of 
mathematical analysis. This provided an accurate method for describing the DSMT device with fewer 
computations. The porosity determinations in this study assumed the pores within the DSMT device to 
be right cylinders (90° to the horizontal) with variable lengths/slits of infinite extent and parallel walls in a 
single layer of atoms with a continuum of interaction potential formed as shown by the molecular models 
in Figure 3.6. Figure 3.6 describes molecular models of the pair-wise interaction energy between PLGA 
chains during pore minimization for the sterilized DSMT device. It should be noted that isotherm profiles 
may vary and therefore detailed examination in accordance with thermodynamic and other processes 
such as chemometric modeling is required to elicit the desired information of surface area and pore 
structure.  
 
Regarding the sterilized DSMT device, γ-irradiation at 25kGy may have exceeded the yield pressure of 
PLGA, resulting in increased energy generated and dissipation above the Tg value. The excess energy 
induced molecular structural changes and resulted in surface deformation of the matrix that led to stress 
relief at heterogeneous stress loci distributed within the DSMT device after direct compression. 
Consequently stress relaxation and surface disruption occurred on a micro-level to alter the morphology, 
porosity and micro-mechanical properties of the sterilized DSMT device. Based on the model, an 
estimation of the transformation potential on the physical properties of PLGA is possible. The combined 
effects of two major factors such as pressure and γ-irradiation energy on inducing transformations within 
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the DSMT matrix was investigated. The simplest system to model in terms of geometry was that of a 
single pore represented by two parallel α and β PLGA chains with stress loci at a distance H (Figure 
3.6a). The pore is formed and three-dimensionally optimized with an average pore size of 200Å as a 
single component followed by pore division as a result of thermodynamic and density-dependant 
equilibrium potential on the surface of the DSMT device (Figure 3.6b-d). Results showed that pressure 
alone is unlikely to induce the polymorphic-like transformations within the DSMT matrix (Figure 3.2). The 
effects of the γ-irradiation energy must be considered in compaction-induced transformation after 
sterilization. The central hole further significantly alters the porosity in a uniform and multi-directional 
manner in view of the increased surface area of the DSMT device over a conventional discoid tablet 
matrix as represented by Equations 3.1 and 3.2 respectively. The larger surface area exposure is crucial 
and significantly alters the micro-mechanical profile as depicted by the chemometric models in Figures 
3.6 and 3.7 as well as the porosity results shown in Figure 3.4.  
 
)d2
2(Dh
4
π
A           Equation 3.1  
 
hD
4
πA 2     Equation 3.2 
 
Where, A=surface area, h=height of solid, D=total diameter and d=diameter of the central hole in the 
case of the DSMT device.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Chemometric models of segmental surface transitions occurring after γ-irradiation of the 
DSMT device depicting a) the application of γ-irradiation as a source of stress loci nativity to two 
sterilized PLGA strands, b) the induction of surface pore formation and shape optimization, c) a 
complete pore formed at minimum energy levels (for maximum stability) in a 3D optimized state and d) 
further pore-division with a geometric fit-model in the coiled state showing the molecular pore volume.  
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Instead of traditional kinetic or phenomenological approaches, it is also preferable to use chemometric 
model-based statistical theory that allows relating the linear isotherms generated to the microscopic 
properties of the system such as the solid-solid interaction energy parameters, the mechanism of pore 
formation, the pore size and the pore geometry. Figure 3.7 depicts the chemometric energy paradigms 
and molecular structural models mechanistically describing the influence of the γ-irradiation process on 
the energy gain and dissipation within the DSMT device matrix after γ-irradiation of the DSMT device. 
The adsorption isotherms generated also conveys data regarding the energetic heterogeneity of the 
DSMT surface. Even completely non-porous surfaces are composed of regions that have greater or 
lesser affinity for adsorbing N2 molecules and this energetic non-uniformity influences the shape of the 
isotherm. Therefore determining the distribution of the chemometric energy paradigms afforded an 
additional means of characterizing the DSMT surface transitions as a result of sterilization. The DSMT 
acquired a constant energy source during γ-irradiation and energy decay was subsequently induced 
through PLGA strand decoiling with minimal energy retained after γ-irradiation (Figure 3.7a). The instant 
energy decay profile of the matrix and the retained energy profile modeled were for the γ-irradiation with 
energy conservation from the developed and inherent energy status of the process (Figures 3.7b and c). 
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Figure 3.7: Chemometric energy paradigms and molecular structural models depicting the influence of 
the γ-irradiation process on the DSMT device matrix where, a) constant energy requirement by the 
DSMT matrix during γ-irradiation, b) energy decay through decoiling with minimal energy retained after 
γ-irradiation and c) instant energy decay profile of the matrix, where, EID= instant energy decay, 
EHD=hold energy decay, ETD=energy decay point with EHD., ETBM energy requirement till irradiation 
complete, TBM= irradiation time, ETn end-point energy relationship at n point of time.  
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3.3.3. Assessment of the physicomechanical properties of the DSMT device 
The physicomechanical transitions of the PLGA-based DSMT device interacting with the γ-irradiation 
process were analyzed. The extent of physicomechanical modification was quantified in order to predict 
the dynamic transitions for flexibility and reproducibility of the DSMT device after sterilization. The PLGA 
in the DSMT device interacted with the γ-irradiation by means of polar-hydrophobic interactions and 
hydrogen bonding. The physicomechanical properties of the matrices were governed by the PLGA 
molecular mass, PLGA concentration, and sterilization reaction time. The ability of the DSMT devices to 
absorb energy was found to correlate with the sterilization process. Non-sterilized samples had an 
increased Fracture Energy of the devices during textural probe penetration. On the contrary, γ-irradiated 
devices displayed an increased resistance to fracture by the textural probe penetration indicating that 
excess energy was absorbed by the DSMT devices during sterilization resulting in crystalline matrices 
with higher fracture energies and Tensile Strength. The general trend revealed was that the γ-irradiated 
DSMT device was less susceptible to fracture and had positive physicomechanical transitions. Hence, 
the sterilized devices were more crystalline and hence less prone to degradation in vivo, thus superiorly 
retarding the release of GCV. The Tensile Strength of the DSMT device was determined from axio-
radial compression tests performed on a Texture Analyzer equipped with a 5kg load-cell and a 2mm 
cylindrical probe in order to accurately measure the maximum penetration force (F). Together with the 
measured diameter and thickness of the DSMT device, the Tensile Strength (σt) was calculated using 
Equation 3.3 (Fell and Newton, 1970). 
 
πdt
2Fσ t                        Equation 3.3 
 
Where, F= maximum penetration force (N) with d= diameter of the DSMT device and t= thickness of 
the DSMT device.  
 
Table 3.4 lists the force values (N) generated from penetration and the Tensile Strength of the DSMT 
compacts. The Tensile Strength of the compacts indicated that the material formed moderately softer 
compacts after γ-irradiation.  
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Table 3.4: Textural analysis values obtained for the non-sterilized and sterilized DSMT devices. 
Formulation Type         Tensile Strength (N/mm2)                     Fracture Energy (N.s-1) 
 
DSMT               26.396±1.062      151.301±6.089 
DSMT(S: 25kGy)              24.426±1.184      140.009±6.785 
 
 
This observation highlights the important differences in the mechanical properties of the non-sterilized 
and sterilized DSMT devices, which is temperature and pressure dependant in their response to applied 
mechanical stress and this observation will subsequently be explained in a stepwise manner. 
 
Powder compaction and compressibility is a key phenomenon for the production of solid dosage 
forms such as tablets (Shotten et al., 1976; Doelker, 1978; Jones, 1978; Barra and Doelker, 1998). In 
this study, the physicomechanical properties such as the robustness of the DSMT device, propensity 
to fragment during manufacture or subsequent handling and porosity when sterilized may have a 
significant effect on the in vivo performance of the device. Hence, the compressibility behavior of the 
constituents of the DSMT device such as the PLGA has been previously analyzed (Choonara et al., 
2006). Powder compaction is a complex process, involving granule movement and re-orientation 
within the powder bed, together with deformation or fracture, resulting in increased contact area and 
intergranular bonding (Shotten et al., 1976; Doelker, 1978; Jones, 1978). This can be affected by the 
modulus and strain behavior of PLGA (i.e. elastic, plastic deformation or brittle fracture), as well as 
geometric factors such as surface rugosity, shape and size distribution of the powder introduced into 
the die cavity prior to compression (Krycer and Pope, 1982; Doelker, 1983; Marshall, 1986; Doelker, 
1988; Rippie, 1990). The compaction behavior also depends on friction; both between powder 
granules and with the compaction die surfaces (Celik, 1992; Wray, 1992).  
 
The combination of these factors generally results in variations of density and strength within 
compacted matrices, which may depend on their shape and can result in fragmentation faults such as 
chipped edges, delamination or capping. Nevertheless, and notwithstanding the considerable 
research effort that has been motivated by the importance for pharmaceutical tablet manufacture, a 
complete understanding of the compaction physics during manufacture of the DSMT device still 
eludes us. Numerous variables such as the solid-state properties and inherent deformation behavior 
of the PLGA, granule size, granule shape, and most significantly the tooling geometry and process 
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conditions can affect the attributes of the resulting DSMT device. Moreover, while it is generally 
accepted that granule rearrangement at a relatively low packing fraction is superseded by various 
relative quantities of deformation and fragmentation at higher compaction pressures and with the use 
of novel donut-shaped tooling as in this study, no direct evidence of densification mechanisms have 
been observed. The physics of this process is elaborated on henceforth from a postulated viewpoint. 
 
3.3.4. Postulated locale on the axial to radial force transmission during DSMT compression 
Theoretically, the radially transmitted force or pressure (stress) may essentially intervene in two ways 
during compression of PLGA into the DSMT device and this is depicted by a model related to the axial 
and radial force transmission (Figure 3.8). Figure 3.8 shows the stresses operating on the powder 
blend under compression when using the novel DSMT tooling. The friction force (Fd) is the force lost 
to the die wall and represents the difference between the two vertical forces. 
 
FdFr (Pr)
D
L
d
Fa (Pa)
Fb (Pb) Fe
 
Figure 3.8: A schematic depicting the forces and pressures operating on the powder blend under 
compression in a punch and die assembly with the protrusion of the novel central rod employed for 
producing the DSMT device. Where, Fa(Pa)=applied force (pressure) by the upper punch, Fb(Pb)=force 
transmitted by the lower punch (in a single-punch press), Fd=force lost to the die (i.e. the axial 
frictional force operating during compression), Fr(Pr)=radial force arising from the horizontal expansion 
of the mass in response to the axial compressive force (pressure) and is reduced as a result of the 
residual force absorbed by the central rod, Fe=ejection force on the lower punch during expulsion of 
the DSMT out of the die, D=die diameter and d=diameter of the central rod, L=height of the compact.  
 
3.3.4.1. Axial transmission 
The radial stress generated by axially pressing a body in a die is present in the numerous equations 
proposed to describe die-wall friction. In the simple model of pressing from one end in a stationary 
cylindrical die, these equations relate the pressure applied by the upper punch (Pa), to the pressure 
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transmitted to the lower punch (Pb), a well known derivation is that of Unckel, (1945) that can be 
modified as in Equation 3.4 to account for the central rod. 
 
d)L/(D4
b
a e
P
P                         Equation 3.4 
 
Where µ= the coefficient of die-wall friction, η= the stress ratio, defined as the ratio between the radial 
pressure (Pr) and the applied pressure (Pa), L= the compact length, and D-d= the diameter provided 
for the DSMT die representing the displacement of the central rod within the die cavity. As µ= the 
coefficient of friction between the powder mass and the die wall, then Equation 3.5 applies. 
 
rd μFF                          Equation 3.5 
 
Where, Fd=force lost to the die (i.e. the axial frictional force operating during compression), µ= the 
coefficient of die-wall friction and Fr= radial force arising from the horizontal expansion of the mass in 
response to the axial compressive force (reduced in the case of the DSMT device production due to 
the residual force absorbed by the central rod). 
 
These basic equations describe an exponential decay of the applied pressure down the compact 
length and postulate constant µ and η values. However, it has been suggested that µ and η may vary 
along the length of the compact according to the conditions of relative interfacial movement or 
modification of tablet tooling, even though the product µη could remain constant (Train et al., 1962). 
This could explain the experimentally observed uneven Tensile Strength between conventional PLGA 
matrices and the DSMT device produced. Both, axial and radial stress gradients are present although 
short compacts are expected to be reasonably homogenous along the compression axis, especially 
when the die is lubricated. In contrast, the radial distribution of the axial pressure on the upper and 
lower punch may show parabolic and symmetric patterns about the lateral central axis of the die 
alongside the central rod (Thompson, 1981). The general conclusion from analyzing these models is 
that geometrical changes may alter the relative radial pressures and the coefficient of friction, µ, 
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affects the intrinsic properties of the compacted device such as the Tensile Strength and Fracture 
Energy of the DSMT device. 
 
3.3.4.2. Radial transmission 
Long (1960; 1962) elucidated the theoretical significance of radial versus axial pressure cycles. Two 
types of the Long’s compression cycles were predicted according to the behavior of the material 
compressed in addition to that of a perfectly elastic body (Figure 3.9). In both cases, line OA (or OA’) 
is representative of perfect elastic behavior of a solid isotropic compact of material that is if the axial 
pressure (Pa) is released, the radial pressure (Pr) would return along this to zero. When the axial 
pressure exceeds the elastic limit (yield pressure) points A or (A’), yield begins and the slope changes 
according to the failure behavior of the material.  
 
 
 
Figure 3.9: Theoretical radial pressure cycles for an ideal elastic body, a body with constant yield 
stress and a Mohr body, where A-A’= yield points, B-B’=maximum applied pressure, C-C’= yield 
points of decompression and D-D’= residual die-wall pressures (Source: Long, 1960).  
 
For a body with a constant yield stress (strength) in shear, the difference between the axial pressure 
and the radial pressure remains constant and the slope of the line AB will equal unity. For a Mohr 
body, i.e. a body with a shear stress depending on the value of the normal stress, after a maximum 
axial pressure is reached (points B and B’), decompression occurs and the compact is no longer 
forced to yield but recovers elastically. The line BC (or B’C’) will be parallel to OA (OA’). At point C (or 
C’) the induced radial pressure exceeds the axial pressure and yield once again occurs. In the case of 
a material with a constant yield stress in shear, the line CD will be parallel to line AB. In the case of a 
Mohr body, the slope of the line C’D’ is the reciprocal of line A’B’ due to stress inversion. Once the 
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axial pressure has returned to zero but ejection has not yet occurred, the compact will remain under a 
residual radial pressure (Carstensen and Toure, 1980; Parrott, 1990). Several reasons may explain 
such deviations and is outlined in Table 3.5 (Long, 1960; 1962).  
 
Table 3.5: Potential reasons for deviations in the radial and axial pressure cycles of a powder blend 
under compression. 
 
 In the case of a perfectly hydrostatic body A (A’) coincides with O and C (C’) with B (B’). The 
cycle degenerates into a single straight line (Long, 1960).  
 
 A compacted powder is not a solid and therefore the isotropic compact and its yield stress cannot 
be the same. Thus, segment OA (OA’) may be curved as porosity continuously decreases and 
point A (A’) may not always be visible. Plastic flow may be confined to the interparticulate regions 
(Carless and Leigh, 1974). Thus, instead of the slope of the OA (OA’) segment, it may be better 
to consider the rest of the cycle where a reasonable degree of densification has occurred. 
 
 If the applied pressure has not been large enough to reach the elastic limit i.e. point A (A’), yield 
will not occur and the change of slope at point C (C’) will not be observed and also affects the 
magnitude of the residual radial pressure. 
 
 If the applied pressure has not been sufficiently high, the CD (C’D’) segment may be missing 
from the cycle, thus affecting the residual radial pressure. 
 
 Die elasticity also affects the shape of the radial compression cycle (Long, 1962). This may be a 
concern when the die volume is reduced to position the central rod when producing the DSMT 
device. Two different situations have to be considered. First, the cycle is complete and only the 
slopes of lines OA (OA’) and BC (B’C’) are reduced. The magnitude of the residual radial 
pressure is unchanged. Second, the cycle is incomplete and line CD (C’D’) is absent and line BC 
(B’C’) continues to intercept the radial pressure axis, causing higher residual radial pressures. 
 
Adapted from: Long, (1960; 1962) 
 
This justifies performing compression studies at sufficiently high applied pressures and comparing 
various polymer grades at a given relative inherent viscosity (Marshall, 1986; Choonara et al., 2006). 
Friction arising from the polymeric material and the die (die-wall friction), the central rod and between 
particles (interparticulate or internal friction) operates during tableting. However, internal friction is of 
significance only at low applied pressures, i.e. during particle slippage and rearrangement, and is not 
a decisive factor in the tableting process. In contrast, the friction between the powder mass, the die 
wall and the central rod is a pivotal issue when a sufficient radial pressure has been generated, i.e. 
beyond a certain consolidation ratio as in the case of the DSMT device.  
 
Friction is present and varies during compression, decompression, pre-ejection and ejection of 
tablets. Challenges often arise in the compression and decompression phases but become evident 
only at ejection (Hiestand et al., 1977; Schrank-Junghani et al., 1984). Friction phenomena occurring 
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during tableting may be estimated through various parameters such as the ratio of the maximum 
lower punch force to the upper punch force (Fd), the ejection force (Fe), the residual lower punch 
force, the work of friction, and the work of ejection that may be calculated from the upper and lower 
punch force measurements using an instrumented tableting press (Doelker, 1994). Factors influencing 
the friction conditions at the die also affect the radial transmission of the applied pressure. Thus, the 
presence of the central rod may reduce both the interparticle friction and friction at the die-wall, and 
hence particles compact more tightly and homogeneously. The result is a decrease in the coefficient 
of die-wall friction, µ, and an increase in radial stress transmission, η. A consequence is that the 
product µη in Equation 3.4 may not be influenced by the presence of the central rod. However, the 
only way to discriminate between the two effects is to monitor the die-wall pressure using a modified 
instrumented tableting press in order to measure η and then calculate µ for the DSMT compression 
cycle. 
 
Apart from the tablet tooling and the product to be compressed, numerous manufacturing conditions 
may in practice also influence the friction coefficient measurements (Strijbos, 1976; 1977). These 
include the method of tablet production (unique or continuous) and applied pressure. The effect of 
internal lubrication (i.e. adding a lubricant to the powder mass) or that of external lubrication (i.e. pre-
lubricating the die and central rod). In the former case, 0.5%w/w magnesium stearate was added to a 
DSMT device formulation. In the latter case, the magnesium stearate was dusted onto the internal die 
cavity and the central rod before compression. Both internal and external lubrication acted favorably 
on the DSMT tableting process. The presence of the central rod generally showed an improvement of 
the tablet mechanical strength. For conventional equi-dimensional PLGA matrices, the radial 
conversion during compression was lower in the absence of a central rod with an increased die-wall 
pressure. An opposite trend may be observed for the DSMT device with a potential increase in radial 
transmission and a slightly reduced residual die-wall pressure absorbed by the presence of the 
central rod. Other studies are generally in line with the results obtained in this study (Shotton and 
Obiorah, 1975; Obiorah and Shotton, 1976; Obiorah, 1978). It is evident that a superior radial 
transmission of pressure alone is not sufficient to explain compactibility. On the other hand, tablet 
formation is also related to a higher residual die-wall pressure, but the strongest tablets are not 
associated with the highest residual die-wall pressure (Doelker and Shotton, 1977). Probably, the 
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effect of the central rod and that of material hardness play a prominent role on the axial to radial 
pressure transmission. 
 
In addition, the donut geometry also has a significant bearing on the micro-mechanical attributes of the 
DSMT device. Physical factors such as particle-particle, particle-die and particle-rod contact surface 
areas during compression are significantly increased. This may induce a gradient for increased tablet 
consolidation and explained the Tensile Strenght and Fracture Energy results reflected in Table 3.4. The 
surface tension affected by the donut shape as compared to a conventional discoid tablet is also 
increased and therefore less critical pharmaceutical excipients such as binder was needed to produce 
the robust DSMT matrix. The increase in surface tension led to superior consolidation and stability of the 
DSMT device. However, the net change is almost negligible or very small due to compensation of 
energy by the outward surface of the donut matrix overriding the increase in inward surface tension. 
This may or may not affect an approximate 2-5% increase in Tensile Strenght or Fracture Energy of the 
donut shaped matrix depending on the rugosity of the matrix polymer selected (Figure 3.10).  
 
 
a) b)
 
Figure 3.10: Schematic diagrams depicting the differences in surfaces available for interaction and 
subsequent consolidation during compression between a) a conventional tablet matrix and b) a donut 
shaped tablet matrix of equal diameter.  
 
Interest in die-wall instrumentation is continuing. However, when examining the literature dealing with 
radial pressure measurement during compression of pharmaceutical materials, one is confronted with 
numerous inconsistencies (Hoag, 2003). One reason is the technical difficulties of die instrumentation 
and calibration that lead to discrepancies in the results reported for similar products. Another reason 
is that the models used for interpreting data have been proposed mostly for conventional solid, 
isotropic bodies and not for specialized geometrical matrices such as the DSMT device. Based on 
literature examination and on textural profiling results from this study die-wall instrumentation may be 
useful for compaction studies and for elucidating the friction phenomena during compaction and 
compression of PLGA into the DSMT device. In this respect, the residual die-wall pressure is of 
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significance as the success of the DSMT device formation is determined by the decompression and 
ejection phases and more emphasis should be placed on analyzing the kinetics of time-dependent 
deformation in the later period of the compression cycle as a result of the central rod. In addition, 
mathematical relationships that consider the material compressibility (volume reduction under 
pressure) have been proposed, but as for the relation between the DSMT matrix strength (material 
compactibility) and the compression parameters inferred from die-wall monitoring, suitable models still 
require development as initiated in Figure 3.11. 
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Figure 3.11: A model depicting typical digitalized signals from an instrumented tablet press of the 
compression/decompression tableting cycles of a) a conventional tablet matrix and b) a DSMT device, 
where, 1a and b=upper punch forces, 2a and b=lower punch forces, 3a and b=upper punch 
displacements, 4a and b=lower punch displacements, 5a and 5b=die-wall force of conventional tablet 
matrix and DSMT device, respectively, 6a=residual lower punch force, 6b=central rod friction during 
DSMT compression and decompression, 7a=ejection force of conventional tablet matrix, 7b=residual 
lower punch force after DSMT compression and 8=ejection force after DSMT compression. 
 
3.3.5. Thermal analysis of the irradiation sterilized DSMT device 
The superimposed thermal profiles generated are shown in Figure 3.12. The DSC curve for native GCV 
shows a first exothermic peak in the range of 150-160°C that was characteristic of disordered 
crystallization or an amorphous drug phase (Yonemochi et al., 2005). A second endothermic event in 
the range of 360-380°C may be attributed to GCV decomposition immediately after melting. The DSC 
curve for pure PLGA is also shown in Figure 3.12. From the DSC curve of PLGA it was possible to 
observe two thermal events. The glass transition temperature (Tg) of PLGA occurred in the range of 50-
60°C with an enthalpy of relaxation of 0.05mW/mg and a midpoint of 55°C. The endothermic 
degradation of PLGA occurred on a single step in the range of 360-380°C. The physical and chemical 
interactions between GCV and PLGA were also studied with the aim of predicting the thermal behavior 
of the biodegradable GCV-loaded DSMT device before and after γ-irradiation sterilization. Thus, 
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physical-mixtures of GCV and PLGA with identical proportions to the GCV-loaded DSMT device were 
analyzed by DSC.  
 
The Tg of PLGA occurred in the range of 50-60°C, followed by an exothermic event in the range of 150-
160°C due to hydration of GCV present in the sample. The notable exothermic shift to a higher ∆H may 
be due to the possible dissolution of the GCV fraction during the PLGA melting phase while heating. In 
previous studies this was well characterized when polymers with low melting point/glass transitions were 
used (Arias et al., 1998; Naima et al., 2001; Yamashita et al., 2003; Bikiaris et al., 2005). 
Consequently as seen in this study the appearance of the GCV:PLGA physical mixture melting point 
was at a lower temperature range than that of native GCV (360-380°C), with premature melting in the 
range of 320-340°C. The endothermic decomposition of PLGA occurred in the temperature range of 
310-330°C. After characterizing the thermal properties of the native GCV and PLGA as well as the 
physical mixture, DSC analysis was performed on the groung samples (5mg) of the sterilized and non-
sterilized GCV-loaded DSMT devices (Figure 3.12). The beginning and intensity of the thermal events 
varied between the sterilized and non-sterilized DSMT device samples. The Tg of PLGA occurred in the 
range of 50-60°C. For both the non-sterilized and sterilized DSMT device an exothermic event typically 
due to hydration occurred in the range of 150-160°C. For the non-sterilized DSMT device a second 
endothermic thermal event occurred in the range of 300-360°C due to melting and the onset of 
decomposition during GCV melting. For the sterilized DSMT devices a third exothermic event was 
observed in the temperature range of 340-360°C. This distinct event was possibly due to the ionization 
effects of the γ-irradiation process resulting in a prominent crystallization phase consistent with the DSC 
curve of native GCV signifying slower decomposition.  
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Figure 3.12: Superimposed thermal profiles for native GCV, native PLGA, a GCV:PLGA physical 
mixture, a non-sterilized GCV-loaded DSMT device and a sterilized GCV-loaded DSMT device, at a 
temperature range of 30-400°C and a heating rate of 10°C/min (N=3). 
 
In order to evaluate the effect of compression on the drug–polymer interactions and on the stability of 
the DSMT device, the data obtained from thermal analysis of the compressed GCV-loaded PLGA 
devices were correlated with the respective physical mixtures. The temperature ranges of the thermal 
events were similar, indicating that the experimental selected conditions for preparation of the GCV-
loaded DSMT device did not change the stability of the drug or polymer. However, the enthalpy values 
involved in the thermal events obtained for the GCV-loaded DSMT device were different from those 
determined for the respective physical mixtures. This could be attributed to the various aggregation 
states of GCV present in different samples. It may be evidenced by a lower relaxation enthalpy identified 
for the Tg of PLGA in the DSMT devices than those obtained for the physical mixtures. It is well 
established that polymer compression has different aggregation states than physical mixtures (Corrigan, 
1995; Gustafsson et al., 1998; Anshuman et al., 2004; Ohta and Bucktona, 2005). The Tg is a 
significant parameter to characterize the physicomechanical behavior of glassy amorphous polymers 
such as PLGA (Vyazovkin and Dranca, 2005; Vyazovkin and Dranca, 2006; Kim et al., 2007). The 
molecular mobility of the polymeric chains has an important role in deciding the physicomechanical 
properties, diffusion of drug molecules through the polymeric matrix, and the enthalpy involved in the 
thermal event may vary with the drug content in the polymeric matrix (Kim et al., 2007).  
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In this study the Tg remained relatively stable for all combinations of samples and ranged between 50-
60°C. From the DSC data obtained, the second thermal exothermic event occurred during hydration and 
thus an increase in enthalpy values was obtained. The maintenance of the thermal properties of the 
DSMT device after γ-irradiation is fundamental for assuring the performance of the device once 
implanted and its ability to behave as expected in controlling the release of GCV. DSC analysis revealed 
that the thermal properties were similar for both GCV-loaded DSMT devices and the respective 
GCV:PLGA physical mixtures, demonstrating that the stress conditions during direct compression and γ-
irradiation did not affect the thermal properties of the structural components of the DSMT device.  
 
3.3.6. Chemical structural transition analysis 
FTIR analysis was performed in this research with an aim to complement the results obtained from 
the thermal analysis by DSC. The FTIR spectra of native GCV and PLGA are shown in Figure 3.13. 
The bands of the carboxyl OH group were assigned in the range of 2500-3500cm-1, the tertiary amine 
at 3527 and 3375cm-1, secondary amine at 3100, CH2–N stretching at 2705cm-1, ketone C-O at 
1708cm-1, C-C bands in the region of 1600 and 1495cm-1 and C–bond stretching in the range of 1100-
1300cm-1, these values corresponding to the characteristic FTIR of GCV (Figure 3.13). From the FTIR 
spectra for PLGA  it was possible to identify the characteristic absorption bands at 1759cm-1, related 
to the PLGA ester group, and axial stretching of sp2 and sp3 carbons in the range of 2900-3000cm-1, 
were assigned (Figure 3.13). The FTIR spectra of the GCV-loaded DSMT device and the GCV:PLGA 
physical mixtures are also shown in Figure 3.13. For both, the GCV-loaded DSMT device and the 
physical mixtures, the characteristic FTIR bands of the functional groups of GCV and PLGA were 
established. On the contrary, the ester carbonyl groups of the polymer could react with the amino 
groups of GCV. However, the maintenance of the FTIR characteristic bands for both, GCV and PLGA, 
and the absence of any new FTIR bands, indicating modifications in the ester carbonyl and amine 
functions demonstrate that GCV is only dispersed in the PLGA polymeric matrix. These results are in 
agreement with the thermal analysis data indicating that there is no significant interaction between 
GCV and PLGA used to manufacture the DSMT device. In all samples, the FTIR spectra of the DSMT 
device exhibited a transmission pattern that was the sum of the two components in relation to their 
abundance indicating that no interactions between GCV and PLGA occurred (Figure 3.13). Moreover, 
the NH deformation signal recorded at 1534cm-1 confirmed the presence of GCV in the PLGA matrix. 
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Figure 3.13: Superimposed FTIR spectra of a) native GCV, b) native PLGA, c) a GCV:PLGA physical 
mixture, d) a non-sterilized DSMT device and e) a sterilized DSMT device. 
 
 
The results of this research demonstrated that through thermal analysis it was possible to deduce the 
pre-formulation characteristics of the biodegradable DSMT device produced by direct compression and 
sterilized by γ-irradiation prior to intraocular implantation. The selected manufacturing and sterilization 
technique of the DSMT device did not provoke any transformations in the physical and chemical stability 
of the DSMT device or its components. It was possible to establish a relationship between the thermal 
behavior of the device, the GCV-loading and subsequent effects of γ-irradiation. It can be concluded that 
direct compression and subsequent γ-irradiation are efficient and reliable processes for the production of 
a stable GCV-loaded DSMT device. Irradiation of biodegradable polyesters such as PLGA may induce 
dose-dependent chain transitions (Figure 3.14) as well as molecular mass reduction thus potentially 
accelerating degradation of the polymer (Reed and Gilding, 1981). The degradation rate of polymeric 
biomaterials due to γ-irradiation may be linked to radical formation (Stevels et al., 1996; Nijenhuis et al., 
1991). In order to prevent radical-induced degradation, antioxidants such as α-tocopherol and ascorbic 
acid esterified with palmitin- or stearic-acid are often added to formulations. However these are mainly 
used as protecting agents for lipophilic materials and thus were not considered in this work. 
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Figure 3.14: Schematic depicting the molecular geometrical changes of PLGA strands after γ-irradiation 
showing a) a PLGA strand segment at initial stages, b) irradiation-induced energy perturbations resulting 
in bond re-orientation, ordering and patterning, c) energy emission-stimulated stereochemical changes 
toward a more stable PLGA conformation, d) intermediatary energy variable conformation between 
structures c) and e), where e) represents the most stable and least energetic PLGA strand conformation 
along with patterning of all methylene hydrogens at similar levels of geometrical coordination.  
 
3.3.7. Chemometric simulation of PLGA radiolysis due to the sterilization process 
Chemometric models of polymeric transitions under γ-irradiation are depicted in Figure 3.15 with 
molecular nodes generated by polymer coiling at the quaternary stage of the PLGA structure when γ-
irradiation was applied. The super-coiling of the polymer and the decoiling stages are stereo-
electronically and structurally compact, thus reducing the surface porosity of the sterilized DSMT 
device. Figure 3.15 denotes each cycle in the structural decoiling mechanism during γ-irradiation and 
the postulated nodes generated that are responsible for pore formation (14-point nodes in the model 
with the polymer interactive morphology linked to the iso-surface for inter-polymeric interactions). The 
internal cavity in Figure 3.15a is shown as a nodal geometric order in Figure 3.15b. The 
physicochemical parameters of this specification can mostly be reached in coiled pore formations for 
any other molecule to mimic the associated bioactivity other than GCV.  
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Figure 3.15: Chemometric structural models depicting the influence of the sterilization process on the 
DSMT device matrix and pore formation after irradiation where the mechanism of pore formation via 
polymeric decoiling is shown. 
 
Figure 3.16 shows the qualitative relationship of the energy absorption and change of the system at the 
initial point (En) and after irradiation at x levels (Ex). The difference is qualitative, though presumed to be 
at a higher end that does not permanently damage the polymeric material. The decay of the energy is 
also comparatively rapid than other conventional sources of energy such as heat or pressure. The plot 
represents a chemometric qualitative plot indicating the energy supplied to the polymeric device during a 
short span γ-irradiation energy relay. In Figure 3.16b the qualitative relationship of the energy emission 
and instant energy loss of γ-irradiation energy packets is depicted. The higher end energy of the 
polymeric device at Ex is rapidly changed during a short period. The energy can be said to be 
reflected back with the energy packets or quantas providing an equilibrating molecular effect and 
distribution of energy within the system. The energy loss is comparatively greater than the gain, 
though loss occurs in quantized and relatively regular relay packets rather than by erratic convection 
(as seen with heat loss). Thus the energy loss (Exs) is greater than the net gain of energy (Exn) by γ-
irradiation owing to the higher stability of the DSMT device after γ-irradiation rather than employing 
other sterilization processes. 
 
 
 
 
 
  66
 
Figure 3.16: Chemometric models depicting the qualitative relationship of a) energy absorption and 
energy change and b) energy emission and instant energy loss of irradiation energy packets within the 
DSMT device after γ-irradiation, where E=energy; T=time En=initial energy; Ex=energy applied, 
Exn=net gain in energy and Exs=net loss in energy. 
 
The copolymer PLGA is an amorphous type material. Amorphous materials do not have distinct melting 
points but rather go through a Tg phase as observed during the thermal studies performed. Secondly, it 
is worth mentioning that poly(lactic acid) (PLA) is thermally unstable (Zhang et al., 1992). Hence, the 
presence of this monomer randomly distributed within the PLGA copolymer backbone structure tends to 
increase chain flexibility and therefore during high energy processes such as γ-irradiation, it’s inclined to 
contribute to the widening in the copolymer molecular mass distribution and decrease the yield 
pressure. The yield pressure indicates the point where forces involved in consolidation have essentially 
been ‘broken’. Sterilization of the PLGA-based DSMT device generated significant energy within the 
internal structure of the device. The excess energy is dissipated and escapes gradually through the 
surface of the device altering the porosity, morphology and ultimately the physicomechanical properties 
such as the Tensile Strenght and Fracture Energy.  
 
Since it would have required significant modification of the current testing equipment to permit data to be 
collected in order to monitor these in situ changes in energy, this phenomenon was explored through 
chemometrical modeling. Presumably at energies above the Tg value, amorphous material would show 
a transformation in behavior with an increased ductility. Subsequently the device transitioned into a 
more rubbery state. It is well-known that above the Tg value molecular motions are very rapid which may 
lead to a decrease in the extent of polymer chain entanglement and an increased mobility of the polymer 
chain segments, whereas below the Tg value these motions are restricted and are regarded as almost 
‘frozen’. Figure 3.17 shows chemometric models representing γ-irradiation of the PLGA-based DSMT 
device within a single molecular voxel. When irregular PLGA strands (Figure 3.17a) are exposed to 
irradiation the irradiation effects produce networking and layering of the matrix upon exposure to γ-rays. 
 
T
E
Ex
Es
Energy Loss,   Ex,s= Ex - EsE
T
Energy Change, 
En
Ex
Ex,n= Ex - En(Qualitative)
a) b)
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Energetic transitions are induced as finite plate energy quanta as successive relays to affect 
stereochemical and molecular geometrical transitions at the atomic binding levels for bond stretching 
and expansion. This produces varying molecular geometrical or stereo sets of the matricized layers as 
depicted in Figure 3.17b where the last layer shows the remaining irregular PLGA strands where 
radiation is still to pass. Eventually the matrix transitions into an ordered configuration as depicted in 
Figure 3.17c. 
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Figure 3.17: Chemometric models representing γ-irradiation of the PLGA-based DSMT device showing 
a) irregular PLGA strands exposed to irradiation, b) the irradiation effects producing networking and 
layering of the matrix under γ-rays and c) total layering of the irregular matrix in an ordered 
configuration. 
 
 
The DSMT device’s morphological changes induced by molecular geometry and limited stereochemical 
organization patterning is shown in Figure 3.18. Initially a random state PLGA geometry and irregular 
morphology exists (Figure 3.18a). Once γ-irradiation is applied the initial effects induces polymeric chain 
disentanglement and re-orientation towards ordered patterning (Figure 3.18b). Complete patterning for 
the irradiation stance when partial energy from γ-irradiation quanta is being absorbed producing 
homogenization and equilibrating effects simultaneously with equi-distant pores in the matrix. The 
minimum energy conformers in a rigidized ordered patterning state after initial irradiation energy effects 
produces relatively equal energy distribution and solvation-like effects with the emission of excess 
energy. At this level the system is at a lower energy state in order to achieve stability over a 
comparatively longer period of time.  
 
The lower energy state of the matrix produces stabilizing effects rather than the patterning and 
orderliness of the matrix (it is for this reason that excess energy when supplied to the matrix is utilized in 
patterning, orderliness, equilibrating and near-solvation-and homogenization effects and the overall 
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energy status of the matrix remains toward baseline. Patterning may be responsible for the longer 
stability, and is responsible for a high energy kill for the detoxification and sterilization process. The 
matrix stability is linked to the lower energy state of the matrix which is lost as E+ from the matrix where 
E is the original startup energy of the matrix. Alternatively it can be represented as E- where energy is 
lost. The energy loss may be due to the quanta of energy exchange at the atomic level 
emissions/discharges of the surplus energy from the matrix while the irradiation is passed 
through/reflected from the inner dimensions of the matrix. The current understanding favors the E+ loss. 
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Figure 3.18: Chemometric models depicting the molecular geometry and stereochemical morphological 
transitions of the DSMT device after irradiation where a) is the random state PLGA irregular 
morphology, b) initial γ-irradiation effects producing polymeric strand disentanglement, c) complete 
orderliness of the irradiated matrix, d) minimum energy conformers in rigidized state for prolonged 
stability, e) stability of the DSMT before and after irradiation, and f) stability depiction as a factor of 
energy and time whereby, (i) before irradiation, (ii) stability after irradiation (the total energy within the 
matrix dissipates while the time is extended and (iii) equilibrium point of the energy level and time factor 
for non-algebraic quantitation of the stability factor. 
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3.4. Concluding Remarks 
 
Characterization of the γ-irradiated DSMT device revealed that the affected transitions favored the 
DSMT to be employed as an implantable intraocular device. PLGA can be regarded as suitably stable 
under compression and γ-sterilization for manufacture of the DSMT device. This is consistent with the 
broader expectation that amorphous type materials have a higher free energy. In addition this study has 
shown that as the characterization techniques for biomaterials progress, it is essential to rigorously 
consider the confounding improbabilities with the data obtained by detailed chemometric and 
molecular modeling approaches in order to draw comprehensive conclusions on the inherent behavior 
of the system at a micro-level. The approach employed has proven to be a flexible and powerful 
research tool for building and exploring models of complex polymeric structural networks subjected to 
various stresses during manufacture. 
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CHAPTER 4 
IN VIVO EVALUATION OF THE DONUT-SHAPED MINITABLET IN THE RABBIT EYE MODEL 
 
4.1. Introduction 
 
The technology for posterior segment drug delivery has progressed remarkably over the last five 
decades. Promising developments are implants designed to deliver drugs intravitreally that allow for 
higher intraocular drug levels (Kulkarni et al., 1962; Hayreh et al., 1966; Yolles et al., 1970; Macoul et 
al., 1975; Laties and Rapoport, 1976; Rapoport, 1977; Cunha-Vaz JG, 1979; Foulds et al., 1980; 
Moritera et al., 1991; Okada et al., 1991; Moritera et al., 1992; Giordano et al., 1993; Akula et al., 1994; 
Hashizoe et al., 1995; Miyamoto et al., 1997; Ding, 1998; Yang et al., 1998; Khoobehi et al., 1999; 
Einmahl et al., 2000; Yasukawa et al., 2000; Herrero-Vanrell and Refojo, 2001; Geroski and Edelhauser, 
2001; Hatefi and Amsden, 2002; Merodio et al., 2002; Jabs et al., 2003; Lallemand et al., 2003; 
Bonferonia et al., 2004; Lee et al., 2004; Yasukawa et al., 2004; Barbu et al., 2005; Myles et al., 2005; 
Benz et al., 2006; Choonara et al., 2006; 2007; Kassem et al., 2007; Motwani, et al., 2007; Eperon et al., 
2008; Li et al., 2009). The Vitrasert® device (Chiron Vision Inc., Irvine, CA, USA) which was approved by 
the US Food and Drug Administration (FDA) in March 1996, has been used with success in practice for 
the prolonged release of ganciclovir (Sanborn et al., 1992; Musch et al., 1997). However the device 
which is implanted through a 4-5mm sclerectomy at the pars plana is non-biodegradable and requires 
an additional surgical procedure to remove the device from the vitreous humor (VH) once the drug-load 
has been depleted. Previous studies using pigmented rabbits demonstrated that intraocular devices 
containing ganciclovir maintained a VH concentration within the therapeutic range for CMV-R for 2-3 
months (Moritera et al., 1991; Smith et al., 1992; Sanborn et al., 1992; Kimura et al., 1992; 1994; Harper 
et al., 1993; Hashizoe et al., 1994; Kunou et al., 1995; 2000; Veloso et al., 1997; Zhou et al., 1998; de 
Rojas Silva et al., 1999; Tan et al., 1999; Bourges et al., 2006). However most presented with a few 
disadvantages such as secondary bursts in the late phases of drug release, separation of suture tabs 
from the drug-loaded pellets and the ease and reliability of securing the devices to the scleral flap has 
not been ideal.  
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In an attempt to solve the challenges associated with achieving prolonged release of drug in the 
posterior segment of the eye and conferring biodegradability to posterior segment intraocular devices, 
previous studies by Choonara and co-workers (2006; 2007) described a novel biodegradable donut-
shaped minitablet (DSMT) employing poly(lactic-co-glycolic) (PLGA) as the polymeric carrier for the 
model antiviral drug ganciclovir. The DSMT device developed in these previous studies was implanted 
at the pars plana of the New Zealand White Albino rabbit eye model employing a simple surgical 
procedure for prolonged intraocular release of ganciclovir in the present study. Therefore the purpose of 
the current study was to evaluate the DSMT device in vivo in the rabbit eye model in order to assess the 
safety and potential of the DSMT device to provide constant drug release as a suitable and versatile 
intraocular drug delivery device.  
 
4.2. Materials and Methods 
 
4.2.1. Materials 
Resomer® grades RG503 (i.v.=0.32-0.44dl/g; Mw=41,000g/moL) and RG504 (i.v.=0.45-0.60dl/g; 
Mw=55,000g/moL) consisting of biodegradable poly(lactic-co-glycolic acid) (PLGA) with a 50% lactide 
content, were purchased from Boehringer Ingelheim GmbH, (Ingelheim, Germany). Ganciclovir (GCV) 
was purchased from Hoffmann-La Roche Inc. (Nutley, NJ, USA). Acyclovir (ACV) was used as the 
internal standard for drug content analysis and was purchased from Sigma-Aldrich Co. (St. Louise, MO, 
USA). Disodium hydrogen orthophosphate (Na2HPO4-), sodium chloride (NaCl) and potassium 
dihydrogen phosphate (KH2PO4-) were purchased from Saarchem-Holpro Analytic (Pty) Ltd., 
(Krugersdorp, Johannesburg, South Africa). All other reagents used were ultrapure grade. 
 
4.2.2. Preparation of the DSMT device  
The preparation of the DSMT device has been discussed earlier in this thesis and can be found in 
Chapter 3, Section 3.2.2. Further details can be read in a research publication by Choonara and co-
workers, 2006).  
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4.2.3. Sterilization of the DSMT device 
A terminal sterilization procedure in accordance with the guidelines stipulated by the UK Panel on 
Gamma and Electron Irradiation, (1987) was used as the preferred method over aseptic processing 
before implantation into the posterior segment of the rabbit eye model as detailed previously in Chapter 
3, Section 3.2.3 of this thesis.  
 
4.2.4. In vivo study design  
Twelve New Zealand White Albino male rabbits weighing 2.5-3.0kg were used for the in vivo animal 
study (Ethics clearance was obtained from the Animal Ethics Committee of the University of the 
Witwatersrand for this study, Ethics Clearance No 2006/40/04, see Appendix D and E). The animals 
were housed individually and were treated in accordance with the Association for Research in Vision 
and Ophthalmology (ARVO) Resolution on the Use of Animals in Ophthalmic and Vision Research 
(Rockville, MD, USA). The animals were held in a vivarium for at least one week prior to the surgical 
procedure (Figure 4.1). The rabbits were divided into two experimental groups of six rabbits each. The 
first group of six rabbits each received GCV-loaded DSMT devices formulated with Resomer® grade 
RG503 and the second group of six rabbits each received GCV-loaded DSMT devices formulated with 
Resomer® grade RG504.  
 
 
 
 
Figure 4.1: A digital image depicting the conditions under which the rabbits were housed in a vivarium 
according to ARVO Resolution guidelines.  
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4.2.5. Pre-operative screening of the rabbit eyes 
All rabbits were examined by slit-lamp bio-microscopy, tonometry, assessment of the menace response 
(i.e. reaction to hand motions toward the eye) and indirect ophthalmoscopic analysis through dilated 
pupils to exclude animals with any pre-existing anterior or posterior segment chorio-retinal abnormalities 
from the study. The rabbits were anesthetized with an intramuscular combination of ketamine 
hydrochloride (40mg/kg) (Pfizer, Morris Plains, NJ, USA) and xylazine (10mg/kg) (Bayer Animal Health 
(Pty) Ltd., Monheim, Germany) in a 4:1 ratio. Pupillary dilation was achieved with a topical instillation of 
cyclopentolate hydrochloride (2mg/mL) and phenylephrine hydrochloride drops (10mg/mL) 
(Cyclomydril®, Alcon Laboratories Inc., Fort Worth, TX, USA) 10-15 minutes prior to surgery. Thereafter 
preoperative facial preparation was undertaken with the right side of the rabbit’s eye region shaven in 
order to improve the ophthalmic surgeon’s visibility during surgery. Both eyes of a rabbit were rinsed 
with balanced saline solution (0.9%w/v) and the rabbit was draped in a conventional sterile manner, 
ensuring that the drapes did not occlude the rabbit’s nose or mouth. A description of the ocular 
appearance of the rabbit eyes and scores based on the severity of clinical signs were recorded. Specific 
signs graded were, ocular cloudiness (corneal edema, aqueous regions) and ocular discharge. To 
ensure intraoperative care the rabbits were positioned on a bed, which was equipped with a full-length 
gel pad. A pillow was placed under the rabbits head to reduce discomfort, and the torso was secured 
and covered with a warm blanket. A blood pressure monitor was used throughout the procedure and a 
pulse oximetry probe was placed on the rabbit’s penis with electrocardiogram leads. A carbon dioxide 
monitor was also positioned inside one of the nasal prongs of an oxygen cannula before placing the 
cannula in the rabbit’s nose. Supplemental oxygen was administered throughout the surgical procedure. 
The rabbit’s oxygen saturation remained stable at 100%. A GCV-loaded DSMT device was implanted 
into the right eyes of rabbits from each group and the left eyes were used as controls. The above 
procedures were consistent for all animals throughout the in vivo experiment. 
 
4.2.6. Surgical procedure for implantation of the DSMT device 
The surgical procedure involved implanting the DSMT device into the vitreous cavity via a pars plana (or 
peripheral retinal) incision. A supero-temporal or supero-nasal fornix-based conjunctival flap was formed 
and haemostasis was achieved. A circumferential 5-6mm incision was made 2mm posterior to the 
limbus. The wound was opened to check for full-thickness penetration into the vitreous cavity. 
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Prolapsing VH was pushed back with the DSMT device and the device was anchored with a 9-0 nylon 
suture passed through the scleral lip and then through the hole in the center of the device and then 
through the other scleral lip. Another two or three 9-0 nylon sutures were used to close the wound. The 
conjunctiva was repositioned but not sutured and chloramphenicol ointment was applied and used daily 
for 3 days after surgery. The positioning of the device was monitored post-operatively. All animals in this 
study were treated in accordance with the ARVO Resolution on the Use of Animals in Ophthalmic and 
Vision Research (Rockville, MD, USA). Figure 4.2 depicts sequential time-frame images of the surgical 
procedure for implantation of the DSMT device.  
 
 
Figure 4.2: Sequential time-frame images of the surgical procedure (±30 min; N=12) and a magnified 
image of the DSMT device implanted into the superonasal region of the vitreous cavity and visible 
through the lens of the rabbit eye model at day 3 after implantation (image no.16).    
 
Care was taken to ensure that the DSMT device was positioned without making contact with the lens 
and in order that the device could be monitored postoperatively. A 9-0 nylon suture was anchored to the 
scleral incision, tied, and cut short to avoid any irritation to the rabbit. Normal saline solution 
(NaCl=0.9%w/v) was used to rinse the implantation site and the device was inspected with an indirect 
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ophthalmoscope to confirm correct intravitreal placement. The rabbit’s face was then cleaned with sterile 
water to remove blood and residual preparation solution. 
 
4.2.7. Post-operative monitoring of the rabbits 
Any possible adverse effects of the DSMT device on ocular tissues were assessed by clinical 
observation (eye reflex and retinal examinations) and histological examination (Figure 4.3). Slit lamp 
examination, tonometric analysis for the measurement of intraocular pressure (IOP) in the test and 
control eyes of the rabbits and indirect ophthalmoscopic examinations were performed to evaluate the 
possible toxic effect of the DSMT device before and after implantation. Tissue reaction was monitored 
clinically by observing changes in the vitreous (vitreous haze) and retina (edema, chorio-retinal atrophy, 
vascular changes, exudative changes, and necrosis) adjacent to the implanted device. The presence 
and appearance of the DSMT device was also noted. Although the accuracy of IOP measurement is 
desirable, it is often the trend of change in IOP that one is most interested in. Numerous tonometers are 
used in animal experimentation, the accuracy of which has already been established in human eyes. 
However, when tonometers designed for human eyes are used in rabbits, their suitability is limited by 
the differences in the corneal anatomy (lack of Bowman’s membrane in rabbits), corneal rigidity, and 
tear film composition. The ideal tonometer selected was a handheld microprocessor-controlled 
tonometer that is a modified “Mackay-Marg” design of the TonopenTM XL (Reichert®, Depew, NY, USA) 
due to its accuracy, consistency and low variability in measurements. The instrument uses only the 
central part of the applanation area for pressure measurement, thereby minimizing the effect of 
differences in central corneal thickness. Dohadwala and co-workers (1998) have demonstrated that the 
TonopenTM XL is the most accurate for IOP measurements in humans and animals. Analysis was 
performed on the test and control eyes of all rabbits. Findings in an initial examination of all animals 
were normal, and baseline IOP measurements were recorded. The TonopenTM XL was first calibrated to 
the manufacturer’s instructions and measurements were repeated until the coefficient of variation was 
<5%. All tonometric measurements were performed by the same ophthalmic surgeon. To correct 
tonometry estimates that provide a closer approximation of the actual IOP in rabbits, Equation 4.1 was 
used as derived by Lim and co-workers (2005) from a linear regression study. Lim and co-workers 
(2005) demonstrated that the TonopenTM XL showed the least error in estimation of true pressure. 
However, there was a high degree of variability in the measurements, especially at higher IOPs, where it 
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significantly undervalued the IOP and therefore a correction factor was introduced (Equation 4.1). 
Despite this variability the TonopenTM XL plays a significant role in cases where the main objective is to 
report a change in IOP trend rather than an absolute measurement. 
 
Actual IOP (mmHg) = 1.12(TonopenTM XL) + 3.07       Equation 4.1 
 
Where, the term ‘(TonopenTM XL)’ is the IOP reading obtained during the measurement.  
 
 
 
Figure 4.3: Digital images depicting the post-operative ophthalmoscopic monitoring procedures (reflex 
and retinal examinations) undertaken to assess the safety and toxicity of the DSMT device. 
 
4.2.8. Enucleation procedure for evaluation of the DSMT device in the rabbit eye model 
A total of two rabbits, one from each group of six were enucleated at pre-determined time intervals. Prior 
to euthanization retinal examinations was performed and 2mL blood samples were removed from the 
marginal ear vein. The rabbits were euthanized with an overdose of intravenous sodium pentobarbitone 
(200mg/kg) (Euthanaze®, Centaur Labs, Johannesburg, South Africa) on days 3, 7, 14, 28, 48, and 72 
after implantation. Following euthanasia, VH was aspirated from the eyes using an 18G needle 
introduced into the VH through the sclera and pars plana 1cm posterior to the limbus. VH from the left 
eyes (non-test eyes) was used as controls. All VH and blood samples (removed from the marginal ear 
vein of the rabbits) were stored at -70ºC prior to GCV concentration analysis by Ultra Performance 
Liquid Chromatography (UPLC). The partially eroded DSMT devices were removed and the ocular 
tissues from the test and control eyes each comprising the cornea, iris, ciliary body, and sclera, were 
collected, immersed in glutaraldehyde/formalin (Fisher Scientific®, Pittsburgh, PA, USA) and 
histopathological examinations were thereafter performed. Figure 4.4 depicts sequential time-frame 
images of the enucleation procedure.  
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Figure 4.4: Time-frame images of the enucleation procedure (± 30min; N=12). 
 
4.2.9. Histomorphological examination to assess the toxicity of the DSMT device 
Possible adverse effects of the DSMT device on the ocular tissues were evaluated by histological 
examination under light microscopy after histological staining of the test and control eye tissue samples. 
Once the rabbit eyes were enucleated at 3, 7, 14, 28, 48 and 72 days after implantation and the partially 
eroded DSMT devices and VH samples were removed, the ocular tissues were immersed in formalin for 
24 hours. Globes were then opened at the equator and separated into anterior and posterior segments 
and the incised specimens were dehydrated, infiltrated, embedded in paraffin, and sectioned with a 
microtone and stained with hemotoxylin and eosin and assessed microscopically. Ocular tissue were 
graded by two blinded observers, for extent of tissue destruction (histological grade based on a scoring 
scheme of 0=normal to 4=no recognizable structure), and type and extent of inflammatory cells present 
in the iris, iridocorneal angle, and ciliary body.  
 
4.2.10. Influence of the DSMT device on the micro-environmental pH of vitreous humor 
The control of enzymatic and structural processes that occur within the posterior segment of the eye and 
protein-protein interactions are likely to be influenced by changes in pH and ionic concentrations as a 
result of PLGA degradation into lactic and glycolic acid through cleavage by enzymatic or non-enzymatic 
hydrolysis (Kuck, 1975; Peracchia and Peracchia, 1980; Summers et al., 1984;). Since the DSMT 
device is PLGA-based it is crucial to have an accurate measure of the internal pH of the VH, as the 
degradation of the DSMT device may influence the inherent pH of the VH. Therefore changes in pH 
within the VH due to degradation of the DSMT device was assessed by ex vivo incubation of 5mL fresh 
VH aspirated from two enucleated rabbit eyes (controls) and swiftly placed into test tubes 10mm in 
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diameter (Figure 4.5). The test tubes were then incubated for 3 months after immersing a DSMT device 
in close proximity to the center of the VH. The micro-environmental pH variation in close proximity to the 
immersed DSMT device (<5mm of the eroding surface) was monitored with a MPT-2 Multi- purpose 
titrator equipped with a rapid response, liquid filled glass pH micro-electrode supported on a vertical 
puller (Malvern Instruments Ltd., Worcestershire, UK). The changes in pH were evaluated from a pH-
time profile. The electrode calibration standards were adjusted to cover the buffer range from pH 6.1-7.5 
with a linear Nernstian response maintained.   
 
 
pH <5mm from eroding DSMT 
Fresh vitreous fluid aspirated 
from the rabbit eye
DSMT immersed at center of 
vitreous fluid
Micro-Electrode 
(Linear Nernstian response)
No turbulent hydrodynamic flow created
Test tubes incubated for 3 months
10mm
Glass test tube
pH=7.25
Superficial 
vitreous
pH=7.4
Addition of 
Lactic acid (pH=6.55)
pH= 6.60+0.04 (N=3)
Resting pH=7.4
Mechanisms capable of extruding H+ against an electrochemical gradient   
 
Figure 4.5: A schematic diagram detailing the experimental procedure used to assess the potential for 
micro-environmental pH changes within the VH as a result of DSMT implantation. 
 
4.2.11. Quantification of in vivo ganciclovir released from the DSMT device 
 
4.2.11.1. Preparation of calibration standards 
Stock solutions of GCV were prepared (5mg/mL) and aqueously diluted further with deionized water to 
prepare spiking solutions with GCV concentrations ranging between 0.1-5.0µg/mL. In order to prepare 
the calibration standards used for generating a standard curve of GCV in VH and for method validation, 
100µL aliquots of the spiking solutions and the internal standard solution of ACV (initial concentration of 
1mg/mL) were added to inert polypropylene tubes that each contained a 250µL aliquot of blank rabbit 
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VH previously thawed and centrifuged at 15000g for 10 minutes. A liquid-liquid phase extraction 
methodology was used for the extraction of GCV from the blank rabbit VH in order to prepare a 
calibration profile. To each calibration standard 250µL of acetonitrile was added to the spiked VH 
standards in a quantification range of 0.1-5.0µg/mL. The tubes were then capped, vortexed (Vortex-
Genie 2, Scientific Industries Inc., Bohemia, NY, USA) for 15 seconds and centrifuged (Optima® LE-
80K, Beckman Coulter Inc., Fullerton, CA, USA) at 15000g for 10 minutes. Aliquots (300µL) of the 
supernatants were filtered through a 0.22µm Millipore® filter and transferred to UPLC injection vials. 
Thereafter 5µL was injected onto the UPLC column for GCV content analysis. The ratio of the peak 
areas (between the internal standard ACV, and GCV) versus the concentration data for the calibration 
standards was fitted by linear regression to generate the calibration curve. This procedure generated a 
set of five calibration standards with concentrations ranging from 0.1-5.0µg/mL of GCV in rabbit VH. The 
five calibration standards were used to construct a standard linear curve and additional calibration 
standards were prepared and analyzed for validation runs for precision and accuracy analysis of the 
assay method. Figure 4.6 displays the standard linear curve constructed for the determination of GCV 
concentrations form the VH samples in the rabbit eye model (R2=0.99).  
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Figure 4.6: Calibration curve of GCV concentrations in blank rabbit VH. 
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4.2.11.2. Extraction of ganciclovir from the aspirated vitreous fluid samples 
Frozen study samples were thawed at room temperature (21±0.5°C) and allowed to environmentally 
equilibrate. The samples were then centrifuged at 15000g for 10 minutes. The sample biological matrix 
matched the matrix employed for the calibration standards. Aliquots (250µL) of the VH samples were 
transferred using a graded micro-syringe (±0.5µL) (Hamilton (Pty) Ltd., Bonaduz, GR, Switzerland) into 
polypropylene tubes. Deionized water (100µL) was added to each tube and the tubes were vortexed for 
15 seconds. The same procedure used for the extraction of the calibration standards (with the addition 
of 250µL acetonitrile) and UPLC injection of calibration standards were applied to the diluted VH 
samples to ascertain GCV content. An appropriate dilution factor was used to adjust the final GCV 
concentration obtained (Figure 4.7).  
 
 
Figure 4.7: A flow diagram detailing the solid phase extraction procedure utilized for GCV concentration 
analysis for the rabbit VH samples. 
 
4.2.11.3. Chromatographic procedure for ganciclovir concentration analysis 
The concentration of GCV released into the rabbit VH from the DSMT device was determined using 
Ultra Performance Liquid Chromatography (UPLC). Analyses were performed on a Waters® Acquity 
UPLCTM system (Waters Corp., Milford, MA, USA) consisting of an Acquity UPLCTM binary solvent 
manager and an Acquity UPLCTM sample manager. Separation of GCV was obtained with an Acquity 
UPLC BEH C18 column (1.7µm; 1×100mm) and a photodiode array (PDA) detector set at 254nm. The 
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binary mobile phase comprised 0.05M ammonium acetate at a pH of 6.8 and acetonitrile in a ratio of 
96:4%v/v. A solvent flow rate of 0.25mL/min was maintained with an average initial pressure of 6500psi. 
The program followed was isocratic and 5µL of the extracted and pre-filtered samples were injected onto 
the column. The column and sample manager temperature was maintained at 21±0.5ºC. Prior to use, 
the column was equilibrated by passing 45mL of mobile phase solvent through the system. The eluant 
was monitored at an analytical wavelength set at 254nm and the entire assay procedure was performed 
at room temperature (21±0.5ºC). ACV was used as the internal standard. A standard linear curve was 
used to assess the concentration of GCV released from the device at various time points. The recovery 
of GCV obtained during the extraction procedure spiked into blank VH samples from the non-test rabbit 
eyes was 102.69±1.50%, indicating the valid evaluation of GCV concentrations in the VH of the rabbit 
eye model. 
 
4.2.11.4. Precision, accuracy and ganciclovir stability analysis during assay procedure 
To assess the precision and accuracy of the assay method employed aliquots of each of the calibration 
standards were repeated in each of three assay runs. Furthermore, two calibration standards at each 
concentration, in addition to those used to generate the standard calibration curves, were prepared and 
analyzed in each of three runs. The data was then analyzed by ANOVA (Single Factor), (Minitab® 
Software V14, Minitab Inc., State College, PA, USA) to generate intra-assay and inter-assay coefficients 
of variation expressed as percentages (CV%). Accuracy was assessed by evaluation of mean recovery, 
defined as the ratio of mean found concentration to nominal concentration, expressed as a percentage. 
Recovery of GCV during the extraction procedures in the VH samples was assessed by replicate 
analysis (N=5) of the lower and upper concentration limits of the calibration standards and compared to 
those obtained by injection of aqueous solutions of GCV prepared at the same concentrations 
corresponding to the standards. Both extracted calibration standards and the aqueous samples were 
injected onto the UPLC column employing the same chromatographic conditions as in the assay method 
developed. The stability of GCV in frozen VH samples was assessed by periodic analysis of the 
calibration standards stored under the same conditions as the test samples and at -70ºC. Stability of 
GCV in the thawed VH samples was evaluated by replicate analysis of the calibration standards at the 
lower and upper concentration limits.   
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4.3. Results and Discussion  
 
4.3.1. Preparation of the DSMT device 
DSMT devices comprising 5%w/w GCV were prepared employing Resomer® RG503 and Resomer® 
RG504. Figure 4.8 depicts a digital image showing the typical size of a sterilized DSMT device prior to 
implantation in the rabbit eye model. 
 
 
Figure 4.8: Digital image indicating the dimensions of a DSMT device in comparison to a USA one dime 
coin prior to implantation into the New Zealand White Albino rabbit eye model.  
 
4.3.2. Pre-surgical assessment of rabbit eyes prior to implantation of the DSMT device 
Typical photographic evaluation in conjunction with indirect ophthalmoscopy and slit-lamp microscopy 
was undertaken for pre-surgically assessing the rabbit’s eyes prior to implantation of the DSMT device 
(Figure 4.9). The photographic images of all animals were shown to be superimposable. Magnifications 
of the images were performed to determine whether subtle variations in capillary diameter occurred. The 
results of the photographic evaluations, in all cases, revealed that there was no detectable change in the 
anatomical features of the rabbit eyes and all findings were within normal limits suggesting that the eyes 
were not irritated. 
 
 
a) b)
 
Figure 4.9: Digital images depicting a) indirect ophthalmoscopic examination and b) slit-lamp 
microscopic examination of the rabbit’s eyes prior to implantation of the DSMT device.  
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 4.3.3. Post-surgical assessment of complications after implantation of the DSMT device 
The DSMT device appeared to be well tolerated up to a last time point reaching 72 days in the rabbit 
eye model and was visible by indirect ophthalmoscopic analysis in the supero-temporal quadrant of the 
eye (Figures 4.10a and b). Of the 12 rabbits studied, three had small postoperative hyphaemas, visible 
after the surgery and for up to 7 days. Two had vitreous hemorrhages and one had a retinal detachment 
by two weeks. There were no infections or inflammation and no cataract formation. At day 3 the surgical 
wound made at implantation was completely healed (Figure 4.10c). Clinically no changes were 
observed in the VH, retina or choroid such as vitritis, vascular changes, exudative changes, necrosis or 
traction. Preliminary histological examinations revealed no significant difference between the test and 
control eyes except for the presence of poorly-formed multi-nucleated giant cell infiltrates around the 9-0 
nylon suture site. In addition, no focal disruption of the normal inner retinal architecture was observed. A 
non-significant inherent anterior segment hemorrhage was detected in one rabbit from the initial 
experimental group of six rabbits that received a DSMT device formulated with Resomer® RG504. 
However, this finding was as a result of intraocular pressure variation during the surgery and not directly 
caused by the presence of the DSMT device. No filtering bleb around the wound or leakage of VH from 
the wound was observed. The matrix of the DSMT device was visually observed and estimated to swell 
gradually due to hydrolysis but was not significant to induce any complications. The DSMT device 
eroded steadily over the 72 day period of the study with minute opaque fragments remaining within the 
VH space. The biocompatibility of the polymer PLGA has been extensively reported in the intraocular 
region (Langer et al., 1983; Heller et al., 1984; Lee et al., 1988; Charles et al., 1991; Giordano, et al., 
1995; Deshpande et al., 1998; Morita et al., 1998; Einmahl et al., 1999).   
 
 
 
Figure 4.10: Post-surgical monitoring and examination of the test and control eyes. Digital images 
showing a) direct ophthalmoscopic examination after 72 days, b) the patent ophthalmic reflex of a rabbit 
with a DSMT implanted into the superonasal quadrant of the eye and c) the surgical wound completely 
healed at day 3. 
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Slit-lamp examinations showed a normal appearance of the ocular surface in all animals after the DSMT 
device was removed. It was noted that rabbit 3 had a rather narrow fornix, due to an oriental lid crease. 
Prior to the experiment, redness was grade I for all rabbits (i.e. no redness) and no changes in redness 
were observed throughout and after the experiment. All rabbits had a normal appearance of the anterior 
segment before implantation of the DSMT device and after removal except for one in which an 
insignificant anterior segment hemorrhage was noted. None of the rabbits showed corneal punctuate 
staining before installation of the device, or afterwards. On the first postoperative day, the right eyes of 
the rabbits were mildly red, but no discomfort was noted. Vision in the right eye was graded as normal, 
with the rabbits not displaying any gross distress or difficulty in identifying their surroundings. Indirect 
ophthalmoscopic examination detected minimal vitreous hemorrhage and verified that the DSMT device 
was in the correct position. The rabbits were re-examined initially daily for 7 days and thereafter at 
weekly intervals after the surgery. At a 1 month postoperative clinical examination, the rabbit’s vision 
was considered normal in both eyes, and the presence of any vitreous hemorrhage had resolved 
(Figure 4.11). 
 
 
Figure 4.11: Digital image showing the patent ophthalmic reflex of a rabbit with a DSMT implanted into 
the superonasal quadrant of the eye. 
 
Tonometric analysis in the rabbit eye revealed that the use of an instrument calibrated for human use 
resulted in a gross underestimate of IOP measurement in the rabbit eye. Therefore this underestimate 
was accounted for by the linear regression model of Lim and co-workers (2005). IOP measurements 
recorded via the use of the TonopenTM XL revealed a trend of no drastic change in the IOP of the 
rabbit’s eyes after implantation of the DSMT device (Figure 4.12). The mean IOP measurements for all 
rabbits (N=12) were within a range of 6-8mmHg and in close proximity to the baseline measurements 
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before implantation of the device and the control eyes. The slight variations noted from the IOP 
measurements are as a direct result of the technique used to measure the IOP from the rabbit eye 
model that is dependent on the corneal anatomy (lack of Bowman’s membrane in rabbits), corneal 
rigidity, and tear film composition as reported by Lim and co-workers (2005). 
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Figure 4.12: Profiles showing the variation in intraocular pressure in relation to the baseline after 
implantation of the DSMT device in the rabbit eye. 
 
4.3.4. Histological examination and toxicology analysis  
A progressive inflammatory response was noted in the ocular tissue, centered predominately around the 
ciliary body and in the posterior segment (Figure 4.13a). The initial response was that of an acute 
inflammatory reaction with hemorrhage, edema and a predominately neutrophilic infiltrate (Figure 
4.13b). The inflammatory reaction then became more chronic in nature with lymphocytes, occasional 
eosinophils, plasma cells and fibroblasts noted (Figure 4.13c). A foreign body type giant cell response 
was also appreciable (Figure 4.13d). The hemorrhage and edema had subsided by day 28. Some 
foreign material was noted in association with the foreign body giant cell response (day 28). After 72 
days, a minimal residual inflammatory response was noted and of significance, there was no evidence 
of a sympathetic ophthalmitis, no evidence of chronic fibrosis and no histopathologic evidence of 
damage to the ciliary body or retina. There was no histopathologic evidence of damage to the ocular 
tissue and no evidence of an exuberant inflammatory response. The retina in the posterior pole 
remained intact (Gould et al., 1994; Dubielzig et al., 1997; Gilger et al., 1999).  
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Figure 4.13: Digital images of hemotoxylin and eosin stained histological slides  showing a) and b) the 
sclerotomy after implantation of a DSMT device at 7 days with foreign material noted (suture) and a 
giant cell response (original magnification ×25); c) and d) residual inflammatory cells infiltrate the matrix 
and the intact retina at the implantation site after 72 days in the rabbit eye model with no evidence of a 
sympathetic ophthalmitis, chronic fibrosis or damage to the ciliary body (original magnification ×50). 
 
Fibroblasts, neutrophils and multinucleated giant cells were infiltrating into the matrix pores in the course 
of degradation, but no significant inflammatory reaction was observed in the VH. No retinal detachment 
occurred around the DSMT implant. At 3 weeks after implantation, the device begun to erode and was 
visually evident in the VH. It was also observed that the sclerotomy site had been closed with fibrous 
connective tissues and the infiltration of inflammatory cells had been further decreased around the 
sclerotomy site. Furthermore, grading by the two blinded observers for extent of tissue destruction 
related that all rabbits were given a score of 0 (normal) for the type and extent of inflammatory cells 
present in the iris, iridocorneal angle, and ciliary body.  
 
4.3.5. Drug extraction and assay procedure 
Figure 4.14 depicts a typical UPLC chromatogram showing the simultaneous separation of GCV and 
ACV (internal standard) from the rabbit VH samples at 3 days after implantation of the DSMT device, 
where GCV was eluted at approximately 1 minute and ACV at 1.35 minutes. Validation of the assay 
method indicated that intra-day and inter-day precision and accuracy as well as the recoveries were 
satisfactory (R2=0.99; RSD±0.02%; see Appendix G). The assay method developed and validated 
employed acetonitrile to precipitate proteins from the VH samples. To avoid any deleterious effects of 
overloading the column with acetonitrile, the injection volume was maintained at 5µL. An Ultraviolet (UV) 
photodiode array (PDA) detector was used for detection and quantification of GCV levels in the VH 
samples. ACV was used as the internal standard. The mobile phase concentration of acetonitrile and 
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ammonium acetate at a pH of 6.8 provided adequate retention of GCV and ACV on the UPLC column. 
The assay method was validated for the range of GCV concentrations from 0.1-5.0µg/mL in VH. The 
signal to noise ratio at the lower limit of quantification (0.1µg/mL) was >10.  
 
GCV: 1.01min
ACV: 1.35min
 
Figure 4.14: Typical 3D Ultra Performance Liquid Chromatogram of GCV and ACV separation from the 
rabbit VH samples.  
 
Analysis of blank VH samples showed no interfering peaks at the retention times of GCV and the 
internal standard ACV (Figure 4.14). The precision of the assay method in VH was assessed by 
determination of the intra-assay and inter-assay coefficients of variation (CV%) of the method from 
replicates of each calibration standard in each of 3 runs (N=8). The accuracy of the assay method was 
evaluated from the calibration standards by the mean recovery defined as the ratio of the mean found 
concentration to the nominal concentration, expressed as a percentage. Absolute recovery of GCV from 
the VH samples was performed by comparison of peak areas from extracted low and high calibration 
standards to those from aqueous standards. A CV%=5.38% and mean recoveries ranging from 97.4-
101.0% (R2=0.99) was obtained.  These results indicated essentially complete recovery of GCV after the 
extraction process. Stability studies of GCV in the rabbit VH indicated no changes in GCV 
concentrations upon storage of the samples frozen over 4 months at -70ºC or upon subjecting the VH 
samples to three freeze and thaw cycles. A simple UPLC method employing an isocratic gradient has 
been validated for the determination of GCV in the rabbit VH samples employing ACV as the internal 
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standard. The validated range and lower limit of quantification (0.1µg/mL) of the method was desirable 
for further pharmacokinetic studies.  
 
4.3.6. In vivo release of ganciclovir in the rabbit eye model from the DSMT device 
As expected the DSMT device manufactured employing PLGA grade Resomer® RG504 provided 
superior control in GCV release than Resomer® RG503 with sustained release of GCV in the VH cavity 
over a period of 72 days (Figures 4.15 and 4.16). The cumulative release of GCV released from the 
Resomer® RG504 DSMT device at a constant GCV loading of 5%w/w is shown in Figure 4.15. The 
cumulative drug release profile was obtained by measuring the percentage of GCV released versus the 
initial content loaded in the DSMT device (Figure 4.15). The data is consistent with a reduced biphasic 
profile as noted from the previous in vitro study by Choonara and co-workers (2006; 2007), that was 
primarily due to the rapid release of GCV deposited on the surface of the rigid Resomer® RG504 matrix 
(Figure 4.15a). However for the current in vivo study the DSMT device was initially equilibrated in sterile 
saline prior to implantation. This additional procedure may have resulted in removal of the patent 
deposition of GCV molecules on the surface of the device. Thus the release of GCV from the device 
was constant and controlled by the degradation rate of the polymer. The release rate increased with the 
decrease of the molecular mass of PLGA. This rate was probably due to the difference in the 
degradation rate of the polymers. Degradation of PLGA could be influenced by the composition of the 
lactide and glycolide content with the higher the glycolide content, the faster the degradation rate (Baker 
et al., 1974).  
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Figure 4.15: Profiles of a) in vitro release (Choonara et al., 2006; 2007) and b) cumulative in vivo 
release of GCV from a Resomer® RG504 DSMT device over a period of 72 days (N=6; SD<3.31 in all 
cases). 
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Devices formulated with Resomer® grade RG503 displayed a higher quantity of GCV release within the 
50% effective dose (ED50) range for the treatment of human CMV-R as compared to DSMT devices 
formulated with Resomer® grade RG504 (Figure 4.16). The in vitro ED50 of GCV for human CMV-R has 
been previously determined to be approximately 0.1-2.75µg/mL (Mar, 1983; Martin, 1983; Smee, 1983; 
Tocci et al., 1984; Plokin, 1985). The intravitreal GCV concentrations were maintained within the ED50 
range over 72 days. In comparison to the previous in vitro release data obtained, the in vivo release 
profile displayed a reduced initial burst phase with <20% GCV released at day 3, 40% by 28 days,  50% 
by day 48 and 69% after 72 days in the rabbit eye model. The in vivo release data has been 
represented as semi-logarithmic plots in order to assess the effective levels of GCV reached within the 
VH in terms of achieving an ED50 for the treatment of CMV-R in HIV+ patients (Figure 4.16). Although 
the DSMT device has maintained the VH concentrations of GCV within the ED50 of GCV for 72 days, in 
order to refine the higher drug release produced by DSMT devices manufactured with Resomer® grade 
RG503, the Resomer® grade RG504 devices produced more controlled GCV release with a reduced 
quantity of GCV released over the same period. The GCV concentrations in the systemic circulation and 
the control eyes were <0.1µg/mL which was the detectable limit of the GCV UPLC assay during the 
study period.   
 
From the previous in vitro drug release study (Choonara et al., 2006), the initial phase of GCV release 
that was termed as a “burst-release phase” was due to drug particles deposited onto the surface of the 
DSMT device that subsequently provided an initial spike of approximately 30% in vitro release of GCV. 
The second phase of release (comprising the remainder 60-65% of the drug-load) was regarded as a 
constant drug release phase that significantly depended on the relatively constant surface area created 
by the donut-shaped geometry of the DSMT. Interestingly, during the current in vivo animal study the 
initial burst-release phase was significantly reduced (<20%) due to the higher viscosity of the rabbit eye 
VH (compared to enzyme and protein-free PBS of pH 7.4; 37°C) that subsequently controlled the 
outward diffusion of GCV during the in vivo study. In addition, the pre-treatment of the DSMT device with 
sterile normal saline solution (NaCl=0.9%w/v) prior to implantation facilitated the removal of patent GCV 
molecules deposited onto the surface of the DSMT device during device manufacture. The release of 
GCV from the DSMT device which has a constant surface area that is controlled by the erosion 
mechanisms of the polymer followed constant drug release kinetics. This was primarily as a result of 
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synchronization of front velocities at the erosion interfaces. For conventional tablet geometries this may 
not be possible as the total surface area accommodating drug release decreases over time even though 
hydrophilic swellable/erodible polymers are employed resulting in a deviation from constant drug release 
kinetics. The absence of a central hole does not allow for compensating the decrease in the releasing 
surface area of the device due to their asymmetrical design.      
Attempts have been made to obtain constant drug release kinetics via the use of semi-permeable 
membranes and non-erodible polymers such as in the case of the Vitrasert® intraocular device (Smith et 
al., 1992; Sanborn et al., 1992). These approaches (that may also be restrictive in terms of drug-loading 
capacity) have been attempted in an effort to minimize the effect of the decreasing releasing surface 
area on achieving constant drug release kinetics. However, such an approach requires advanced 
manufacturing technologies due to the complicated asymmetrical design and multi-component device 
configuration (Heller et al., 1987). Thus, in our present study a simple symmetrical “donut-shaped” 
geometry was used to provide constant drug release kinetics as an implantable extended release 
biodegradable intravitreal drug delivery device. The erosion controlled principles of the PLGA used to 
manufacture the DSMT are exercised with a reduced effect of the releasing surface area over time. 
Generally, drug release from a matrix occurs from all surfaces (circular faces and lateral areas). During 
drug release, the releasing surface area decreases over time. However, the DSMT reduces the effect of 
the releasing surface area laterally. Typically, drug release occurs through the central hole, a lateral 
area and the circular faces (Figure 4.8) and therefore the DSMT can maintain a constant drug releasing 
surface area over time. From the general behavior of observed erosion boundaries and diffusion fronts 
during GCV release from the DSMT, it was evident that the decrease of releasing surface area from the 
outer lateral area was compensated by the increase of releasing surface area from the central hole. This 
resulted in a constant drug releasing surface area laterally. After 2 months post-implantation the central 
hole in the device was still proportionately open although the size of the device was slightly reduced due 
to erosion. This finding suggested that GCV diffused through channels within the polymer matrix during 
biodegradation. However the mass of the polymer did not change until the production of oligomers, 
which were sufficiently small to solubilize by random hydrolytic chain scission. 
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Figure 4.16: Semi-logarithmic plot of GCV released from the DSMT device after 72 days of implantation 
in the VH of the rabbit eye model (N=12). The upper and lower bounds of the 50% effective dose (ED50) 
of GCV for human CMV-R replication are also shown.  
 
4.3.7. Micro-environmental pH variation analysis within the vitreous humor 
It was usually observed that the superficial VH immediately adjacent to the immersed DSMT device 
exhibited higher pH values than the VH immediately surrounding the device. The pH, measured as 
close as possible to the device, was 7.25±0.01 (N=3). The pH electrode was inserted using a Narashige 
micro-manipulator and was submerged towards the DSMT device by careful hydraulic micro-
movements to avoid creating any unnecessary turbulent hydrodynamic flow. A slight drop in pH was 
routinely recorded as the electrode passed in proximity to the DSMT device with a slightly more acid pH 
than the entire VH sample (pH 7.20±0.01) around a superficial surface diameter of 5mm (Figure 4.17). 
The pH, measured away from the superficial layer was 7.40±0.02 (N=3). Attempts were made to perturb 
the inherent pH of the VH by adding incremental volumes of lactic acid of pH 6.55 (a significantly > 
volume than would be produced on degradation of the PLGA-based DSMT device in the VH) and 
incubated for 90 days. Samples were measured before and after incubation. After the lactic acid 
incubation period the pH recorded within the VH was 6.88+0.02 (N=3) and not significantly different from 
the resting pH of 7.40. After further addition of lactic acid solution of pH 6.55, the inherent pH was 
reduced to 6.60±0.04 (N=3). It would appear that the VH was able to maintain its internal pH close to a 
value of 7.40 in the presence of a more alkaline medium but could not do so in the presence of a largely 
acidic medium. The effect of lactic and glycolic acid perfusion from PLGA degradation can be seen in 
Figure 4.17. On exposure to degradation, an alkalinization is observed of some 2 pH units and this is 
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followed by a return towards the control value of pH 7.40. The characteristic biphasic response was 
observed in all experiments (N=3) but the amplitude of the pH change recorded was dependent on the 
position of the pH electrode tip (Figure 4.5). The response was smaller when the electrode was placed 
close to the DSMT device, presumably because the tip was insulated from pH fluctuation by overlying 
layers of well-buffered VH. In most experiments the pH overshoots on return to control and very minimal 
periods of acidosis was noted from which it recovered over an average period of 10 days. The pH of the 
VH has been measured by a number of indirect techniques. Duke-Elder (1946) found the intraocular 
fluid to be ’alkaline to litmus’ and concluded that indicator methods had generally shown the VH to be 
more acid than blood. Davison and Luck (1956) obtained a value of 7.20 for the pH of rabbit VH. The 
present study represents an ex-vivo measurement of pH in the rabbit VH. The fact that the pH was 
found to be slightly higher at 7.40 supports Duke-Elder’s (1946) notion that the higher pH values are due 
to a loss of CO2, from the eye when the globe is opened. Estimates of pH in mammalian VH by indirect 
methods range from 7.40 (Bellows, 1944) to 6.9 (Greiner et al., 1981). This indicates the presence of 
mechanisms capable of extruding H+ ions against, an electrochemical gradient.   
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Figure 4.17: Ex vivo changes in vitreous pH induced by implantation of the DSMT device. pH transients 
for electrodes at a superficial surface of 5mm from the submerged DSMT device. For both formulations 
the initial alkalinization phase (7.41) was followed by an acidic overshoot of pH 7.39 on return to control 
(7.40).  
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4.4. Concluding Remarks 
 
In this study we have demonstrated that the biodegradable DSMT device may provide a significant 
innovation to the current cache of intravitreal drug delivery technologies for the treatment of posterior 
segment eye diseases such as CMV-R. The DSMT device was well tolerated in the rabbit eye model 
without any adverse effects or toxicity over the entire duration reaching 72 days in this study. 
Histopathological examination revealed that the device was non-toxic to intraocular tissue structures. 
GCV release in the VH of the rabbits from the DSMT device was maintained within the ED50 range for 
the treatment of human CMV-R. Our study has shown that constant drug release can be obtained with 
the DSMT device due to the unique geometry of the device as well as the use of PLGA with varying 
molecular mass, lactide:glycolide ratios, drug loading capacities and compressive forces during 
tableting. The DSMT device is sufficiently flexible and may be used for the effective long-term intravitreal 
delivery of drugs for the treatment of various posterior segment eye diseases.  
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CHAPTER 5 
EXPLORATORY DATA ANALYSIS EMPLOYING COMPARTMENTAL AND NON-
COMPARTMENTAL PHARMACOKINETIC MODELING ANALYSIS  
 
5.1. Introduction 
 
The posterior segment of the eye may be affected by various vision impairing diseases such as viral 
retinitis, bacterial and fungal endophthalmitis, proliferative vitreoretinal disorders and diabetic 
retinopathy. Topical and systemic administration of drugs may not deliver effective therapeutic 
concentrations to the posterior segment of the eye (Lesar and Fiscella, 1985; Geroski and Edelhauser, 
2000; Lee et al., 2004). Due to the protective blood-ocular barriers approximately <1% of topically 
applied drug is available to the anterior segment and only a small fraction of drug present in the anterior 
segment reaches the posterior segment of the eye (Lee and Robinson, 1986; Lee et al., 2004). In 
addition, the blood-aqueous and blood-retinal barriers limit the penetration of drug molecules to the 
internal tissues of the eye such as the retina and choroid from the systemic circulation (Cunha-Vaz, 
1979). Direct intravitreal drug administration and intraocular devices have been employed as an 
effective means of treating the majority of vitreo-retinal diseases proliferating in the posterior segment of 
the eye (Graham and Peyman, 1974; Cochereau-Massin et al., 1991). Therefore knowledge regarding 
the distribution and elimination of drug molecules from the vitreous cavity is necessary in order to 
develop optimal drug therapy. A major limitation in assessing the ocular pharmacokinetics of drugs from 
in vivo animal models such as the New Zealand White Albino rabbit is the fact that a single rabbit must 
be used for a single time point. Thus in order to obtain a comprehensive pharmacokinetic (pK) profile 
with minimal variability approximately 6-20 rabbits needs to be sacrificed at each time point as a 
sufficient number of intervals must be selected to adequately characterize the distribution and 
elimination processes in the posterior segment of the eye (Schoenwald, 1990).  
 
The application of pK modeling is significant in the drug molecule approval process and the 
development of novel drug delivery systems. In preclinical studies pK modeling is used to interpret 
toxicokinetic data and to extrapolate results from animals to man via physiological modeling and 
allometric scaling. pK modeling assists in the interpretation of dose-response and dose-escalation 
  95
studies and therefore has been used in several instances by regulatory agencies to recommend a 
dose and/or regimen which were not originally studied as part of the clinical program. As further 
indication of the growing acceptance of the value of pK modeling, the United States Food and Drug 
Administration (FDA) (1999) have released a document on the “Guidance for Industry on Population 
Pharmacokinetics” (Aarons, 1997). Several International Conference on Harmonization (ICH) 
guidelines have also been published in this regard (ICH Guidelines, 1999). pK modeling allows one to 
describe the quantitative relationship between the administered dose or dosing regimen and the 
observed in vivo concentration of the drug (Holford and Scheiner, 1986; Fleishaker and Ferry, 1995; 
Lima, 1995). Progress in ophthalmic drug delivery has been impressive (Hecht, 1995; Reddy and 
Ganesan, 1996) and numerous products have been or are currently being developed and these include 
topical solutions (Nagataki and Mishima, 1980), suspensions (Garny, 1981), ointments, gels (Miyazaki, 
1982; Lewis et al., 1986), intravitreal and subconjunctival injectables (Kelly et al., 1989; Barza et al., 
1993; Berthe et al., 1994), iontophoretic systems (Friedberg et al., 1991) and intraocular implantable 
devices (Grass et al., 1984; Choonara et al., 2006; 2007). One of the most significant tools to develop 
and evaluate these products is with the use of accurate compartmental and non-compartmental pK 
models. The primary objective of a pK model is to enhance the accuracy of estimating the dynamic state 
of drug behavior in an actual pre-clinical or clinical situation (Reddy and Ganesan, 1996). Numerous pK 
models have been reported in the literature and represent varying levels of sophistication with several 
reviews published on this subject (Mishima, 1981; Maurice and Mashima, 1984; Lee and Robinson, 
1986; Schoenwald, 1993; Urtti and Salminen, 1993; Frangie, 1995; Jarvinen et al., 1995). 
 
In the present study compartmental and non-compartmental pK models were explored for potential 
application to intraocular drug delivery employing the DSMT device (Choonara et al., 2006; 2007). 
Intravitreal injection and implantable devices for GCV have been used for the treatment of CMV-R in 
patients with HIV/AIDS (Ussery et al., 1988; Cantrill, 1989; Cochereau-Massin et al., 1991). However, 
since not only the efficacy but also the toxicity of GCV is influenced by the concentration at the site of 
action, the local concentration following intravitreal GCV delivery needs to be carefully examined. The 
pharmacokinetics of intravitreal drug injection has been analyzed by compartmental pK modeling that 
assumes drug molecules to be uniformly distributed throughout the VH (Ben-Nun et al., 1989). However, 
this assumption may not be applied to prolonged release drug delivery devices such as the DSMT due 
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to the constant rate of GCV release and elimination across the surrounding ocular tissues in the 
posterior segment of the eye. A significant concentration difference may be produced between the 
surface of the DSMT device and the elimination pathway boundaries such as the retina/choroid/sclera 
(RCS) membrane and the posterior aqueous segment. The drug concentration and distribution in the 
VH is influenced by the rate of drug elimination through the RCS membrane and surrounding tissues. 
The elimination profile of drug in the rabbit eye following intravitreal injection of drug was previously 
described by a cylindrical vitreous body model (Ohtori and Tojo, 1994; Uno et al., 1994). 
 
Therefore, the primary objective of this study was to characterize and compare the pK fate of GCV 
released from the DSMT device in the rabbit eye model. The simplest single- and multi-compartment pK 
models were selected in representation of the posterior segment of the rabbit eye. The cylindrical 
diffusion/partitioning pK model for predicting the performance of GCV released from the DSMT device 
was extended. A series of in vivo experimental drug release data for determining the most superior pK 
model and parameter estimates was established. The in vivo GCV concentration profiles obtained from 
animal studies undertaken in the New Zealand White Albino rabbit eye model was compared with 
several compartmental and non-compartmental pK models and predicted profiles from the pK models 
using the model parameters determined from in vivo experiments. Since the DSMT device is a matrix 
device with a novel geometric design in which GCV molecules are uniformly distributed throughout the 
polymer matrix an assumption was made during the pK modeling process that the release rate 
decreased with increasing time for GCV release.  
 
5.2. Materials and Methods 
 
5.2.1. Materials 
For the purposes of this component of the research the DSMT device manufactured using PLGA grade 
Resomer® RG504 was selected for further kinetic modeling and data analysis due to its ability to provide 
superior control of GCV release in the vitreous cavity than devices manufactured with Resomer® 
RG503. The materials used for preparations of the DSMT device have been discussed earlier and can 
be found in Chapter 3, Section 3.2.1 of this thesis.  
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5.2.2. Preparation of the donut-shaped minitablet device 
The preparation of the DSMT device employing PLGA grade Resomer® RG504 has been discussed 
earlier in this thesis and can be found in Chapter 3, Section 3.2.2. Further details can be read in a 
research publication by Choonara and co-workers (2006).  
 
5.2.3. The in vivo pharmacokinetic study protocol 
The study protocol followed was identical to the procedure delineated in Chapter 4, Sections 4.2.4-
4.2.11 of this thesis.  All animals were treated in accordance with the Association for Research in Vision 
and Ophthalmology (ARVO) Resolution on the Use of Animals in Ophthalmic and Vision Research 
(Rockville, MD, USA). 
 
5.2.4. Pharmacokinetic modeling employing compartmental and non-compartmental algorithms 
WinNonLin® software (V5.2.1 with IVIVC Toolkit Build 2008033011, Pharsight Software, Statistical 
Consultants Inc., Apex, NC, USA) was used as a tool for pK modeling and the computation and 
estimation of all pertinent pK parameters. Input data comprised in vivo GCV release data obtained from 
the described in vivo experimental protocol of DSMT devices manufactured with Resomer® grade 
RG504 and implanted into six New Zealand White Albino rabbits whereby VH samples were obtained 
and analyzed via UPLC over a period of 72 days. In vivo data obtained form DSMT devices 
manufactured with Resomer® grade RG504 were selected for pK modeling as it showed superior control 
in GCV release as decribed in Chapter 4, Section 4.3.6 of this thesis.   
 
5.2.4.1. pK model structure and selection 
Successful pK modeling of the DSMT device (described by a single bolus dose of GCV released over 
time) is dependent upon the meticulous selection of relevant pK models that are based on the dose 
and the duration of GCV released in the VH obtained from the in vivo VH concentration-time profiles 
obtained from the in vivo studies in the rabbit eye model. Based on the in vitro and in vivo GCV 
release dynamics from the DSMT device via exploratory data analysis (EDA) and the 
pharmacokinetics and pharmacodynamics of the drug GCV, two tentative compartmental (referred to 
hereunder as pK models A and B) and two non-compartmental (referred to hereunder as pK models 
C and D) pK models were selected. Prior to pK model fitting to the in vivo GCV release data, the EDA 
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suggested the tentative structure of the pK model and the initial estimates of the pK model 
parameters. In addition, WinNonlin® was also used to accurately derive the initial parameter estimates 
in order to avoid data convergence to a local minimum. The in vivo GCV release data obtained from 
the in vivo animal study was fitted to the tentative pK models selected in order to confirm or suggest 
modifications to the pK models chosen. Once a desirable pK model was selected the model was fitted 
to the in vivo experimental data using non-linear regression analysis in order to estimate the pK model 
parameters and the precision of the pK parameter estimates. Once data iteration was complete the 
pK modeling process outputs were diagnostically evaluated via pertinent statistical descriptors such 
as the goodness of fit, correlation between parameters, residual analysis, parameter accuracy and 
precision, the Schwartz Bayesian Criterion (SBC) (Schwartz, 1978), Condition Number (CN) and 
Akaike Information Criterion (AIC) (Akaike, 1978). This formed the basis of assessing the suitability of 
the pK models for fitting the in vivo GCV release data from the DSMT device and explicated the data 
and comparisons of competing pK models. Plots of observed and fitted data superimposed on semi-
logarithmic scales as well as residual plots were generated in order to search for the best fitting pK 
model. The pK parameters were determined using the two compartmental (pK models A and B) and two 
non-compartmental pK models (pK models C and D) (specifically for sparsely-sampled data obtained 
from the mean GCV concentrations at various time points after single dose administration) using the 
GCV release data obtained from the in vivo animal studies (Figures 5.1 and 5.2). A WinNonLin® 
compiled pharmacodynamic (pD) model was also explored for assessing “drug effect data” (Figure 5.3). 
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Figure 5.1: Schematics of WinNonlin® compiled one compartmental pK models showing a) no lag-time 
first-order elimination (K01<K10) (pK model A) and b) no lag-time first-order elimination (K10=K01) (pK 
model B).  
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The concentration of GCV in the VH based on the compartmental pK models A and B can be 
described by Equations 5.1 and 5.2 respectively. Equation 5.3 represents the estimated GCV 
clearance parameters for both pK models. 
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Where, Ct=GCV concentration at time t, D=dose implanted, V=volume of distribution, K=GCV release 
rate constant (zero-order input), K01=rate at which GCV enters the vitreous compartment from the DSMT 
device and K10=rate at which GCV leaves the vitreous compartment (first-order elimination).   
 a) b)
 
Figure 5.2: Schematics of WinNonlin® compiled non-compartmental pK models of a) VH concentration 
of GCV via extravascular administration (pK model C) and b) VH concentration of GCV via constant 
release from the implanted DSMT device (pK model D). 
 
 
 
 
Figure 5.3: Schematic of WinNonlin® compiled pharmacodynamic model for drug effect data estimation. 
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5.2.4.2. Selection of a suitable algorithm for pK modeling 
WinNonLin® software was also used to establish a “best fit” pK model to the in vivo release data via 
estimation of the variance-inflation factors for the pK parameters with the “goodness of fit” as a pertinent 
statistical criterion for accurate pK parameter estimates. WinNonLin® provided the “least squares” 
estimates of the various parameters for the pK models employing a linear approximated Levenberg and 
Hartley modified Gauss-Newton regression algorithm for rapidly minimizing the sum of squared 
residuals to achieve convergence (Hartley, 1961; Davies and Whitting, 1972; Beck and Arnold 1977). 
The Levenberg-Hartley (Gauss-Newton) regression algorithm is known to perform well on a wide class 
of pK modeling processes including ill-conditioned data sets whereby certain pK parameters are absent 
such as in this case. Although the Gauss-Newton algorithm conventionally requires the estimated 
variance-covariance matrix of the parameters, the Levenberg-Hartley modification suppresses the 
magnitude of the change in parameter values between iterations, thus enabling the algorithm to perform 
well on ill-conditioned data sets. Convergence criteria of 0.0001 were used during the minimization 
process and a maximum of 50 iterations were allowed. Convergence was achieved with a relative 
change in the weighted sum of squares (<0.0001).  
 
5.2.4.3. Determination of parameter bounds for pK model estimation 
Desirable bounds were set on the admissible pK parameter space resulting in “constrained estimation”. 
This was undertaken in order to achieve the flexibility in obtaining pK parameter estimates that were 
realistic for models that comprised non-negative parameters for instances where the data set produced 
a negative actual least squares estimate due to error (also known as unconstrained estimation). 
Boundary limits on the parameter space prevented the algorithm from deviating. With the Levenberg-
Hartley modified Gauss-Newton regression algorithm in WinNonLin®, two successive transformations 
were used to affect bounding of the pK parameter space. The first transformation was from the bounded 
space as defined by the input limits to the unit hypercube and the second transformation used the 
inverse of the normal probability function to delineate an infinite pK parameter space resulting in a 
transformation of the parameter space (reparameterization) that made the pK modeling process more 
tractable (Draper and Smith, 1981; Ratkowsky, 1983). Table 5.1 outlines the lower and upper bounds 
set for the compartmental and non-compartmental pK modeling process. 
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Table 5.1: Parameter bounds used for constrained and non-constrained pK model estimation. 
Parameter Value Lower Upper 
 
Dose time (day) 
Bolus dose implanted (µg) 
Length of implantation (day) 
 
Compartmental pK modeling 
 
Model A 
aV (mL) 
 
0 
5000 
72 
 
 
 
 
0.3960 
 
- 
- 
- 
 
 
 
 
0 
 
- 
- 
- 
 
 
 
 
0.500 
bK01 (day-1) 
cK10 (day-1) 
 
Model B 
dVF (mL) 
eK (day-1) 
 
Non-compartmental pK modeling 
Therapeutic window (µg/mL) 
Time bounds (days) 
Lamda z 
0.0010 
0.5000 
 
 
0.3960 
0.0008 
 
 
- 
-  
- 
0 
0.1 
 
 
0 
0 
 
 
0.1 
0 
28 
0.010 
1.000 
 
 
0.800 
1.000 
 
 
2.75 
72 
72 
 
aVolume of distribution of the vitreous compartment 
bThe rate at which GCV enters the vitreous compartment from the DSMT device 
cThe rate at which GCV leaves the vitreous compartment 
dVolume of distribution based on the terminal phase, where F is the fraction of GCV absorbed  
eZero-order input or GCV release rate constant from the DSMT device  
 
 
5.2.4.4. Establishment of pertinent pK parameters 
The apparent rate constants of the terminal-phase elimination rate (via linear regression of the 
logarithms of the VH concentration-time profiles) (k) and the apparent volume of distribution (Vd) were 
fitted. Individual estimates of these parameters were obtained and the fits were evaluated by 
inspection of the residuals. The maximal VH concentration (Cmax) and time of Cmax (Tmax) were 
calculated from the fitted curves. The clearance (Cl) and the area under the VH concentration-time 
curve (AUCt0-∞) was calculated by the trapezoidal rule and extrapolated to infinity using standard pK 
algorithms from the fitted curves. Complete absorption of GCV from the site of DSMT device 
implantation was assumed. In vivo VH drug release profiles of the GCV-loaded DSMT devices were 
also established by deconvolution through convolution (Dutta et al., 2004). 
 
5.2.5. Pharmacokinetic analysis for in vitro-in vivo correlation (IVIVC) establishment 
A predictive mathematical model for description of the relationship between an in vitro property of the 
DSMT and a relevant in vivo response was developed. WinNonLin® software (V5.2.1 with IVIVC Toolkit 
Build 2008033011, Pharsight Software, Statistical Consultants Inc., Apex, NC, USA) was used as a tool 
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for pK computations and estimation of all pertinent pK parameters for the development of a Level A 
time-scaled in vitro-in vivo correlation (IVIVC) (US FDA, 1997). Input data comprised in vitro GCV 
release data obtained from the Resomer® RG504 DSMT devices as well as pK data obtained from the 
described in vivo experiment on the six New Zealand White Albino rabbits whereby VH samples were 
obtained and analyzed via UPLC.  
 
5.2.5.1. Deconvolution through convolution analysis 
Convolution is the prediction of in vivo drug concentrations using a mathematical model based on the 
convolution integral (Levin, 2006). Deconvolution is the estimation of the time course of drug input (in 
this case the in vivo release of GCV) using a mathematical model based on the convolution integral 
(Levin, 2006). Majority of deconvolution methods used in pK data analysis is to estimate the rate of 
drug bioavailability in a numerical form. However, analytical deconvolution methods are usually 
restricted to simple pK models that do not contain shunts and/or time delays, and thus can be 
approximated by multi-exponential models. Thus the pK conditions described in our in vivo study 
conforms to the requirements of deconvolution through convolution (DTC) as the GCV release from 
the DSMT device into the VH may be described by simple non-compartmental and/or one-
compartmental pK models due to the enclosed environment of the posterior segment of the eye 
facilitated by the highly restrictive blood-ocular barriers. Therefore this enabled us to determine the 
numerical and/or the analytical form of the system weighting function approaching the GCV 
bioavailability rate even under conditions when the deconvolution methods may not be superiorly 
functional. Furthermore, this approach required neither a special functional form of the weighting 
function nor equal time intervals of the measurement of the drug concentration profiles, and no 
preliminary smoothing and/or interpolation of the profiles were necessary. The approach was based 
on linear system analysis, with linearity defined in the general sense of the linear superposition 
principle. The concentration, C(t), of GCV within the VH after release from the DSMT device may be 
represented by Equation 5.4. 
 
           t
0
tgtfdττtgτftC                      Equation 5.4 
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Where t represents time and (t-τ) represents the time since the quantity of GCV described by f(τ) was 
introduced into the VH over a interval of time Δτ. f(t) is the function that, when integrated between the 
limits of t=0 and t, yields the cumulative quantity of GCV released to the impulse input point which is 
the vitreous cavity and ‘*’ denotes the convolution operation. 
 
Equation 5.5 is the convolution equation that formed the basis for the evaluation of the GCV input rate 
f(t). The function g(t) was the unit impulse response (disposition function) and was equal to the 
probability that a molecule that entered the impulse input point (vitreous cavity) at t=0 was present in 
the VH at time t divided by the volume of the VH. The process of determining the input function f(t) 
was termed deconvolution as it is required to deconvolve the convolution integral to extract the input 
function that was embedded in the convolution integral. The unit impulse response function g(t) 
provided the precise linkage between the GCV-level response C(t) and the input rate function f(t). The 
principle of DTC was employed via WinNonLin® pK software to determine the input function. The DTC 
method was an iterative procedure that comprised three steps. First, the input function was adjusted 
by altering the parameter values. Second, the new input function was convolved with g(t) to produce a 
calculated GCV-level response and finally the agreement between the observed data and the 
computed GCV-level data was quantitatively evaluated according to an objective function. The three 
steps were repeated until the objective function was optimized. Specifically for this data set, a one-
compartment model was fit to the observed vitreous GCV concentration-time data to obtain the 
parameters of the disposition function as shown in Equation 5.5. 
 
     λteλτ 1
tτ,minλe0CtC 
                                 Equation 5.5 
 
Where C0=the dosing intercept of GCV loaded in the DSMT and λ=the elimination rate constant for a 
one-compartment pK model (representing the vitreous cavity), and τ=duration of GCV release from 
the DSMT device. 
 
The observed GCV vitreous concentration-time data were deconvolved using the disposition 
parameters (λ and C0) to obtain the input or GCV release rate versus time profile (Equation 5.6). The 
fractional input versus time profile was used to determine the duration of GCV release.  
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Observed in vitro profile WinNonLin® estimated 
disposition function 
Inferred input profile 
 
in vitro GCV release profile 
conc. vs. time*-1 
 
in vivo GCV release profile   = 
conc. vs. time 
 
 
GCV release rate profile 
 
 
Where *–1 is the deconvolution operator                   Equation 5.6 
 
       
5.2.6. Establishment of an in vitro-in vivo correlation 
The inclusion of in vitro dissolution tests in the USP 32 supported the proposition that there is a 
significant relationship between in vitro dissolution and in vivo bioavailability. Release rate data, when 
considered along with data on the drug’s solubility, partition coefficient and dissolution constant, can 
provide an indication of the drug’s release potential following administration (Ansel and Popovich, 1990). 
Dissolution data has been used for predicting in vivo performances of drugs (Hanson, 1982), for 
elucidation of the mechanism of drug release from a drug delivery system and also as a warning for 
poor drug bioavailability from drug delivery systems that display erratic release patterns in comparative 
studies (Levy, 1965; Wood, 1966; Gibaldi and Weintraub, 1970; Bergan et al., 1973; Prasad et al., 
1983.; Shah et al., 1983). Therefore, it is important that research includes efforts to develop in vitro tests 
that will be valid predictors of relative bioavailability under in vivo conditions.   
 
Drug release experiments of the GCV-loaded DSMT device was performed with a modified USP 
dissolution apparatus at 37±0.5°C using 4mL of simulated vitreous humor (SVH) in each vessel at an 
agitation rate of 20rpm (Choonara et el., 2006). Samples were removed at predetermined time 
intervals and analyzed by HPLC. Experiments were run in triplicate and results expressed as a mean 
% (±SD) dissolved at a given sampling time. The in vitro drug release studies were set-up to simulate 
release of GCV from the DSMT device into the posterior segment of the rabbit eye model. The GCV 
release data obtained from the in vivo study was used to estimate the cumulative GCV release by an 
adapted Wagner-Nelson method (Axelrod and Reichenthal, 1953; Wagner and Nelson, 1964; Newton 
et al., 1981; Bonati et al., 1982; Blanchard and Sawers, 1983). VH concentrations of GCV were used 
to determine the various pK parameters. The fraction of GCV released in vivo was calculated by the 
mean (N=6) VH concentration-time profile and the fraction of GCV released in vivo was profiled 
against the fraction released in vitro at corresponding time intervals. The slope, intercept, and 
correlation coefficient describing the relationship were determined by linear regression and a Levy 
  105
plot. It is important to point out that such a correlation is only valid if the given drug is uniformly 
absorbed (Axelrod and Reichenthal, 1953; Rall, 1980; Newton et al., 1981). In this case the GCV did 
not require any absorption as drug was immediately available at the enclosed site of action i.e. the 
vitreous cavity. Thus, the model drug GCV used in the study meets this requirement without any 
restrictions.  
 
5.3. Results and Discussion 
 
5.3.1. Vitreous humor sampling and drug content analysis 
As described in Chapter 4, Section 4.3.5 of this thesis, the UPLC chromatograms of the VH samples 
retrieved from the rabbits revealed that GCV was successfully eluted with the presence of two distinct 
chromatographic peaks representing GCV at approximately 1.00 minute and the internal standard ACV 
at 1.35 minutes after injection. Validation of the assay method indicated that intra-day and inter-day 
precision and accuracy as well as the recoveries, and relative standard deviation values (%RSD) were 
satisfactory.   
 
5.3.2. Interpretation of the compartmental pK model analysis 
During analysis it was found that 1000 iterations were sufficient to converge release data to a minimum 
mean square error with a convergence criteria setting of 0.0001. The pK models were further analyzed 
by the strong parametrical support from statistical descriptors such as the Condition Number (CN) as a 
measure of the pK model validity (numerical stability) of the fit. The CN is computed as the square 
root of the ratio of the largest to the smallest eigenvalue of the matrix of partial derivatives of the pK 
model with respect to the model parameters. For this particular dataset the CN values were 0.100×108 
and 0.209×108 for the compartmental pK models A and B, respectively (Table 5.2). Smaller CN values 
are ‘superior’ to larger values. Figure 5.4 displays the observed and fitted VH concentration-time 
profiles for the two compartmental models analyzed.  
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Figure 5.4: VH concentration-time profiles of GCV released from the DSMT device depicting the 
observed and fitted relationships for a) compartmental pK model A and b) compartmental pK model B 
(N=6; SD<0.19 in all cases).  
 
 
In order to assess the accuracy of the pK model fitted and weighting scheme residuals were 
analyzed. A functional approach for examining the residuals was undertaken by the generation of 
scatter plots in order to determine whether the residuals tended to be randomly scattered within a 
lower and upper horizontal band. If the residuals were not randomly scattered, this suggested that 
either the model or weighting scheme was unsatisfactory (Figure 5.5). The residuals for pK model B 
had a poor fit of the model to the data (Figure 5.5b). PK model A showed a random scatter in the 
residuals (Figure 5.5a). In addition, the frequency of altering ± signs (also known as ‘iterations’ in the 
residuals) was largest for pK model A than pK model B (there were 17 and 13 iterations, 
respectively).The absolute magnitude of the residuals, or the amplitude, was also smaller for pK 
model A. This therefore suggested that pK model A mimicked the in vivo data better than pK model B. 
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Figure 5.5: Relative residual plots obtained for GCV concentration-time data fitting employing a) 
compartmental pK model A and b) compartmental pK model B.  
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Tables 5.2 and 5.3 provide a summary of the pK parameters and goodness-of-fit criteria for each pK 
model analyzed. PK model A had a lower AIC value than pK model B. Thus, pK model A displayed 
the most superior fit based upon its lower CN value and uniformly higher parameter precision relative 
to pK model B (Table 5.2). A uniform weighting scheme for this study performed superiorly due to the 
relatively small range of the VH concentration data. The pK modeling approach required fewer 
assumptions and was automated.  
 
Table 5.2: Diagnostic criteria used to assess pK model “goodness of fit” (N=6). 
Statistical Descriptor pK Model A pK Model B 
   
Corrected Sum of Squared Observations 0.153 0.153 
Sum of Squared Residuals 0.344×10-1 0.333×10-1 
Correlation (observed vs. fitted) 0.879 0.481 
Akaike Information Criterion (AIC) -17.578 -3.690 
Swartz Bayesian Criterion (SBC) 17.741 -3.799 
Condition Number (CN) 0.100×108 0.209×108
 
  
 
Figure 5.6 shows the convergence profiles obtained for fitting each of the compartmental pK models A 
and B. In both instances data was converged to a minimum sum of squares that approached zero. PK 
model A converged earlier than pK model B further signifying the superior fit of the in vivo data to the 
model. 
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Figure 5.6: Convergence profiles obtained for fitting a) compartmental pK model A and b) 
compartmental pK model B. 
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Table 5.3: Summary of estimated secondary parameters for the pK models analyzed (N=6).  
Parameter             Estimate     Standard Error  CV% 
 
Compartmental pK model A  
AUC (day.µg/mL)   12.36   1.750      1.418 
K01 HL (day)          22.72     3.220      1.480 
K10 HL (day)          0.694          0.130       1.844 
ClF (mL/day)            0.405         0.570      1.419 
Tmax (day)             10.41        1.350       1.293 
Cmax (µg/mL)           0.377          0.053        1.418 
 
Compartmental pK model B  
 
AUC (day.µg/mL)   8.73×109  3.39×1014     38.80 
KHL (day)          7.07×105    1.37×1010     19.40 
ClF (mL/day)    1.00×10-6          2.22×10-2       38.90 
Tmax (day)             1.02×106        1.98×1010      19.50 
Cmax (µg/mL)           3.15×103          6.12×107        19.40 
 
  
 
5.3.3. Interpretation of the non-compartmental pK model analysis 
Results of the non-compartmental pK model analysis are shown in Figure 5.7 and a summary of the 
estimated pK parameters are listed in Table 5.4 for pK models C and D. As expected the Tmax, Cmax, 
AUCall and AUMC were identical for both non-compartmental pK models. Both models revealed that 
after 28 days the GCV concentrations reach was 0.46µg/mL and was maintained up to 72 days as 
noted by the linear AUC-time profile (Figure 5.9). PK model C revealed a 3-point (28-72 days) 
terminal slope (lambda z) (λz) of 0.0066day-1 and an intercept of -5462 by means of log-linear 
regression (R2=0.77) (Figure 5.7). The low λz and the relatively high MRT suggested that the VH 
acted as a drug reservoir. For extravascular pK model C the fraction of GCV absorbed/released could 
not be estimated. Therefore volume and clearance for the model were actually volume/F or clearance/F 
where F was the fraction of GCV absorbed/released. Analysis employing pK model D revealed that the 
λz could not be estimated as no parameters could be extrapolated to infinity. The AUC0-72 computed 
by the linear trapezoidal rule with linear interpolation was 27.165day.µg/mL. The Linear Trapezoidal 
rule with Linear Interpolation (to find C* at t*) was used as the preferred computational approach for 
both non-compartmental pK models. Uniform weightings were used for λz calculations with the “best 
fit” method employing log regression used for both models. The lower and upper therapeutic window 
was 0.10µg/mL and 2.75µg/mL respectively. The λz was determined for pK model C and not for pK 
model D. The MRT parameters were adjusted for the duration of implantation of the DSMT device.  
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Table 5.4: Final parameter estimates generated from fitting the non-compartmental pK models. 
Parameter                                Units                Estimated Values 
       pK Model C  pK Model D  
R2                                      -    0.7734                   - 
No. points lambda z                           -               3   0 
Lambda z        day-1        0.0066   - 
Lambda z low              day           28   - 
Lambda z upper              day           72   - 
HL Lambda z                 day    104.9384  - 
Tmax    day   28.0000    28.0000 
Cmax                                    µg/mL    0.46000                 0.46000 
Cmax D                               µg/mL/µg          0.0001   0.00010 
Tlast                                     days   72.000                 72.0000 
Clast                                   µg/mL                 0.35000   0.35000 
AUClast                             day.µg/mL               27.1650   27.1650 
AUCall                             day.µg/mL               27.1650   27.1650 
AUCINF obs                   day.µg/mL               80.1529   - 
AUCINF D obs                 day.µ/mL/µg               0.0160   - 
AUC %Extrap obs              %                66.1085   - 
Vz obs                       mL                9444.0772  - 
Cl obs                       mL/day                62.3807   - 
AUCINF pred                  day.µg/mL               82.3862   - 
AUCINF D pred                day.µg/mL/µg               0.0165   - 
AUC %Extrap pred             %                67.0273   - 
Vz pred                      mL                9188.0723  - 
Cl pred                      mL/day                60.6898   - 
AUMClast                        day.day.µg/mL             1006.50   1006.50 
AUMCINF obs                 day.day.µg/mL               12737.7119  - 
AUMC %Extrap obs            %                92.0983   - 
AUMCINF pred                day.day.µg/mL               13232.1472  - 
AUMC %Extrap pred           %                92.3936   - 
MRTlast                                 day                 37.0512   2.05120 
MRTINF obs                  day                158.9176  - 
MRTINF pred                 day                160.6112  - 
TimeLow                                day                 0.7500   0.75000 
TimeDur                                 day                69.250   69.2500 
TimeHgh                                 day                 0.0000   0.00000 
TimeInfDur   day   265.1609  -  
TimeInfHgh                              day                 0.00000   0.00000 
AUCLow                              day.µg/mL                6.96250   6.96250 
AUCDur                              day.µg/mL               20.2025   20.2025 
AUCInfDur     day.µg/mL                39.7072   - 
Tmax: Time of maximum observed concentration 
Cmax: Maximum observed concentration occurring at Tmax 
Tlast: Time of last measurable (positive) concentration 
Clast: Concentration corresponding to Tlast 
AUClast: AUC from the dosing time to the last measurable concentration 
AUCall: AUC from the dosing time to the time of the last observation. Here AUClast=AUCall 
AUMClast: AUMC from the dosing time to the last measurable concentration 
MRTlast: MRT from the dosing time to the time of the last measurable concentration  
RSq: Goodness of fit statistic for the terminal elimination phase 
Lambda z: 1st order rate constant of the terminal (log-linear) portion of the curve 
Lambda zlow: Lower limit on time for values to be included in the calculation of λz 
Lambda zupper: Upper limit on time for values to be included in the calculation of λz 
HL Lambda z: Terminal half-life  
AUCINF obs: AUC from dosing time extrapolated to infinity based on the last observed concentration  
AUCINF D obs: AUCINF obs divided by the dose 
AUC%Extrap obs: % AUCINF obs due to extrapolation from Tlast to infinity 
Vzobs: Volume of distribution based on the terminal phase 
Clobs: Total Cl for extravascular administration = Dose/AUCINF obs 
AUCINF pred: AUC from dosing time extrapolated to infinity based on the last predicted concentration 
AUC%Extrap pred: % AUCINF pred due to extrapolation from Tlast to infinity 
Clpred: Total Cl for extravascular administration = Dose/AUCINF pred 
AUMCINF obs: AUMC extrapolated to infinity based on the last observed concentration 
AUMC%Extrap obs: Percent of AUMCINF obs that is extrapolated 
AUMCINF pred: AUMC extrapolated to infinity based on the last predicted concentration 
AUMC%Extrap pred: Percent of AUMCINF pred that is extrapolated 
MRTINF obs: MRT extrapolated to infinity 
MRTINF pred: MRT extrapolated to infinity  
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The fitted VH concentration-time profiles of GCV release from the DSMT device and the pK model C-
fitted λz are shown in Figure 5.7. Release of GCV into the vitreous cavity from the DSMT device was 
controlled with an initial “burst” followed by an uptake with a fitted λz of approximately 44 days (range 
28-72 days). 
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Figure 5.7: The non-compartmental pK model C fitted AUC and terminal t1/2 of GCV after implantation 
of the DSMT device in the rabbit vitreous compartment (N=6; SD<0.16 in all cases).  
 
 
Results from the pharmacodynamic (pD) model fitting in order to determine the GCV effects are 
shown in Table 5.5. The pD model utilized fitted the in vivo GCV release data relatively well with an 
R2=0.82. The input baseline and threshold values represented the ED50 of GCV for the treatment of 
human CMV-R that ranged between 0.1-2.75µg/mL. The AUC below and above the baseline and 
threshold values were computed. The DSMT device was able to efficiently modulate the release of 
GCV into the VH with the concentration of GCV remaining below the baseline throughout the 72 days 
of this study. In addition GCV levels were maintained above the threshold for a period of 71.24 days. 
This was ideal as there was no evidence of dose dumping or unfounded spikes in GCV release that 
may contribute to side-effects due to GCV concentrations increasing beyond the baseline. Instances 
of GCV concentrations below the threshold value only occurred for a duration of 0.76 days. 
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Table 5.5: Parameter estimates from fitting the pharmacodynamic model for drug effect data. 
Parameter Units Estimated Value 
 
R2 
 
- 
 
0.82 
Tmin day 0.00 
Tmax day 28.00 
Baseline µg/mL 2.75 
AUC>baseline day.µg/mL               0.00 
AUC<baseline day.µg/mL               169.92 
Time>baseline day 0.00 
Time<baseline day 72.00 
Time%<baseline % 100.00 
Threshold µg/mL 100.00 
AUC>threshold day.µg/mL               0.021 
AUC<threshold day.µg/mL               0.038 
Time>threshold day 71.24 
Time<threshold day 0.76 
Time%<threshold % 1.05 
Tonset day 0.00 
Toffset day 0.76 
Timebetween BT day 71.24 
 
 
5.3.4. In vivo release of ganciclovir in the rabbit eye model from the DSMT device 
The cumulative release of GCV from the DSMT device at a constant GCV loading of 5%w/w is shown in 
Figure 4.15. The cumulative drug release profile was obtained by measuring the percentage of GCV 
released versus the initial content loaded in the DSMT device (Figure 4.15). The data is consistent with 
a reduced biphasic profile as noted from the in vitro study by Choonara and co-workers (2006; 2007), 
that was primarily due to the rapid release of GCV deposited on the surface of the rigid matrix (Figure 
4.15a). However for the current in vivo study the DSMT device was initially equilibrated in sterile saline 
prior to implantation. This additional procedure may have resulted in removal of the patent deposition of 
GCV molecules on the surface of the device. Thus the release of GCV from the device was constant 
and controlled by the degradation rate of the polymer. The release rate increased with the decrease of 
the molecular mass of PLGA. This rate was probably due to the difference in the degradation rate of the 
polymer grades Resomer® RG503 and Resomer® RG504. Degradation of PLGA could be influenced by 
the composition of the lactide and glycolide content with the higher the glycolide content, the faster the 
degradation rate (Baker et al., 1974). The DSMT device provided sustained release of GCV in the VH 
cavity over a period of 72 days as shown in Chapter 4, Section 4.3.6 of this thesis (Figure 4.16). Devices 
formulated with Resomer® grade RG503 displayed a higher quantity of GCV release within the ED50 
range for the treatment of human CMV-R as compared to DSMT devices formulated with Resomer® 
grade RG504 (Figure 4.16).  
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5.3.5. Deconvolution and relative bioavailability analysis 
Deconvolution of observed vitreous GCV concentration-time data against the in vitro release profile 
provided the cumulative in vivo release-time profile (Figure 5.8). The individual cumulative release-
time profile did not reveal any evidence of dose dumping. The mean cumulative release-time profile 
presented in Figure 5.8 showed that GCV relative bioavailability was ~70%, and the mean release 
duration was 72 days. In conjunction with the mean input AUC-time profile (Figure 5.9), this indicated 
that GCV was released in a zero-order manner. However, the rate of release was marginally high 
during the initial 3 days after implantation of the DSMT device and tailed off at a zero-order release 
rate after an average of 10 days, with 70% of the total GCV released after 72 days. The observed 
release rate-time profile was not unexpected for a zero-order prolonged release device implanted in 
the vitreous cavity where the extent and rate of release predictably occurs in the VH and a lower 
extent and slower rate of absorption occurs through surrounding ocular tissues. The duration of GCV 
release from the DSMT device was 72 days, and the zero-order release rate was 2.02±0.01µg/h for a 
5mg GCV-loaded DSMT device. It should be recognized that the 2.02±0.01µg/h release rate 
represents an approximation of the zero-order rate for the entire duration of release (72 days) (i.e., 
the rate is faster in the initial few hours after implantation and decreases after 7-10 days).  
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Figure 5.8: Drug release profiles of the in vitro GCV release and the observed mean cumulative in 
vivo release profile extracted using deconvolution analysis for single-dose GCV released from the 
DSMT device. 
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Figure 5.9: Profile showing the cumulative linear increase in GCV concentration over a period of 72 
days computed from the AUC of the mean in vivo VH concentration-time profile (R2=0.99).  
 
5.3.6. In vitro-in vivo correlation (IVIVC) 
The intravitreal transit time for the DSMT device was annulled (t=0 hours) as the device was 
implanted directly at the site of action. Following evaluation of the pK parameters, the in vivo drug 
release from the DSMT device was calculated employing a Wagner-Nelson method (Figure 5.8). In 
accordance with the in vitro profiles, the DSMT released GCV immediately without any lag-time. In 
vitro GCV release was relatively fast. By comparison, GCV release was more controlled over a longer 
time period when the DSMT was implanted in vivo. To better compare the in vitro profiles with those 
representing the in vivo release at corresponding time points and to elucidate the predictive power of 
the in vitro study, in vivo GCV release calculated from the mean VH concentration-time profile was 
described using a Levy plot (Levy et al., 1965). The Levy plot shown in Figure 5.10 demonstrated that 
the in vitro drug release study performed was useful in terms of predicting the in vivo GCV release 
from the DSMT device with a 90% accuracy (R2=0.90; slope=<1). This can be attributed to the 
diffusion and bio-distribution of GCV within the vitreous cavity once released from the DSMT device 
which could not be fully simulated under in vitro conditions. Previous authors working on the 
development of IVIVC’s have also observed that, in general, in vitro results tend to run ahead of in 
vivo data (Brockmeier and Hattingberg, 1982; Brockmeier et al., 1985). 
 
  114
 
TVitro
0 10 20 30 40 50 60
TV
iv
o
0
10
20
30
40
50
60
Line of unity
%In vitro vs. %In vivo
Regression
R2=0.90
y = 4.90+0.77x
 
Figure 5.10: Levy plot showing the relationship between the fraction of GCV released in vivo and the 
fraction released in vitro (R2=0.90; slope<1) over corresponding time periods.  
 
A Level A correlation was obtained as a point-to-point relationship was established between the in vitro 
dissolution and the in vivo input rate (i.e. in vivo dissolution). 
  
 
5.4. Concluding Remarks 
 
The GCV relative bioavailability was approximately 70%. GCV exhibited superior prolonged release 
characteristics without any dose dumping. On average 2.02±0.01µg/h of GCV was released into the 
vitreous cavity from every 5mg GCV-loaded DSMT device over 72 days. Results from this study 
indicated that the method adopted for the in vitro drug release study was sufficiently powerful, 
convenient and discriminating for predicting GCV release behavior from the DSMT device with a 
relatively desirable IVIVC obtained in keeping with the complexities of the study conditions. A Levy 
plot demonstrated that the in vitro drug release study performed was useful in terms of predicting the 
in vivo GCV release from the DSMT device with a time-scaled Level A IVIVC correlation obtained 
(R2=0.90). The selected pK models are yet to be challenged by testing the pK model on a new set of 
experimental data for model validation. 
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CHAPTER 6 
CONCLUSIONS, RECOMMENDATIONS AND FUTURE OUTLOOK 
 
6.1. Conclusions 
 
The DSMT device developed throughout this research has proved to be an effective and versatile 
biodegradable intraocular drug delivery system that provides rate-modulated release of the antiviral 
model drug GCV to the posterior segment of the eye for the treatment of CMV-R. This has been 
established from the in vivo animal studies undertaken in the New Zealand White Albino rabbit eye 
model. In keeping with the aims and objectives of this research the following conclusions were achieved: 
 
The effects of irradiation sterilization on the stability of the DSMT device revealed that the affected 
transitions favored the DSMT to be employed as an implantable intraocular device. PLGA can be 
regarded as suitably stable under compression and γ-sterilization for manufacture of the DSMT device. 
In addition, this research has shown that as characterization techniques for biomaterials progress, it is 
essential to rigorously consider the confounding improbabilities of the data acquired by undertaking 
detailed chemometric and molecular modeling approaches in order to draw comprehensive conclusions 
on the inherent behavior of the system at a micro-level.  
 
A blueprint surgical procedure for implantation of the DSMT device in the New Zealand White Albino 
rabbit eye model has been successfully developed. In this research we have demonstrated that the 
biodegradable DSMT device may provide a significant innovation to the current cache of intravitreal drug 
delivery technologies for the treatment of posterior segment eye diseases. The DSMT device was 
relatively easy to implant within ±30 minutes and was well tolerated in the rabbit eye model without any 
adverse effects or toxicity over the entire duration reaching 72 days in this study.  
 
A stable and sensitive UPLC assay method utilizing 3D chromatography for quantification of GCV from 
VH samples was optimized. GCV release in the VH of the rabbits from the DSMT device was 
maintained within the ED50 range for the treatment of human CMV-R. Our research has shown that 
constant drug release can be obtained with the DSMT device due to the unique geometry of the device. 
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The DSMT device is sufficiently flexible and may be used for the effective long-term intravitreal delivery 
of drugs for the treatment of various posterior segment eye diseases.  
 
The safety, biocompatibility or potential toxicity of the DSMT device was assessed via histopathological 
examination, direct and indirect ophthalmoscopy, intraocular pressure measurements and clinical 
observation. These studies revealed that the DSMT device was non-toxic to intraocular tissue 
structures. Pharmacokinetic modeling revealed that the relative bioavailability of GCV in the VH was at 
least 70% and the device released GCV in a prolonged manner without any dose dumping. On average, 
approximately 2.02±0.01µg/h of GCV was released into the VH from a 5mg GCV-loaded DSMT device 
over 72 days.  
 
Results from this study indicated that the method adopted for the in vitro drug release study was 
sufficiently powerful, convenient and discriminating for predicting the GCV release behavior from the 
DSMT device with a relatively desirable IVIVC obtained in keeping with the complexities of the study 
conditions. A Levy plot demonstrated that the in vitro drug release study previously performed was 
useful in terms of predicting the in vivo GCV release from the DSMT device with a 90% accuracy 
described by a Level A IVIVC correlation obtained. 
 
6.2. Recommendations 
 
Several implantable intravitreal drug delivery devices have been developed and many more are 
currently under design. However, none of the marketed products have yet proved to be an all 
encompassing device that is relatively safe and uncomplicated for patient use, allows for simple 
implantation procedures to secure the device in the posterior segment of the eye by ophthalmic 
surgeons, is fully biodegradable and provides zero-order drug release in the vitreal cavity over a period 
of several months to even years. In order to design an effective intravitreal drug delivery device, the 
challenges lining the pathway to success must be considered as discussed in this thesis. Firstly, local 
drug delivery intended for a single eye should not treat the contra-lateral eye. In addition, for certain 
diseases not limited to the eye, local drug delivery fails to treat the manifestations of extra-ocular 
disease. Cases in point are infectious diseases such as CMV or ocular inflammatory diseases with 
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systemic involvement, such as Behçet's disease, Vogt-Kayanagi-Harada disease, and sarcoidosis. 
Higher intravitreal concentrations of drug attained with intravitreal devices may offer a greater 
therapeutic effect, but may also be associated with increased ocular toxicity. Drugs that demonstrate 
safety in the eye over short durations may be toxic upon extended intraocular exposure. Furthermore, 
the surgical complications of device implantation have been considered, namely, vitreous hemorrhage, 
retinal detachment, and endophthalmitis. These complications have occurred rather often, especially 
when surgical penetration of the vitreous cavity is required for device implantation.  
 
Future research should thus focus on the development of devices that are geometrically smaller and do 
not require full-thickness penetration of the vitreous cavity but rather rely on drug diffusion across the 
sclera. It is envisaged that the use of nanotechnology would provided this much needed alternative. 
Device applicability should also be established in the early stages of design. Investigators should identify 
what a ‘sufficient dose for a reasonable duration’ is for the targeted disease, where ‘sufficient dose’ is 
the steady-state concentration of drug needed to produce the desired effect in the animal model and, 
ultimately in humans, and ‘reasonable duration’ is the duration needed to either cure the disease or to 
ameliorate and maintain suppression of disease symptoms.  
 
Only brief exposure (effective steady-state concentration for a few hours, days, or weeks) is required in 
cases where the target disease is acute. Contrarily, for chronic conditions, a more prolonged exposure 
(months or years) to an effective steady-state concentration of the drug is necessitated. Historically it 
has been acknowledged that biodegradable devices (with relative ease of implantation and lower side-
effects profile) are more applicable for short-term (hours, days) or intermediate-term (weeks, months) 
drug delivery and is all that is required to treat acute disease and where chronic therapy is required (>1 
year) non-biodegradable devices may provide superior control of drug release, improved retrievability in 
the case of serious side-effects, and fewer invasive procedures than a biodegradable device. However, 
with the advent of several innovative technologies in polymeric and biomaterials science, researchers 
are continually identifying biocompatible polymeric materials that are capable of providing prolonged 
drug delivery with the novelty of biodegradability. In addition, the commercialization of intravitreal 
devices is another significant obstacle, which rests largely on psychological factors inherent to 
clinicians and patients, who generally feel more at ease with traditional eye-drop therapy. 
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Several achievements and failures in the marketplace has brought further clarity to the field in 
recognizing that the development of implantable intravitreal drug delivery devices is not simply a matter 
of in vitro engineering of the device in order to achieve a controlled rate and duration of drug release. 
Both patient and physician factors are just as critical, if not more significant, in the successful application 
of the technology. These factors continue to confound scientists in their quest to develop successful 
intraocular devices that can deliver drug for significantly prolonged periods of time for the treatment of 
posterior segment eye diseases that require chronic suppressive maintenance therapy. Furthermore, 
various biomaterials have been employed for designing intraocular drug delivery devices. The use of 
biomaterials in intraocular drug delivery will inevitably increase in the future as the frontiers of 
biomaterials science are surpassed. However their biocompatibility and patient comfort will need to be 
improved in tandem.  
 
6.3. Future Outlook 
 
In light of the above the novel DSMT device certainly opens up a number of new opportunities with 
regards to innovator drug delivery devices. The device can be modified in numerous ways to produce a 
drug delivery system demonstrating desirable release kinetics with zero-order drug release, using 
biodegradable polymers of a suitable inherent viscosity. The device can be applicable to a wide range of 
bioactives, whereby chronic suppressive therapy is required and intravitreal levels need to be sustained 
over shorter periods such as several weeks to months or for prolonged release over one to two years. 
Targeting one of the research outputs such as the United States patent that has been filed for protecting 
the intellectual property of the DSMT device followed by licensing of the technology to a suitable 
Pharmaceutical Company promotes the potential for economic growth within the country. Having such 
technology developed within South Africa would allow the country to compete on an international level in 
the biotechnology sector against importation of innovator and generic products. Due to the flexibility in 
the design of the DSMT device there are circumstances where the technology can be applied to several 
other regions of the human body other than the eye and the period over which bioactives are released is 
measured in months. An example of such an application is represented by its use as a contraceptive 
device implanted into the gluteus maximus muscle and releases an estrogen or similar compound over 
a period of between 3-6 months. Another example is the implantation of the device within blood or 
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lymphatic vessels or intraperitoneally. Figures 6.1-6.3 shows several drawings describing the alternative 
embodiments of the DSMT device invention.  
 
a) b) c) d)
 
Figure 6.1: Schematic drawings of various embodiments of the DSMT device with a) a side-perspective 
view of a first embodiment of the invention; b) a second embodiment of the invention; c) a third 
embodiment of the invention; and d) a fourth embodiment of the invention for the sustained, in situ, 
delivery of a pharmaceutical composition to a human or animal body (US Patent Application # 
11/285,035). 
 
a) b)
 
Figure 6.2: Schematic drawings of a) a cross-sectional side view of an embodiment of the invention of 
Figure 5.1a and b) a cross-sectional side view of and embodiment of the invention of Figure 5.1b.for the 
sustained, in situ, delivery of a pharmaceutical composition to a human or animal body (US Patent 
Application # 11/285,035). 
.  
 
 
 
a)
b)
 
Figure 6.3: Schematic drawings of a) a side-view of the DSMT device of Figure 5.1a sutured within the 
intraocular cavity and b) within an artery, alternatively a lymphatic vessel as a fifth embodiment of the 
invention for the sustained, in situ, delivery of a pharmaceutical composition to a human or animal body 
(US Patent Application # 11/285,035). 
.  
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Appendix E: Results of Animal Health Analysis for Disease Screening 
 
 
  
 
 
CENTRAL ANIMAL SERVICE 
 
Tel: 011717-1312 
   Fax:  011 643-4318 
___________________________________________________ 
 
DEAR ANIMAL USERS 
 
It is with great satisfaction that we can inform Central Animal Service users of the positive outcome of our 
animal disease surveillance program. 
 
Central Animal Services sent a batch of 20 rats, 20 mice and 20 rabbits, a statistically representative sample from 
our stock animals, to Golden Vetpath for disease screening. This was done to check that the animals supplied to 
researchers are all in good health. 
 
Golden Vetpath is a division of Idexx Laboratories and has a sister company in Germany called Biodoc. 
 
All the serology tests were done by Biodoc and a full post mortem, histopathology and bacteriology were 
conducted by Vetpath. 
 
The results were as follows:  
 
 The rats, mice and rabbits were free of any infectious viral or bacterial diseases.  
 There was no indication that any of the animals were infected or carried mycoplasma.  
  
 
The surveillance program will continue on a bi-annual basis and the next batch of animals will be sent for 
surveillance in the next few months. We feel confident that we can maintain the health status of our animals so 
that you as the researcher can continue to do high standard research. 
 
We will keep you updated on the results of our health monitoring on a regular basis. 
 
 
Kind regards 
 
 
Erika Vercuiel (Principle Vet Nurse) and the CAS team 
11th February 2008. 
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Appendix F: Isotron Certificates of DSMT Device Sterilization 
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Appendix G: UPLC Chromatograms for assay method validation and drug content analysis  
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